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CHAPTER 1
Introduction and Overview
1.1 Basic neurochemistry
1.1.1 Dopamine neuroanatomy
The brain is a complex structure containing at least 100 billion neurons, with
proteins, peptides, and various small molecules working together to execute a variety of
functions including movement, emotions, learning, memory, and metabolic functions
such as heart rate and breathing (1, 2). A disruption in any one of these neurochemical
systems can have significant consequences on the organism. One of the most widely
investigated chemical messengers within the central nervous system (CNS) is
dopamine (DA) due to its involvement in the brain reward pathway, movement,
cognition, learning, as well as with several neurological disorders such as
schizophrenia, Alzheimer’s disease, Huntington’s disease, attention deficit hyperactivity
disorder (ADHD), and Parkinson's disease (3, 4). Under normal physiological
conditions, DA regulates locomotor activity. For example, a low dose of a drug of abuse
such as cocaine, methamphetamine, or ethanol (also referred to as psychostimulants)
increases locomotor activity, which is often attributed to an increase in extracellular DA
levels in a specific brain region, the striatum (5-8).
Within the brain, DA neurons emanate from two sub-regions located in the
midbrain, the substantia nigra (SN) and the ventral tegmental area (VTA; Figure 1.1)
(2). Cell bodies from the SN project primarily to the dorsal striatum (from here on in this
dissertation the structure will be referred to as the caudate putamen (CPu)), and
constitute the nigrostriatal pathway. This DA projection plays a critical role in initiation
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Figure 1.1 Sagittal mouse brain slice (side view) emphasizing major dopamine (DA)
projections. DA neurons projecting from the substantia nigra (SN) to the caudate
putamen (CPu) make up the nigrostriatal pathway. The mesolimbic pathway is right
below the nigrostriatal pathway where DA projections originate from the ventral
tegmental area (VTA) and projects to two major targets, the nucleus accumbens (NAc)
or the cortex. Figure has been adapted and modified from Mouse Brain Atlas (9).
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and execution of motor coordination, as well as in learning processes (10, 11). The
second major source of DA cell bodies are located adjacent to those originating from
the SN, in the area referred to as the VTA, and project to numerous brain regions such
as the nucleus accumbens (NAc), olfactory bulb, amygdala, hippocampus, and
prefrontal cortex. DA neurons that terminate in the NAc from the VTA are often referred
to as the mesolimbic pathway, while DA neurons that project to the cortex are typically
referred to as the mesocorticolimbic pathway. The mesolimbic pathway is known to be
involved in addiction, reward, pleasure, and aggression (10, 12). The mesocorticolimbic
pathway on the other hand is known to be involved in cognition, motivation, and emotion
(10).
1.1.2 Dopamine transmission in the brain
Neurons

are

specialized

cells

that

transmit

chemical

messengers

(neurotransmitters) across a synaptic cleft, a gap between neurons that is a few
nanometers wide. Neurotransmitters are released from the sending (presynaptic) to the
post-synaptic receiving neuron. Examples of neurotransmitter molecules include:
acetylcholine, glutamate, aspartate, glycine, γ-aminobutyric acid (GABA), DA,
norepinephrine, and serotonin (10). The focus of this section will be on the synthesis
and degradation of the neurotransmitter DA.
Cytosolic DA (3,4-dihydroxyphenethylamine) is synthesized in two steps from the
amino acid L-tyrosine (Figure 1.2). The rate-limiting first step involves hydroxylation at
the third position (C3) of the phenol ring by the tyrosine hydroxylase (TH) enzyme and
its

co-factors

Fe2+,

O2,

and

tetrahydrobiopterin

to

generate

L-3,4-

dihydroxyphenylalanine (L-DOPA). The second step uses L-aromatic amino acid
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decarboxylase (AADC) and pyridoxal phosphate, a vitamin B6 cofactor to convert LDOPA into DA by removing the carboxyl group. Newly synthesized DA is packaged into
synaptic vesicles located in the presynaptic terminal by vesicular monoamine
transporter 2 (VMAT2). Vesicular storage protects DA from catabolism by monoamine
oxidase (MAO). When recruited by an action potential the vesicles dock and fuse to the
plasma membrane, where vesicular DA is rapidly released from the presynaptic neuron
to the extracellular environment (Figure 1.3). Once outside the neuron, DA can: (1) bind
to post-synaptic receptors to propagate the neurochemical signal, (2) diffuse away from
the synapse, (3) be enzymatically degraded into its catabolites, or (4) be taken up by
the DA transporter for recycling (reuptake). The DA transporter is a 12 transmembrane
protein, whose primary function is to terminate the extracellular DA signaling through
rapid reuptake into the presynaptic nerve terminal (13-15). This enables DA recycling
and limits the duration of receptor activation or signal transmission (16). Besides the DA
transporter clearing DA from the extraneuronal space, the enzymes MAO and catecholO-methyltransferase

(COMT)

enzymatically

break

down

DA

into

3,4-

dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine (3-MT), respectively (1,
10). Finally, both DOPAC and 3-MT can be further catabolized to form homovanillic acid
(HVA) (1, 10).
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Figure 1.2 Dopamine (DA) synthesis and catabolism.
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Figure 1.3 A schematic representation of a dopamine (DA) synapse. In the presynaptic
neuron, DA is synthesized from L-tyrosine,
tyrosine, sequestered in vesicles, and upon an action
potential, released into the synapse. Th
The post-synaptic
synaptic neuron contains the DA
receptors, which upon activation by DA, cause signal propagation in the form of
secondary messengers to cause cellular responses. Abbreviations: TH, tyrosine
hydroxylase; L-DOPA, L-3,4--dihydroxyphenylalanine; AADC, L-aromatic
aromatic amino acid
decarboxylase; VMAT, vesicular monoamine transporter; DAT, DA transporter; HVA,
homovanillic acid; MAO, monoamine oxidase; COMT, catechol
catechol-O-methyltransferase;
methyltransferase;
AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate.
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Although DA uptake and catabolism are essential to regulate extracellular DA
levels, the main purpose of extracellular DA is signaling between neurons. The postsynaptic neuron contains receptors to propagate the DA signal. There are at least five
known DA receptor subtypes that belong to the seven-transmembrane G proteincoupled receptor (GPCR) family and are divided into two groups: DA D1-like receptors,
which include D1 and D5, and DA D2-like receptors, which include D2, D3, and D4
subtypes (4, 17, 18). D1-like receptors stimulate adenylyl cyclase (AC), increasing the
levels of secondary messenger cyclic adenosine monophosphate (cAMP) and neuronal
activity. However, D2-like receptors inhibit AC, reducing cAMP levels as well neuronal
activity. Besides activating post-synaptic receptors, extracellular DA can also stimulate
receptors located on the presynaptic terminals, which are referred to as autoreceptors.
Depending on whether autoreceptor is D1- or D2-like, activation of these DA
autoreceptors can either up- or down-regulate extracellular DA levels, respectively.
Specifically, stimulation of DA D2-like receptors reduces extracellular DA levels via a
negative feedback mechanism, regulating DA synthesis and/or release (19, 20).
1.1.3 Brain-derived neurotrophic factor
Neurotrophic factors are endogenous soluble proteins that regulate the cell cycle,
growth, differentiation, and survival of neurons (21). Examples of the neurotrophic family
are nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived
neurotrophic factor (GDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) that
mediate their functions through protein tyrosine kinase (Trk) receptors. The Trk
receptors are glycoproteins that have a molecular weight in the range of 140 – 145 kDa.
Each neurotrophin appears to bind to a unique isoform of the Trk receptors. For

8
example, NGF has greater specificity towards the TrkA receptor, NT-3 interacts with
TrkC, while both BDNF and NT-4 bind to TrkB (10, 22). BDNF, a 27 kDa homodimeric
protein, upon expression is transported to nerve terminals through the axon and
undergoes exocytotic release from presynaptic vesicles (23-25). Extracellular BDNF
binds to TrkB receptors, causing receptor dimerization, which leads to phosphorylation
of tyrosine residues within the cytoplasmic domain, activating the kinase (26).
Phosphorylated tyrosine residues recruit specific proteins, such as GBR2, SHC, and
SOS, that activate Raf, a serine/threonine protein kinase (Akt) (23). Trk activation
induces numerous signaling cascades through three known pathways: the Ras/mitogen
activated

protein

kinase

(MAPK),

phosphatidylinositol-3-kinase

(PI3K),

and

phospholipase C, γ (PLCγ) (Figure 1.4). Activation of these signaling cascades
eventually regulate the transcription factor, cAMP response element binding (CREB),
leading to an attenuation or potentiation in gene expression. Continuous activation or
inhibition of these signaling events regulate synaptic plasticity, synaptic transmission,
neurotransmitter release, neurogenesis, and cell survival (10, 23, 27-29).

9

derived neurotrophic factor (BDNF) signaling pathways through the
Figure 1.4 Brain-derived
tyrosine kinase (TrkB) receptor. Abbreviations used: PLCγ,, phospholipase C, γ; protein
kinase C, PKC; Akt, serine/threonine kinase; BCL2, B
B-cell
cell lymphoma 2; BAD, BCL2BCL2
associated death promoter; DAG, diacylglycerol; MAPK, mitogen activated protein
kinase; P; phosphorylation; MEK
MEK,, MAPK kinase; PI3K, phosphatidylinositol-3-kinase;
phosphatidylinositol
IP3, inositol-1,4,5-triphosphate;
triphosphate; IP3 R, IP3 receptor; CREB, cAMP response element
binding protein. Modified from Nestler et al. (2009), and Kaplan and Miller (2000) (10,
23).
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1.1.4 Modulation of the dopamine system by BDNF
There is considerable evidence that the interactions between BDNF and the DA
system are reciprocal, although the exact mechanism of how BDNF may regulate DA
dynamics has remained unknown (29-31). BDNF regulates striatal function directly by
activating TrkB receptor (Figure 1.4) (32). BDNF infused directly into the brain has been
shown to influence the survival and function of DA neurons, affect the turnover ratio
between DA and its catabolite DOPAC, and potentiate the activity-dependent release of
DA (29-31). Evidence suggests that BDNF expression can augment DA transmission in
the reward pathway of the VTA-NAc circuit (33). Mouse models with reduced BDNF
expression demonstrate a variety of alterations in the DA system, indicating that BDNF
has some influence on this system. Studies have shown that mice lacking one copy of
the BDNF gene (BDNF+/-) have higher tissue DA concentrations in the striatum, and
decreased DA release in superfused striatal tissue fragments (34, 35). BDNF knockout
(BDNF-/-) and BDNF+/- mice have reduced expression and density of DA D3 receptors in
the CPu, NAc core and shell, and in the Islands of Calleja (36-38). Additionally, BDNF
conditional knockout mice show reduced evoked DA release in the CPu and NAc shell
but not in the NAc core, and exhibit altered DA D2 receptor expression in the CPu (39).
Taken together, these studies suggest that BDNF can augment striatal DA functioning
in a region-specific manner.
1.1.5 Neurological diseases associated with dysfunction in the dopamine system
It is too simplistic to hypothesize that dysfunction in regulation of one molecule is
a direct cause of a neurological disease; rather, it is array of systems and molecules
that likely contribute to the progression of a neurological disease. However, at this time
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we do not have the scientific tools to evaluate all of these systems simultaneously.
Instead, we have taken the novel approach to examine two discrete molecules – BDNF
and DA. Interestingly, neurological diseases that primarily involve a dysfunction or
dysregulation of the DA system appear to have the BDNF system altered as well. To
better understand these systems, we have used a model of reduced BDNF expression
to evaluate its impact on the DA system.
Parkinson’s disease is characterized by greater than 80% loss of nigrostriatal DA
neurons (10). The overt symptoms of Parkinson’s disease involve the loss of motor
function and include a resting tremor, bradykinesia (slowness in movement), and rigidity
(10). Although a significant loss of DA neurons is observed in Parkinson’s disease, the
causes of this impairment of the DA system are still unknown. There are several factors
that increase one’s likelihood of developing Parkinson’s disease, such as advanced age
(> 65 years old), genetics, and environment (10, 40). Besides significant alterations in
the DA system, additional studies have shown impairments in BDNF, such as reduced
BDNF messenger ribonucleic acid (mRNA) and protein levels in the few surviving DA
neurons (41-43). These findings suggest that hypofunction of BDNF during one’s
lifetime may play a role in the neuronal loss. However, it is not understood whether low
BDNF levels cause the neuronal degeneration or result from it. Our hypothesis is that
low BDNF levels predispose the DA system to neuronal degeneration, because the
primary role of BDNF is to ensure survival and maintenance of neurons.
Huntington’s disease is a fatal neurodegenerative disorder that is typically
inherited (10, 44). Huntington’s symptoms typically manifest in mid-life, with the mean
age of onset being between 35 and 44 years and include the following dysfunctions:
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motor, psychiatric, and cognitive (44). One of the leading candidates associated with DA
neuronal loss is a mutation in the Huntingtin gene, leading to increased expression and
accumulation of a mutated Huntingtin protein (44). The mutated Huntingtin gene
contains excessive CAG trinucleotide repeats, usually greater than 36 (44, 45).
Interestingly, the Huntingtin gene mutation is hypothesized to decrease the expression
of BDNF protein in the cerebral cortex, as well as reduction in BDNF protein transport to
the striatum (46, 47). However, how the Huntingtin protein regulates BDNF expression
and protein levels is unknown.
Finally, a dysregulation in both DA and BDNF has been linked to ADHD, which is
characterized by inattention, hyperactivity, and impulsiveness. The cause of the ADHD
disorder is not well known, though a dysfunction in the midbrain DA systems is primarily
involved (48, 49).

Additionally, several studies have linked the val66met single

nucleotide polymorphism in BDNF to increased susceptibility to ADHD (50-52). A
decrease in midbrain BDNF activity is thought to be in part involved in the pathogenesis
of ADHD as well (49).
Besides being involved in several neurological diseases, the DA system is known
to play a key role in drug addiction. Drugs of abuse such as cocaine, ethanol, and
methamphetamine are known to elevate extracellular DA levels (5-8). Recent evidence
suggests that underlying genetic susceptibility may contribute to drug addiction; for
example, BDNF dysfunction may play a critical role in the addiction process (53, 54).
Due to the overwhelming studies linking BDNF to DA related neurological diseases and
disorders, it is important to study how BDNF levels alone modulate the DA system.
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1.2 Neurochemical techniques
Analytical techniques have played a critical role in neurochemical measurements
(55-57). Most techniques that have been used to monitor extracellular DA dynamics
typically focus on electroanalytical methods such as fast scan cyclic voltammetry
(FSCV), constant potential amperometry, differential normal pulse voltammetry, high
speed chronoamperometry, and in vivo microdialysis connected to high performance
liquid chromatography (HPLC) with electrochemical detection (58-62). An advantage of
using in vivo microdialysis to sample DA is that it allows for monitoring of multiple
analytes (e.g., other monoamines and DA catabolites), because microdialysis samples
are coupled to separation techniques (HPLC or capillary electrophoresis, CE) and
electrochemical detectors. By sampling at low flow rates, in vivo microdialysis measures
baseline neurotransmitter levels (without stimulation).
A limitation of microdialysis is that it has poor temporal resolution (i.e., sampling
for minutes; typically longer than 5 minutes). On the other hand, using direct electrode
approaches such as FSCV, constant potential amperometry, and high-speed
chronoamperometry provides sub-second temporal resolution enabling real-time
monitoring of the rapid dynamics of DA release and uptake. The analytical advantage of
DA is that it is easily oxidized, making it ideally suited for electrochemical monitoring.
When FSCV and in vivo microdialysis are used together, they complement each other,
by measuring different parameters of DA dynamics. FSCV can be used to probe DA
sequestration, DA mobilization, DA release, DA uptake and DA autoreceptor
functionality (14, 56, 60, 63-77). In vivo microdialysis on the other hand, enables
measurements of baseline levels of extraneuronal DA and DA metabolism (59, 78-86).
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1.2.1 Fast scan cyclic voltammetry
Voltammetry involves a group of electroanalytical methods in which current is
measured as voltage of an electrochemical system is changed. Examples of such
techniques

are

cyclic

voltammetry,

hydrodynamic

voltammetry,

square

wave

voltammetry, and linear sweep voltammetry. What differentiates these techniques from
one another is the shape of the applied voltage waveform. For example, cyclic
voltammetry uses a triangle waveform versus linear sweep voltammetry, which uses a
linear waveform. In either case, the waveform defines how the voltage is applied to the
electrode surface. When cyclic voltammetry is used, the potential of the working
electrode is made sufficiently positive or negative (depending on the initial and switching
potentials that define the triangle waveform) to drive electron transfer. When the
working electrode surface becomes sufficiently negative or positive, the analyte of
interest either gains electrons from the surface of the electrode or the analyte transfers
electrons to the surface, respectively. The electron transfer process generates charge
that is measured as current and is proportional to the concentration of the electroactive
analyte as defined by Faraday’s law (Equation 1).
Q = nFN

(1)

Where Q (Coulombs) is the total charge, n is the number of moles of electrons
transferred per molecule, F is Faraday's constant (9.649 x 104 Coulombs/mole), and N
is the number of moles of analyte. At the switching potential (peak of the triangle), the
applied voltage is reversed until it reaches its initial potential. If the analyte of interest is
chemically reversible, then the corresponding reduction/oxidation peak is observed. The
resulting current is recorded and the corresponding current versus voltage plot is
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generated. In a reversible system, the voltammetric peak current for forward scan at
25ºC is defined by the Randles-Sevcik equation (Equation 2) (87, 88),
ip = (2.69 x 105) n3/2AD1/2v1/2C*

(2)

where ip is the peak current, n is the number of moles of electrons transferred, A is the
working electrode surface area, D is the diffusion coefficient of the analyte, v is the scan
rate, and C* is the analyte concentration.
Cyclic voltammetry can be divided into sub-categories depending on the scan
rate. FSCV differs from conventional cyclic voltammetry by using scan rates greater
than 100 V/s. Advantages of faster scan rates is that they permit enhanced selectivity
and lower the limits of detection (Figure 1.5). Because FSCV completes the triangle
waveform in less than 10 seconds, real time oxidation/reduction measurements can
typically be made every 100 ms. Due to its sub-second time resolution, micrometerdimension spatial resolution, and the analytical advantage of DA being easily oxidizable
has made FSCV an extremely powerful neurochemical technique to measure DA
dynamics. The carbon fiber microelectrode used in FSCV is typically less than 10 µm in
diameter, making it amenable to placement in anatomically discrete brain regions such
as the NAc core versus the shell. In vivo FSCV has provided DA measurements from
the NAc core and shell of freely moving or anesthetized animals (66, 89-93). Similar to
in vivo FSCV, slice FSCV can be performed in anatomically distinct sub-regions using
thin sections of brain tissue (69, 82, 94-96).
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Figure 1.5 Schematic representation of fast scan cyclic voltammetry (FSCV). In the
upper left corner: A series of triangle waveforms (each lasting 8 ms) are applied to the
microelectrode
oelectrode every 100 ms at a scan rate of 400 V/s. Dopamine (DA) is oxidized to
dopamine-o-quinone,
quinone, which releases 2 moles of electrons and 2 protons during the rise
in potential being applied to the carbon fiber ((-0.4
0.4 to +1.2 V). On the descending phase
off the triangle waveform (+1.2 to -0.4 V), any remaining dopamine-o-quinone
quinone near the
electrode surface is reduced to DA. The carbon fiber microelectrode measures the
anodic and cathodic current, respectively (lower right corner).
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1.2.2 Slice voltammetry
For more than two decades, brain slices have been used as an important tool for
monitoring DA dynamics in guinea pigs, rats, monkeys, and mice (90, 97-99). In the
1990’s the emergence of genetically modified mice, such as DA D2 receptor knockout
mice, DA transporter knockout mice, or transgenic models that mimic certain
characteristics of neurological diseases, led to the popularity of fast neurochemical
techniques to better understand how the brain adapts to these genetic manipulations.
Slice voltammetry allows for the opportunity to probe DA dynamics, such as electrically
stimulated DA release, DA uptake, DA autoreceptor function, and heteroreceptor control
of presynaptic DA release. All of the above mentioned DA dynamic parameters can be
probed with the appropriate pharmacological agents such as DA uptake inhibitors or
releasers, DA receptor agonists and antagonists, VMAT inhibitors, and other
neurotransmitter systems, such as nicotinic agonists (70, 96, 100-102).
Using brain slices to probe DA dynamics allows for control over temperature and
stimulation parameters, and reduces interference due to pH changes, which are difficult
to control during in vivo experiments. Moreover, the use of a slice perfusion chamber
allows for easy and reproducible application of pharmacological agents and can be
used to probe their effect locally without contributions from connecting brain regions or
the periphery. Overall, slice voltammetry (Figure 1.6) allows for an efficient and easy
way to assess DA dynamics in the absence or presence of pharmacological agents in
various brain regions.
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Figure 1.6 Representative image of electrode placement in slice FSCV. In this figure
the stimulating and working electrodes are placed on the right side of the caudate
putamen (CPu) of a mouse brain slice. The CPu is identified from the anatomical
landmarks that are visualized on the slice, such as the corpus callosum and the anterior
commissure.
missure. The CPu is located between the anterior commissure and the corpus
callosum. On the left lower side of the brain slice, approximate locations of the striatal
sub-regions
regions of nucleus accumbens (NAc) core and shell are shown. Figure has been
adapted and
nd modified from Mouse Brain Atlas (9).
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Once brain slices are obtained, a carbon fiber working microelectrode is inserted
directly into the region of interest. In order to evoke DA release from neurons, a
stimulating electrode is placed on top of the brain slice (Figure 1.6). Due to the fast scan
rate, a large, but stable background current is generated at the microelectrode.
Software is used to subtract the background charging current and therefore generate a
meaningful cyclic voltammogram for DA. Using TH-1 software (ESA Inc., Chelmsford,
MA), three pieces of data are generated: (1) current versus voltage (CV) plot, (2) current
versus time trace, and (3) pseudo-color plot (Figure 1.7). The background subtracted
cyclic voltammogram (Figure 1.7A) exhibits a large peak at ~ +0.6 V with respect to a
Ag/AgCl reference electrode, which is characteristic of where DA is oxidized, while a
second and smaller peak is observed at ~ -0.2 V, representing the reduction of DAortho-quinone. The locations of the oxidation and reduction peaks in the cyclic
voltammogram are used to chemically identify DA. The current versus time plot (Figure
1.7B) indicates current generated at ~ +0.6 V, with electrically evoked DA release
(defined as the rising phase in a current), and DA being taken up by the DA transporter
(defined as the decay phase in a current). Post-calibration of the electrode with a known
concentration of DA is performed at the end of the experiment and the current (nA) is
converted into concentration (µM).
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Figure 1.7 Representative FSCV dopamine (DA) measurements from the caudate
putamen (CPu) of a mouse brain slice. (A) Corresponding cyclic voltammogram of
current (nA) versus voltage (V); (B) Plot of current (nA) versus time (s); (C) PseudoPseudo
color plot. The color plot is a three dimensional plot of the voltammetric current
(encoded in color, z-axis)
axis) plotted against time (x
(x-axis)
axis) and applied potential (y-axis).
(y
The color plot is used to visually identify the oxidization of DA an
and
d reduction of DADA
ortho-quinone.
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1.2.3 Flow injection analysis
Flow injection analysis (FIA) involves injection of a small but well-defined volume
or concentration of an analyte into a continuously flowing carrier stream containing the
appropriate buffer, creating a concentration gradient of the sample. In contrast to other
conventional continuous flow procedures, FIA does not necessarily require complete
mixing of the analyte and reagent(s). With good timing of all events, it is typically not
necessary to wait for chemical equilibrium to be attained. Transient signals such as
current, voltage, or fluorescence are read out, permitting the measurements to be
accomplished within a very short time (usually in less than 30 seconds). FIA is the
method by which the carbon fiber microelectrode is calibrated. Using a T-shaped flow
cell, the carbon fiber microelectrode is placed in a stream of flowing buffer and a plug of
DA is injected manually from a syringe (Figure 1.8). When the sample plug reaches the
tip of the carbon fiber microelectrode, the electrode’s response is measured (Figure
1.9).
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Figure 1.8 Schematic diagram of a flow injection analysis (FIA) set up for
microelectrode calibration using a T
T-shaped flow cell.
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Figure 1.9 Representative data from flow injection analysis used to calibrate the carbon
fiber microelectrode. The electrode in this example is calibrated with a 10 µM dopamine
(DA) standard. (A) Pseudo-color
color plot of DA oxidation and reduction, (B) DA cyclic
voltammogram,
ogram, and (C) current versus time plot. The current versus time plot
demonstrates the introduction of DA standard solution at ~ 16 s (red arrow) using the
flow injection system. The color plot is a visual aide used to identify the oxidization of
DA and reduction of DA-ortho
ortho-quinone.
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1.2.4 Chemical selectivity
The main limitation of voltammetry techniques is that oxidation and/or reduction
occurs for all electroactive species as long as sufficient voltage is applied to the
electrode, making chemical selectivity a primary concern in biological samples. Within
the brain, DA is part of the neurotransmitter family known as the monoamines, which is
comprised of serotonin and norepinephrine, and all are electroactive (Figure 1.10).
Additionally, DOPAC and 5-hydroxyindoleacetic acid, degradation products from DA
and serotonin, respectively, are present in 100-fold greater concentrations than their
parent molecules and are also electroactive. An advantage of FSCV is that the chemical
identity of an electroactive species is defined by both the oxidation and reduction peak
potentials. For example, norepinephrine and DA have similar oxidation and reduction
potentials at +0.6 V and -0.2 V, respectively. On the other hand, serotonin has oxidation
and reduction potentials of +0.7 V and 0.0 V, respectively. Because DA and
norepinephrine are structurally similar, it is difficult to distinguish their cyclic
voltammograms. However, the carbon fiber microelectrode is more sensitive to DA than
norepinephrine, as shown by the larger cathodic current (Figure 1.10).
Chemical species in a cyclic voltammogram can be identified by the ratio of the
oxidative and reductive peaks or peak location and shape (89). The shape of a cyclic
voltammogram is determined by electron transfer kinetics and how strongly the analyte
adsorbs on the carbon fiber (89). To assist with DA detection in the brain, the electrodes
are placed in known dopaminergic-rich regions with little or no norepinephrine or
serotonin, like the striatum, which includes the CPu and NAc core and shell.
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Figure 1.10 Representative cyclic voltammograms for 10 µM: (A) dopamine (DA), (B)
norepinephrine, and (C) serotonin. All cyclic voltammograms were obtained using flow
injection analysis with a Ag/AgCl reference electrode. A triangle waveform was applied
from -0.4 V to
o +1.2 V and back to -0.4
0.4 V at a scan rate of 400 V/s for each
neurotransmitter. The dashed line at +0.6 V for all cyclic voltammograms is shown
because this represents the voltage where the maximum amount of DA oxidized. Note,
for (B) and (C) the peak is slightly shifted from this maximum.
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Besides using the characteristic voltammogram to identify DA, pharmacological agents
such as DA receptor agonists or antagonists, or DA uptake blockers can be
administered to characterize the signal as dopaminergic in nature.
1.2.5 In vivo microdialysis
Microdialysis is an in vivo neurochemical technique that samples from a freely
behaving animal. The microdialysis probe consists of a semi-permeable membrane with
a molecular weight cutoff typically in the range of 5 – 30 kDa to allow for exclusion of
large molecules, such as proteins, and to provide some selectivity during sampling. The
probe is continuously perfused with a buffer like artificial cerebrospinal fluid (aCSF) that
mimics the extracellular fluid in the brain. Analytes diffuse from the tissue of interest
(high analyte concentration) to the dialysate probe (low analyte concentration) and are
collected for analysis (59, 103).
Upon stereotaxic surgery, a guide cannula that targets the brain region of interest
is implanted and held in place by dental cement and screws. After the animal has
recovered (in our lab ~ 4 – 6 hours) the guide cannula is removed and a concentric
microdialysis probe is inserted for analyte sampling (Figure 1.11). Concentric probes
are commonly used during microdialysis due to their strength and stability (104). After
an equilibration period (~ 12 – 16 hours) the analytes are sampled in a freely moving
and behaving animal (Figure 1.12) (105). Syringe pumps are used to infuse the
perfusate at very low flow rates of ~ 0.5 – 5.0 µL/min to ensure optimal probe recovery
(106). The fluid that is collected during microdialysis is referred to as the dialysate and
contains the analytes of interest, such as DA and its metabolites. The low volume (5 –
20 µL) dialysate samples are usually free of macromolecules such as proteins.
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Figure 1.11 A schematic diagram for the semi-permeable membrane of a microdialysis
probe. The perfusate buffer (filled circles) is infused through the concentric microdialysis
probe. The small molecules such as neurotransmitters (triangles) perfuse down their
concentration gradient towards the dialysis probe for collection. Molecules with high
molecular weight above the membrane cutoff (e.g., 6 kDa), such as proteins (squares),
are excluded.

28

Figure 1.12 Diagram for in vivo microdialysis sampling from a freely moving mouse
using off-line
line collection. After off
off-line
line dialysate collection is complete, the microdialysis
samples are injected, separated using HPLC, and detected with an electrochemical
detector.
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Analytes in the dialysate must be separated and quantified to determine their in
vivo concentrations; some of the most common methods of separation include capillary
electrophoresis and HPLC (55). The separation can be directly connected to the
microdialysis set up (on-line) or samples can be collected and analyzed later (off-line).
During on-line analysis of dialysate, problems such as sample degradation and handling
sub-microliter volumes are reduced (105). However, on-line analysis requires complex
miniaturization and expensive instrumentation for accurate control of the small volumes.
These limitations have made off-line analysis to be the method of choice, where
injections are made manually (8, 59, 83, 84, 107, 108). In our lab, off-line separation of
DA and its metabolites is done using HPLC.
1.2.5.1 Electrochemical detection
An advantage of using microdialysis is that the separation method can easily be
coupled to a wide variety of detection techniques such as electrochemical, enzymatic
assays, mass spectrometry (MS), or fluorescence (55, 59, 109, 110). As stated above,
the monoamine neurotransmitter family, which includes DA, DA catabolites (DOPAC
and HVA), serotonin, and norepinephrine are electroactive. After separation, detection
and quantification of these analytes is typically achieved using electrochemical
detection. There are numerous electrochemical detectors commercially available, each
with their own inherent advantages and disadvantages. The two most widely used
methods to make electrochemical measurements are amperometry and coulometry.
These techniques utilize the fact that catecholamines are readily oxidized at potentials
that do not oxidize many of the other species in the cerebrospinal fluid. In amperometric
cells, a small fraction (< 10%) of the analytes are oxidized (or reduced) at the surface of
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the working electrode (11). Amperometric cell design requires the HPLC eluent to be
perpendicular to the surface of the working electrode, hence approximately only 10% of
the analyte reaches the surface and is oxidized. In coulometry, 100% of the analyte is
oxidized or reduced by the working electrode surface (11, 81, 84). This nearly complete
redox of an analyte of interest can be achieved with coulometric detection because the
mobile phase is passed directly through the vitreous carbon electrode. Conversion of all
of the analyte during coulometric detection does not always imply better detection
because the increased background current reduces the signal-to-noise ratio (S/N). In
many cases amperometric and coulometric cells provide similar S/N. However, an
amperometric electrode is easy to polish and regenerate a ‘like new’ surface; unlike the
flow-through porous carbon electrode (coulometric) where electrode fouling often makes
re-using the electrode nearly impossible (111). The most desirable figures of merit for
these electrochemical detectors are low detection limits, high sensitivity, and selectivity
when desired (11, 81, 111).
One of the most common methods for detecting analytes from a dialysate sample
is using HPLC connected to electrochemical detection as it provides better chemical
selectivity compared to electrochemical methods alone (e.g. FSCV). The eluent from
HPLC separation is directly monitored for electroactive analytes from the dialysate.
Commercially available electrodes typically use a three-electrode system consisting of a
working electrode, reference electrode, and auxiliary electrode. A known potential
difference is applied to the working electrode relative to the reference electrode and the
resulting current is recorded at the working electrode. The electric charge (current)
measured is proportional to the analyte concentration (Equation 1).
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1.3 Research objectives
The overarching research objective of this thesis is to understand if and how
BDNF modulates the DA system in the striatum, a brain region that is associated with
Parkinson’s disease, drug addiction, and ADHD (46, 54, 112-115).
1.3.1 Overall Hypothesis: Vulnerability to neurological diseases is a complex interplay
between genetics and environment. Recent evidence suggests that alterations in the
expression and function of BDNF protein may not only regulate DA dynamics, but also
play a critical role in susceptibility to neurological disease (42, 46, 53, 54, 112, 115117). We hypothesize that life-long reduction in BDNF levels may lead to a
hyperdopaminergic system, which may increase one’s risk factor for developing
Parkinson’s disease, drug addiction, or ADHD. As a result of a hyperdopaminergic
system, we predicted decreases in DA release, DA uptake, and DA D2 and D3
autoreceptor functions in mice lacking one copy of the BDNF gene (BDNF+/-) compared
to wildtype mice. To understand the long-term consequences of low endogenous BDNF
levels on DA dynamics, aged (~ 18 months old) BDNF+/- and wildtype mice were
evaluated to determine if the combination of low endogenous BDNF levels and a
hyperdopaminergic

phenotype

lead

to

an

increased

susceptibility

towards

neurodegenerative diseases like Parkinson’s disease. We hypothesize that a
constitutive reduction in BDNF levels would lead to more severe impairments in the DA
system of BDNF+/- mice as compared to their control wildtype littermates. We tested our
overall hypothesis through four research objectives as outlined below.
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1.3.2 Research objective 1:

Develop a voltammetric assay to characterize the

functionality of DA D2 and D3 autoreceptors in the mouse striatum. Parts have been
previously published in the manuscript by Francis K. Maina and Tiffany A. Mathews in
ACS Chemical Neuroscience, 2010 (94).
DA D2 and D3 autoreceptors are located on presynaptic terminals and are
known to control the release and synthesis of DA. DA D3 receptors have a fairly
restricted pattern of expression in the mammalian brain. Their localization in the NAc
core and shell is of particular interest because of their association with the rewarding
properties of drugs of abuse. Current tools to evaluate DA D2 and D3 receptor function
include microdialysis, autoradiography, voltammetry, and magnetic resonance imaging
(MRI) (118-123). FSCV has been used extensively to characterize the DA D2 receptor
functionality throughout the striatum. However, its use to characterize the DA D3
receptor has been limited (14, 70, 71, 76, 124-126). Using background subtracted
FSCV, our goal was to investigate the effects of DA D2 and D3 agonists on electrically
stimulated DA release and uptake rates in the mouse CPu and NAc core and shell. We
hypothesized that, due to the differential expression of DA D2-like receptors in the
striatum, FSCV will be able to distinguish the functionality between DA D2- and D3receptors agonists. To our knowledge, this was the first time that the functionality of DA
D2 and D3 autoreceptors was compared across the different regions of interest; CPu,
NAc core, and NAc shell in the striatum using FSCV.
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1.3.3 Research objective 2: To determine if low endogenous neuronal BDNF levels
influence the dopaminergic system using wildtype and BDNF +/- mutant mice
The long-term objective of the Mathews’ laboratory1 is to use BDNF+/- mice as an
animal model in two discrete disease models: alcoholism and aging. However, before
using the BDNF+/- mice in behavioral protocols, it is necessary to understand if BDNF
has the ability to influence DA dynamics in these mice. For example, with respect to the
serotonin system, in vivo microdialysis studies have revealed that in the hippocampus,
BDNF+/- mice have increased basal extracellular serotonin levels and decreased
serotonin uptake compared to their wildtype littermate controls (127). There has been
considerable interest in the serotonin-BDNF relationship due to the hypothesized dual
role in the effectiveness of anti-depressants (29, 128). Despite the fact that BDNF levels
regulate the expression of the DA D3 receptor, few studies have investigated whether
BDNF levels influence other facets of DA dynamics (36). To understand the role of
endogenous BDNF on the dopaminergic system in vivo, BDNF+/- mice were evaluated
using a variety of neurochemical techniques including in vivo microdialysis and slice
FSCV. Low BDNF levels in BDNF+/- mice are hypothesized to lead to a poorly
developed dopaminergic system (35). In vivo microdialysis was used to determine
extracellular levels of DA and its catabolites. This was to provide information on the
overall tone of the DA system. FSCV was used to measure DA release and uptake
dynamics more discretely. An advantage of using FSCV to evaluate the dopaminergic
system is that it provides an opportunity to probe DA release, DA uptake, DA
1

Since the goal of the Mathews’ laboratory is to understand the biological role of BDNF in vivo, to
strengthen and support our hypothesis from my voltammetric results on the in vivo role of BDNF some of
the results in the following chapters show collaborative work from other Mathews’ laboratory group
members. The roles of each can be found in the contribution section of this dissertation as well as in the
individual chapters.
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autoreceptor functionality, and the ability of exogenous BDNF to influence DA release
and uptake. We hypothesized that an impaired DA system due to low BDNF levels
would lead to attenuated presynaptic DA dynamics of release and uptake.
1.3.4 Research objective 3: Do lifelong BDNF reductions negatively influence striatal
dopamine dynamics?2
Results from research objective 2 indicated that BDNF+/- mice have a 2.5-fold
increase in basal extracellular DA levels as compared to their wildtype littermates at 3
months of age. A leading hypothesis in neurodegenerative diseases is that too much
DA could be neurotoxic because is easily oxidized by reactive oxygen species (129131). Aged BDNF+/- mice (9 to 21 months) exhibit reduced locomotor activity as
compared to their wildtype littermates (34, 132). Often locomotor activity measurements
are an indirect way to assess the function of the DA system. Furthermore, the Dluzen
laboratory has suggested that low BDNF levels are associated with an attenuation in
nigrostriatal DA system function, which would agree with locomotor activity results in
aged BDNF+/- mice (35). To understand if lifelong decrements in BDNF levels negatively
influence the nigrostriatal pathway, mice deficient in BDNF were evaluated at 3 (see
above research objective #2) and ~ 18 months of age and compared to their littermate
controls. Because young BDNF+/- mice have reduced BDNF levels and elevated DA
levels, our working hypothesis was that these mice are more susceptible to age-related
changes in the striatum versus wildtype mice. Similar to research objective #2,

2

The objective consists of collaborative work from Kelly Bosse Ph.D. and Johnna A. Birbeck who
performed in vivo microdialysis experiments to complement the slice voltammetry experiments. For the
specific and detailed roles of each please see the contribution section of this dissertation as well as
chapter 5.
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neurochemical techniques including slice FSCV and in vivo microdialysis were used to
evaluate striatal DA dynamics.
1.3.5 Research objective 4: How do low endogenous BDNF levels influence the
function of the dopamine transporter?3
One commonality between all drugs of abuse such as methamphetamine,
cocaine, and alcohol is their ability to elevate terminal extracellular DA levels, although
through different mechanisms. Specifically, methamphetamine increases extracellular
concentrations of DA mainly by competitively inhibiting DA uptake at the DA transporter.
Our studies from Research Objective #2 suggest that DA uptake is reduced in BDNF+/mice. Additionally, autoradiographic studies have shown that DA transporter density in
BDNF+/- does not differ from that of wildtype mice (37, 133). Furthermore, when BDNFdeficient mice were exposed to a neurotoxic dose of methamphetamine, they were
found to be less susceptible to methamphetamine-induced neurotoxicity in the
nigrostriatal dopaminergic system as compared to wildtype mice (35, 134). Taken
together, these results suggest that DA transporter function is impaired or reduced in
the CPu of BDNF+/- mice.
To understand how low endogenous neuronal BDNF levels influence DA
transporter function, the effect of methamphetamine on the DA transporter was
evaluated in both wildtype and BDNF+/- mice at two discrete time points using slice
FSCV and in vivo microdialysis. We hypothesized that the reduced DA clearance

3

The objective includes collaborative work from Kelly E. Bosse Ph.D. and Johnna A. Birbeck who
performed in vivo microdialysis experiments to determine the role of BDNF deficiency on DA transporter
function in vivo. The microdialysis results complement the slice (in vitro) voltammetry results, overall
providing a better understanding on the role of BDNF. For the detailed roles of each please see the
contribution section of this dissertation as well as chapter 6.
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observed in the CPu of young BDNF-deficient mice is a result of reduced DA transporter
function and aging would further impair it.
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CHAPTER 2
Materials and Methods
The objective of this chapter is to describe experimental protocols that are
common to all chapters in this dissertation.

Any variations or changes in these

protocols are directly addressed in the relevant chapter.
2.1 Animals
Mice having only one active brain-derived neurotrophic factor (BDNF) gene
(BDNF+/-) on a C57Bl/6 genetic background and wildtype C57Bl/6 mice were obtained
from Jackson Laboratory (Bar Harbor, ME) at 3 – 5 weeks old. Male and female
breeders were then paired and housed in the animal care facilities at Wayne State
University. BDNF wildtype (will be referred to as wildtype) and BDNF+/- mice offspring
were bred and raised in house. Genotype identification was performed using
polymerase chain reaction (PCR) analysis of tail DNA (Section 2.2). The mice were kept
in groups of 3 – 5 animals per cage with food and water ad libitum on a 12 hr light-dark
cycle. All procedures were designed to minimize discomfort to the animals. Experiments
were conducted during the light cycle (0600 – 1800 h) with young adult mice aged 3 – 4
months or at least 18 months for studies in aged mice. Experimental protocols adhered
to the National Institutes of Health Animal Care Guidelines and were approved by the
Wayne State University Institutional Animal Care and Use Committee.
2.2 Genotyping
Breeding, weaning, and genotypic analysis were performed and overseen by Kelly E.
Bosse, Ph.D. and Brooke Newman with the assistance from Johnna Birbeck, Parvejz
Khan, Natasha Bohin, Andrezj Czaja, Katie Logan, and Christopher Rogalla.
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Immediately after mice were weaned, genomic DNA was obtained from tail tissue
(~ 0.3 – 0.5 cm) and frozen (-80°C) until needed. T ails were lysed in 500 µL of lysis
buffer (100 mM Tris-base, 1.5 mM NaCl, 5 mM EDTA, 0.2% sodium dodecyl sulfate; pH
8.5) containing 0.1 mg/mL proteinase K (New England BioLabs, Ipswich, MA). Tail lysis
was completed within 15 hours at 55°C, with agitation. Tail lysis samples were
centrifuged (Eppendorf, Hauppauge, NY) for 32 minutes at high speed (20,000 x g) to
remove tissue and cellular debris. Isopropyl alcohol (500 µL) was added to the
supernatant to extract genomic DNA followed by centrifugation at 20,000 x g for 16
minutes. A DNA pellet at the bottom of the vial was retained and washed by adding 500
µL of 75% ethanol (v/v) followed by centrifugation for 5 minutes at 20,000 x g. The
supernatant was carefully removed and discarded, leaving the DNA pellet. Nanopure
water (6 µL) was added to the DNA pellet and placed in a desiccator with the cap open.
The genomic DNA was re-suspended in 85 µL TE buffer (10 mM Tris-base and 1 mM
EDTA at pH 8.5) followed by centrifugation for 30 seconds at 20,000 x g. Samples were
then stored at 4°C for at least 24 hours before use.
An approximation of how much DNA present was determined by measuring
ultraviolet (UV) light absorbance at 260 nm (UV-1800 Shimadzu (Shimadzu, Columbia,
MD)). DNA was diluted to a final concentration of 350 ng/mL, from which 2 µL was
added to PCR reagents. Wildtype and BDNF mutant targeted alleles were separately
amplified using the following primers: wildtype: 5’-CCAGCAGAAAGAGTAGAGGAG-3’;
BDNF

mutant:

5’-GGGAACTTCCTGACTAGGGG-3’;

and

common:

5’-

ATGAAAGAAGTAAACGTCCAC-3’ as specified by Jackson Laboratories. The PCR
reagent (22.8 µL) contained 0.096 mM of each deoxyribonucleotide triphosphate
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(dNTP’s: dATP, dCTP, dGTP, dTTP), 1.28 mM MgCl2, 1 µM of one of the primers, and
1.2 µL PCR buffer A (10 mM Tris–HCl, 1.5 mM MgCl2, 50 mM KCl; pH 9.0) in 15.9 µL
nanopure water. Then, 0.2 µL Taq DNA polymerase (1 unit) was added to each sample.
PCR was performed using a thermocycler (Robocycler® gradient 96, Stratagene
(Agilent), Santa Clara, CA). The cycling conditions were: 94°C (melting) for 5 minutes,
58°C (annealing) for 1 minute, 72°C (extension) for 2 minutes, followed by 35 cycles at
95°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes. PCR reaction products
were then separated on 2% agarose gels (6 µL:lane) in TBE buffer (89 mM Tris–base;
89 mM boric acid; 1 mM EDTA; 1 mM NaOH, pH 8.0) at 125 – 135 V and visualized
using ethidium bromide. Wildtype mice were identified from genomic DNA that yields
only one band for the active BDNF gene in the first column. The BDNF+/- mice were
identified from two separate bands; the first band identifies genomic DNA for the active
BDNF gene, while the second band identifies the inactive BDNF gene (Figure 2.1). The
BDNF gene is inactivated by insertion of a neomycin (NEO) resistant cassette, and has
a higher molecular weight compared to the active BDNF gene and travels less during
gel electrophoresis (Figure 2.1).
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electrophoresis
ctrophoresis image of wildtype (WT) and BDNF+/Figure 2.1 Representative gel ele
mice. Five lanes are shown; the first 2 lanes illustrate genotype identification of a WT
mouse, while the second 2 lanes highlight genotype identification of a BDNF+/- mouse,
with the final lane showing the b
base
ase pair (bp) ladder. A mouse is identified as a wildtype
mouse when only the first lane exhibits one band (275 bp) and there is no band present
in the second lane. A mouse is identified as a BDNF+/- mouse when both lanes exhibit a
band. Similar to the wildtype
dtype mice the band for the WT BDNF gene is present in the first
column, and the second lane determines the presence of mutant BDNF (340 bp), which
is only present in BDNF+/- mice. Image courtesy of Brooke Newman.
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2.3 Brain slices
Mice were anesthetized with CO2 and the brain was rapidly removed and cooled
in a pre-oxygenated (95% O2 / 5% CO2) high sucrose-artificial cerebrospinal fluid
(aCSF) buffer for 10 minutes. The sucrose-aCSF buffer consisted of: 180 mM sucrose,
30 mM NaCl, 4.5 mM KCl, 1 mM MgCl2, 26 mM NaHCO3, 1.2 mM NaH2PO4, and 10
mM D-glucose (135). The brain was sectioned with a vibrating tissue slicer (Vibratome,
St. Louis, MO) into 400-µm-thick coronal slices. Brain slices containing dopamine (DA)
rich regions of interest such as the caudate putamen (CPu) and nucleus accumbens
(NAc) were obtained. Slices were maintained in oxygenated aCSF at room temperature
for 1 hour before use. A slice was transferred to a custom made submersion recording
chamber (Custom Scientific, Denver, CO) and allowed to equilibrate in oxygenated
aCSF at 32°C for 30 minutes before DA measurements we re performed.
2.4 Fast scan cyclic voltammetry
2.4.1 Microelectrode fabrication
Carbon fiber microelectrodes were fabricated in house using a previously
described method with minor modifications (58). First, a 7 µm diameter carbon fiber
(Goodfellow, Oakdale, PA) was aspirated through a borosilicate glass capillary (A-M
Systems, Carlsborg, WA) using vacuum suction. The capillary containing the carbon
fiber was heated and pulled using a micropipette puller (Narishige, Tokyo, Japan) to
generate two microelectrodes with a tight glass seal around the carbon fiber. The
exposed carbon fiber was trimmed to a length of 50 – 200 µm beyond the glass carbon
fiber seal (Figure 2.2).
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Figure 2.2 Representative scanning electron microscope image showing a
microelectrode at 500x magnification (acceleration voltage, 25 kV). The length of the
carbon fiberr that extends beyond the glass seal is ~ 190 µm.
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The microelectrode was then backfilled with 150 mM KCl and a lead wire
(Squires Electronics, Cornelius, OR) was inserted to make an electrical connection with
the carbon fiber. The silver/silver chloride (Ag/AgCl) reference electrode was made from
a 250 µm diameter silver wire (A-M Systems, Carlsborg, WA). The silver wire was
coated with a thin layer of silver chloride by anodizing at (+1 V) in a solution of 1 M HCl
for 5 – 10 minutes. A two electrode configuration with a working carbon fiber
microelectrode and Ag/AgCl reference electrode was used to determine DA release and
uptake rates in the CPu and NAc.
2.4.2 Stimulator calibration
To detect DA from a brain slice, an additional electrode known as the stimulating
electrode was placed on top of the brain slice to apply an electrical current, inducing DA
release from surrounding neurons. To ensure consistent stimulating current output, the
stimulator was calibrated. Previously, John et al. described the stimulation parameters
to evoke DA release from the mouse striatum (includes CPu and NAc). The optimal
current to be supplied to the stimulating electrode was determined to be 350 µA (62,
136). In order to determine the voltage that would provide a 350 µA current, a
Neurolog® stimulator (Digitmeter, Hertfordshire, England) was calibrated. Using National
Instruments Labview™ software (Austin, TX), the voltage output to the stimulator was
varied from 2.5 – 5.75 V and the resulting current measured using a digital multimeter
MTI-058 (Megatone Electronics, Taipei, Taiwan). Interpolation of a linear plot of current
versus voltage was used determine that the voltage needed to generate a current of
350 µA was 4.5 V (Figure 2.3).
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Figure 2.3 Calibration plot for the Neurolog® stimulator. The dashed line indicates the
optimal applied potential voltage of 4.5 V to obtain the desired current of 350 µA.
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2.4.3 Data acquisition
The potential at a carbon fiber microelectrode was held at -0.4 V versus the
reference electrode, ramped to +1.2 V and back to -0.4 V (400 V/s) every 100 ms (10
Hz) (62, 71, 73, 74, 92, 137). All electrode and stimulation parameters were controlled
by TH software (ESA Inc., Chelmsford, MA). The data collection system uses two
peripheral component interconnections (PCI) 6221 boards manufactured by National
Instruments (Austin, TX). The main board has an analog to digital converter (ADC) and
a digital to analog converter (DAC) (Figure 2.4). This main board is responsible for
generating the waveform input, as well as recording the current difference at the
microelectrode. The second board contains a DAC output that stimulates when
triggered. When the triangle waveform is applied, a stable background current is
produced before DA is released. This background is digitally subtracted from the
voltammograms following DA stimulation (89). Characteristic background subtracted
voltammograms for DA demonstrate peak oxidation currents for DA at approximately
+0.6 V and the peak reduction currents for DA-ortho-quinone at approximately -0.2 V. A
low-noise ChemClamp potentiostat (Dagan Corporations, Minneapolis, MN) was used
for FSCV measurements. The slice chamber was perfused at 1 mL/min with 32°C
oxygenated aCSF. DA was evoked every 5 minutes by either one (monophasic, 350 µA,
and 4 ms pulse width) or multiple pulse stimulation from the adjacent stimulating
tungsten electrodes (Plastics One, Roande, VA) generated from the Neurolog®
stimulator. The stimulating electrode was placed directly on the slice, approximately 100
– 200 µm away from the carbon fiber electrode (62, 74). The microelectrode was placed
approximately 75 µm below the surface of the slice.

46

Figure 2.4 Schematic diagram showing the experimental set up for fast scan cyclic
voltammetry measurements. National Instruments (NI) peripheral component
interconnections (PCI) 6221 boards link the computer to the potentiostat, and convert
signal from analog to digital
ital converter (ADC) or digital to analog converter (DAC) during
the measurements.
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2.4.4 Microelectrode post-calibration
Flow injection analysis (FIA) was used to determine the electrode response to
the 3 µM concentration of DA at the end of the experiment. The microelectrode was
placed in a stream of calibration buffer (Figure 1.8), which was a modified artificial
cerebrospinal fluid (aCSF) solution consisting of (in mM): NaCl (126), KCl (2.5),
NaH2PO4 (1.2), CaCl2 (2.4), MgCl2 (1.2), and NaHCO3 (25); pH 7.4. The modified aCSF
was pumped continuously at a flow rate 2 mL/min using a syringe pump through a Tshaped flow cell. The second syringe contained a known concentration of DA (3 µM),
which was manually injected. The electrode measures the amount of current generated
from the oxidation of the known concentration of DA. The calibration factor for the
electrode was defined as the amount of current per micromolar concentration (nA/µM).
Implanting electrodes in brain tissue decreases the sensitivity of the electrode, resulting
in a decreased response time. Every effort was made to obtain a post-calibration factor
for each electrode to determine the sensitivity.
2.4.5 Data analysis
The resulting current versus time plots obtained were fitted by nonlinear
regression as described by Jones et al. in software written in Labview™ (National
Instruments, Austin, TX) (62, 68, 138). The electrically stimulated DA release and
uptake rates were determined using a set of Michaelis-Menten based equations
(Equation 3) (62, 68, 90, 138).

d [DA]
= f [DA] p
dt

Vmax
(K m /[DA] + 1)

(3)
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The apparent Km is a constant, which correlates the affinity of DA to DA
transporter and was set during the analysis of stimulated [DA] and maximal uptake rates
as maximum velocity (Vmax). The Km value (0.16 µM) used in all data analysis was
obtained from the literature (62, 68, 139, 140). Stimulated DA release per pulse ([DA]p)
at a given stimulation frequency f and maximal uptake rates (Vmax) were then evaluated.
It is assumed that each stimulation pulse evokes a constant amount of DA and uptake
of DA by DA transporter is a saturable process (62, 68, 71). The rise in electrically
stimulated DA signal after electrical stimulation is a competition between release and
uptake, where release mechanisms dominate. On the other hand, the decay phase of
the electrically stimulated DA is attributed to diffusion, enzymatic breakdown of DA, and
DA uptake (77, 141). However, diffusion and enzymatic breakdown of DA are
considered ‘slow’ events when using FSCV, and therefore the decay phase is primarily
attributed to uptake (77, 141).
2.5 In vivo microdialysis
Stereotaxic surgery and all in vivo microdialysis experiments were performed by
Kelly Bosse, Ph.D. or Johnna Birbeck as previously described (142). Briefly, young
adult mice aged 8 – 16 weeks were anesthetized with an intraperitoneal (i.p.) injection
of Avertin (20 mL/kg). Shaving and sterilization of the skin covering the skull was done
with two applications of Betadine and alcohol. To limit discomfort, mice were placed on
a heating pad (~ 37°C) and lidocaine (0.5 mg/kg) was su bcutaneously injected near the
surgical site. After ensuring surgical plane anesthesia, a small incision was made to
expose the skull and the area was cleaned and dehydrated using 10% hydrogen
peroxide. The head was secured on a Kopf® stereotaxic frame (David Kopf Instruments,
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Tujunga, CA) using two ear bars that do not puncture the tympanic membrane. Two
small holes were drilled into the skull for the probe placement and a support screw. The
CPu coordinates (in mm: Anterior (A), +0.80; Lateral (L), -1.3; Ventral (V) -2.5 from
Bregma) were determined from Paxinos and Franklin mouse atlas (9). A CMA/7 guide
cannula (CMA Microdialysis, Chelmsford, MA) was implanted in the CPu and anchored
to the skull with dental cement and a screw (BAS, Lafayette, IN). The microdialysis
probe (CMA/7, 2 mm length, 240 µm diameter, Cuprophane, 6 kDa cut-off; CMA
Microdialysis, Chelmsford, MA) was inserted into the guide cannula upon mouse
recovery. Artificial CSF (composition in mM: 147 NaCl, 3.5 KCl, 2 Na2HPO4, 1.0 CaCl2,
1.2 MgCl2; pH 7.4) was perfused through the probe overnight at a flow rate of 0.4
µL/min. After approximately 12 hours, the flow rate was increased to 1.1 µL/min for an
hour of equilibration. Afterwards, dialysate samples containing DA and other small
molecules were collected offline from freely moving mice at 20 minutes intervals.
Zero net flux is a quantitative microdialysis technique that allows for estimation of
basal extracellular concentration of analyte in a tissue. The x-intercept of the zero net
flux regression line gives an estimate of the “true” extracellular concentration of the
analyte that is corrected for the probe recovery (103, 143). The technique also
approximates relative “in vivo” probe recovery using extraction fraction (Ed) values,
determined from the slopes of the zero net flux regression lines (143). The Ed, also
referred to as extraction efficiency, is a measure of diffusion between the effluent
dialysate and the analyte concentration in the extracellular space of the tissue
surrounding the probe (79). To determine the “true” basal extracellular DA concentration
in freely behaving mice, an infusion pump (CMA/402) was used to perfuse a known
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amount of DA (0, 5, 10, or 20 nM in aCSF) through the microdialysis probe, where each
concentration was delivered to the CPu for 90 minutes (83, 103, 144). The dialysate
was analyzed using HPLC coupled to an electrochemical detector as described in
Section 2.6.
A high K+ concentration in aCSF depolarizes neurons, inducing exocytotic
release of neurotransmitters like DA and subsequently elevating extracellular levels.
First three stable baseline samples were collected, then the aCSF was switched to a
solution containing high K+ (composition in mM: 120 KCl, 30.5 NaCl, 2.0 Na2HPO4, 1.2
MgCl2, 1.0 mM CaCl2; pH 7.4), which was infused through the microdialysis probe for 20
minutes (83). After the 20 minute perfusion with high K+ aCSF, the perfusate was
switched back to standard aCSF solution.
2.6 High performance liquid chromatography (HPLC) and electrochemical
detection
Kelly E. Bosse, Ph.D. and Johnna A. Birbeck performed all HPLC analysis, which
included HPLC separation with electrochemical detection and data analysis.
DA

and

its

catabolites,

3,4-dihydroxyphenylacetic

acid

(DOPAC)

and

homovanillic acid (HVA) levels from dialysate samples were separated and quantified
using HPLC coupled to an electrochemical detector. Dialysis samples (20 µL) were
manually injected onto a C18 (2)-HST HPLC column (100 mm x 3 mm, 2.5 µm particle
size) (Phenomenex, Torrance, CA) for separation followed by detection using an ESA
5014B microdialysis cell (E1 = -150 mV; E2 = +220 mV; ESA Coulochem III (ESA Inc.,
Chelmsford, MA). An ESA 5020 guard cell (ESA Inc., Chelmsford, MA) was placed inline before the injection loop and set at +350 mV potential. The mobile phase

51
composition was: 75 mM NaH2PO4, 1.4 – 1.8 mM 1-octanesulfonic acid, 0.025 mM
EDTA, 10% acetonitrile, and 0.002% triethylamine; pH = 3.0, adjusted with 85%
phosphoric acid, delivered at a flow rate of 0.4 mL/min by an isocratic LC-20AD pump
(Shimadzu, Columbia, MD). DOPAC, DA, and HVA retention times were ~ 5, 6, and
12.5 minutes, respectively. Analyte peak area was integrated and quantified against
known standards using LC Solutions Software (Shimadzu, Columbia, MD). After
microdialysis experiments, mice were euthanized by CO2 inhalation and their brains
were rapidly removed for histological verification of probe placement in the CPu.
2.7 L-DOPA tissue content
Tissue content studies for the analysis of L-DOPA content were performed by Kelly E.
Bosse, Ph.D. assisted by Joseph Roberts. The tissue content studies involved collection
of the tissue samples, analysis that included HPLC separation with electrochemical
detection, and data analysis.
The activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in DA
biosynthesis, was evaluated by measuring L-3,4-dihydroxyphenylalanine (L-DOPA)
accumulation in brain tissue samples. Briefly, the L-aromatic amino acid decarboxylase
(AADC) enzyme was inhibited with 3-hydrazineomethyl phenol dihydrochloride (NSD1015) and γ-butyrolactone (GBL) was used to minimize autoreceptor feedback effects
during the regulation of DA biosynthesis (145). Mice were injected with GBL (750
mg/kg, i.p.) and 5 minutes later with NSD-1015 (100 mg/kg, i.p.). Mice were first
sacrificed 40 minutes after NSD-1015 injection and the brain was rapidly removed. The
CPu was then rapidly dissected and frozen in liquid nitrogen. Brain tissue samples were
stored at -80°C until time of analysis. To measure L-DO PA tissue accumulation,
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samples were weighed and homogenized in 0.1 M HClO4 using an Microson™
ultrasonic cell disruptor (Qsonica, Newtown, CT) and centrifuged for 10 minutes at 9000
x g. L-DOPA was quantified from the resulting supernatant using HPLC separation with
a Luna C18 reverse phase column (50 x 2 mm, 3 µm particle size) (Phenomenex) and
electrochemical detection was achieved with an ESA 5011A analytical cell (E1 = -150
mV, E2 = +200 mV) and Coulochem III detector (ESA Inc.). The mobile phase was
composed of 1 mM EDTA, 2.4 mM sodium octanesulfonate, 7.8 mM chloroacetic acid,
10 mM NaH2PO4, 80 mM citric acid, and 3% acetonitrile; pH 3 and delivered by LC-20
AD isocratic pump at a flow rate of 0.4 mL/min. L-DOPA peak area was integrated and
quantified against known standards using LC Solutions Software.
2.8 Chemicals
Components of the mobile phase, buffers, genotyping reagents, NSD-1015, GBL,
Avertin, standards (DA, DOPAC, L-DOPA, and HVA) were either of HPLC grade or the
highest purity available and purchased from Sigma-Aldrich (St. Louis, MO) and Fisher
Scientific (Pittsburgh, PA). Concentrated HNO3, HClO4, boric acid, triethylamine,
agarose PCR plus, and citric acid were obtained from EMD (Gibbstown, NJ). Primers,
MgCl2, and dNTP’s were obtained from Invitrogen (Carlsbad, California).
2.9 Statistical data analysis
Statistical analysis and graphing of the microdialysis results was performed by Kelly E.
Bosse, Ph.D. or Johnna A. Birbeck.
Briefly, all statistical analyses were carried out using GraphPad Prism (GraphPad
Software Inc., San Diego, CA). Data are shown as means ± standard errors of the
means (SEMs). When a comparison between two means was required, these data were
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analyzed by Student’s t-tests. When three or more means needed to be compared,
these results were analyzed by a one-way analysis of variance (ANOVA) with the
appropriate post-hoc tests. When the mean’s interaction needed to be assessed
between two independent variables like genotype and treatment, a two-way ANOVA
was performed. In all cases, statistical significance was defined as P < 0.05.
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CHAPTER 3
Functional Fast Scan Cyclic Voltammetry Assay to Characterize
Dopamine D2 and D3 Autoreceptors
(Adapted from Maina and Mathews (2010) ACS Chemical Neuroscience 1, 450-462)
(Copyright License Number: 2633741370556)
3.1 Introduction
Dopaminergic histological and neurochemical studies demonstrate regional
differences within the striatum, which can be further subdivided into three distinct
anatomical regions (the caudate-putamen (CPu), the nucleus accumbens (NAc) core,
and the NAc shell) (93, 146, 147). Dopamine (DA) cell bodies, which innervate the NAc
and the CPu, arise from two distinct areas in the midbrain, the ventral tegmental area
(VTA) and the substantia nigra (SN), respectively (2). A variety of neurochemical
studies have demonstrated differences in DA levels between these regions. For
example, the CPu is known to have higher extracellular DA levels and greater DA
uptake as compared to the NAc (90, 96, 148, 149). Within the NAc, the core is known to
exhibit greater electrically evoked DA release and uptake than the shell (150). In vivo
microdialysis data also confirm that extracellular DA levels are greater in the core than
the shell (78, 151). However, it is not clear whether these observations are solely due to
the reduced expression of the DA transporter from the dorsal to ventral striatum, or if
they are impacted by varied expression levels of DA autoreceptors.
Stimulation of D2 receptors on presynaptic terminals results in feedback
inhibition, reducing extracellular levels of DA via regulation of DA synthesis and release
(19, 20). Additionally, there is evidence that implies the DA D3 receptor also regulates
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DA release in terminal regions such as the NAc (108, 152, 153). Importantly, the
anatomical distribution of the D2 and D3 receptors is very distinct. Specifically, the D3
receptor shows localization in the mesolimbic pathway, including the NAc, Islands of
Calleja, and olfactory tubercles (20, 154, 155). The highest levels of this receptor in the
striatum appear to occur in the NAc shell, not the core (36, 156). In contrast, evidence
suggests that the DA D2 receptors are more homogeneously distributed throughout the
striatum (157, 158).
There is intense interest in characterizing the functional effects of DA D2 and D3
agonists because of their potential therapeutic involvement in diseases such as
schizophrenia and Parkinson’s. However, a major problem with characterizing these
agonists is their lack of selectivity for a given receptor. The development of D2 and D3
receptor knockout animals has facilitated the characterization and classification of D2
and D3 receptor agonists. Both microdialysis and voltammetric techniques have been
used to examine D2-like agonists in D2 and D3-receptor knockout mice (70, 80, 123,
125, 159). However, conflicting neurochemical results obtained in these experiments,
which used D2 or D3 knockout mice, highlight a concern with respect to using knockout
mice: lifelong constitutive reduction could easily alter other facets of the DA system,
which may make it more difficult to characterize selective D2-like agonist as either D2 or
D3 specific (123, 159). Therefore, it is critical to develop new strategies to better identify
the functional properties of potential D2 and D3 agonists.
Current tools to evaluate DA D2 and D3 presynaptic receptor function include
microdialysis, voltammetry, and magnetic resonance imaging (MRI) (67, 71, 80, 118).
Typically, microdialysis is used in neurochemical studies because of its ability to sample
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numerous neurotransmitters and provides greater sensitivity of these baseline levels.
However, the limitation with using microdialysis to characterize DA autoreceptor
function is its poor temporal resolution and inability to discriminate sub-anatomical brain
regions such as the NAc core from shell, especially in mice. Recently, Chen et al.
demonstrated that pharmacological MRI is a valuable tool for characterizing DA
receptor function, because it is a non-invasive technique that allows for multiple,
simultaneous measurements in a variety of brain regions and provides the ability to
perform longitudinal studies (118). However, few labs have the expertise or MRI
equipment to perform these studies. On the other hand, voltammetry has been used
routinely in vitro and in vivo to characterize the functionality of DA receptors (70, 71, 76,
82, 124-126, 160). The advantages of using voltammetry are its’ fast temporal
resolution (100 ms), which allows for the measurements of both release and uptake in
the presence of D2-like agonists, and the small size of the carbon fiber microelectrodes,
which allows for sampling from discrete sub-anatomical regions such as the NAc core
versus shell. Additionally, it is well established that D2-like agonists mediate DA
release, and there is increasing evidence that D2 like autoreceptors may mediate DA
uptake (152, 161-166). Thus, voltammetry is particularly useful to characterize both of
these parameters that are influenced by DA agonists.
This study characterized the functional effects of DA D2 and D3 receptor
agonists in the CPu, NAc core, and shell. Fast scan cyclic voltammetry (FSCV) with a
carbon fiber microelectrode (~ 7 µm in diameter) was used, allowing for discrete
anatomical detection of electrically stimulated DA. We have decided to use in vitro
FSCV (slice FSCV) experiments to eliminate contributions from the DA cell bodies.
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Commercially available D2, D3, or mixed D2/D3 agonists (e.g. quinpirole, 7-OH-DPAT,
and (+)-PD 128907) were used to evaluate autoreceptor function (70, 76, 124, 159, 160,
167). The effect of B-HT 920 was also examined, because it is a reported DA D2
agonist, but with very limited use in voltammetry and microdialysis studies (85).
Although there are many voltammetric studies that have examined autoreceptor
functionality, to our knowledge this is the first reported study that examines anatomically
distinct brain regions to characterize D2-like agonists as either selective D2 or D3
agonists, or mixed D2/D3 agonists (70, 71, 76, 124-126, 160). The results here suggest
that the mode of action for DA agonists’ functionality can be specifically assigned based
upon their potency and efficacy within the discrete anatomical sub-regions. The utility of
this functional voltammetric assay will assist future characterization of selective agonists
that could be used as potential therapeutic agents.
3.2 Materials and methods
Male C57Bl/6 mice aged 8 – 16 weeks purchased from Jackson Laboratory were
used. Coronal brain slices containing DA rich regions of interest such as CPu and NAc
were prepared as described in Section 2.3. FSCV experiments to measure electricallyevoked DA release and uptake rates were performed as described in Section 2.4.
Briefly, after at least 3 stable DA baseline recordings (≥ 30 minutes), 0.001 – 10 µM DA
agonist solutions of (−)-quinpirole hydrochloride, (4aR,10bR)-3,4a,4,10b-tetrahydro-4propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride ((+)-PD 128907),
5,6,7,8-Tetrahydro-6-(2-propen-1-yl)-4H-thiazolo[4,5-d]azepin-2-amine

dihydrochloride

(B-HT 920) or (±)-7-hydroxy-2-dipropylaminotetralin hydrobromide (7-OH-DPAT) were
perfused over the slice for 30 minutes at a flow rate of 1 mL/min. The chemical
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structures of the DA D2 and D3 agonists are shown in Figure 3.1. A cumulative dose
response curve was chosen because John and Jones previously demonstrated that
cumulative concentrations of drugs do not affect release or uptake as compared to
applying only a single concentration of the drug (62). The effect of each drug
concentration was recorded for 30 minutes. In the reversing experiments both agonists
and antagonists were used. A single dose of the D2 or D3 agonist (300 nM) was
perfused over the slice for 30 minutes. Then to determine if the antagonist could reverse
the effects of the agonist, 10 µM of (S)-(-)-sulpiride or nafadotride (Figure 3.1) was
perfused over the slice immediately after the agonist for 30 minutes. The peak oxidation
current for DA was converted into concentration from a post electrode calibration with 3
µM DA as described in Section 2.4.4. Current versus time plots were analyzed as
described in Section 2.4.5 to determine electrically stimulated DA release and uptake
rates.
3.2.1 Chemicals
All of the DA agonists and antagonists were purchased from Tocris Bioscience
(Ellisville, MO) except quinpirole, which was purchased from Sigma-Aldrich (St. Louis,
MO). All solutions of the drugs and DA were diluted in the aCSF from stock solutions.
3.2.2 Statistical data analysis
All statistical analyses were carried out using GraphPad Prism. Data are shown
as means ± standard errors of the means (SEMs) of at least five brain slices, derived
from different animals. When DA agonists were used the change in the current versus
time profile was evaluated as a change in [DA]p, which represents the inhibition of DA
release via the D2-like autoreceptors. This change in electrically stimulated DA release
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Figure 3.1 Chemical structures of the dopamine D2 and D3 receptor agonists and
antagonists.
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was compared to pre-drug values (each animal served as their own control), leading to
a percent change in stimulated DA efflux. Using GraphPad Prism, the dose response
curve was plotted as a log concentration (M) of agonist versus percent of baseline
(maximal stimulated DA release); the data was fitted using a non-linear regression
curve fit to determine half maximal effective concentration (EC50). The log EC50
obtained after administration of DA D2 or D3 agonists were subjected to a one-way
ANOVA with Tukey post-test by comparing CPu, NAc core, and shell. Effect of DA D2
or D3-like agonists on DA uptake was analyzed using a one-way ANOVA with Dunnett's
post-test by comparing pre-drug Vmax values to DA agonist treatment. In all cases,
statistical significance was defined as P < 0.05.
3.3 Results and Discussion
3.3.1 Effect of dopamine D2 agonists on electrically stimulated dopamine
DA autoreceptors regulate the extracellular levels of DA through a negative
feedback mechanism in which increasing agonist concentration results in a reduction in
extracellular DA. The most common method for evaluation of DA receptor density is
autoradiography, which employs the use of radioactive ligands to quantify receptor
levels (119-122, 158). Within the striatum (including the CPu and NAc), it is well known
that the D2 density is fairly homogeneous, while the D3 receptor density is greatest in
the NAc shell region (17, 155, 158, 168, 169). The striatum was chosen as the region of
interest to take advantage of this divergent D2 and D3 receptor distribution in order to
better differentiate D2 and D3 receptor agonists and antagonists. Using FSCV, the
activity of DA release-regulating autoreceptors was evaluated in the dorsal CPu, and
separately in the core and the shell of the NAc. In all brain regions evaluated, increasing
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concentrations of the D2 or D3 receptor agonists (0.001 – 10 µM) were added to slices
at 30-minute intervals. Upon addition of each agonist, a plateau in DA release was
reached within 15 – 25 minutes. The peak DA release was determined during this
plateau and expressed as a percent of the pre-drug (control) concentration.
The two D2 agonists, quinpirole and B-HT 920, were evaluated by first examining
their effects on DA release stimulated by a single electrical pulse in the CPu, NAc core,
and NAc shell. Representative voltammetric traces of electrically evoked DA in the CPu
in the absence or presence of quinpirole (0.03, 0.1, and 1 µM) are shown in Figure
3.2A. The observed responses for these two agonists were nearly indistinguishable
(Figure 3.3). The amount of DA evoked before drug application was approximately 2 µM
(n = 10), 1 µM (n = 10), and 0.6 µM (n = 10) for CPu, NAc core, and NAc shell,
respectively. Similarly, the log EC50 values and corresponding EC50’s for B-HT 920 were
– 7.0 ± 0.2 (102 ± 32 nM, n = 5), – 7.1 ± 0.2 (82 ± 29 nM, n = 5), and – 7.2 ± 0.1 (70 ±
18 nM, n = 5) for CPu, NAc core, and shell, respectively. The EC50 values for quinpirole
and B-HT 920 are summarized in Table 3.1. No difference was observed for quinpirole
(one-way ANOVA (Tukey post-test); F2,19 = 0.60; P = 0.56) or B-HT 920 (F2,14 = 0.52; P
= 0.61) between their EC50 values in the CPu, NAc core, or NAc shell. The results with
both D2 agonists show that DA D2 receptors have a fairly homogeneous expression
throughout the striatum (from the CPu to the NAc) as evidenced by similar functional
effects of D2 agonists on DA release across the striatum. Our results correlate with
autoradiography studies that have shown that DA D2 receptor density is fairly
homogeneous throughout the striatum (17, 155, 158, 168, 169).
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Figure 3.2 Representative concentration versus time plots showing the concentration
dependent effects of agonist on stimulated DA efflux and uptake. (A) D2 agonist
quinpirole in the CPu and (B) D3 agonist 7-OH-DPAT in the NAc shell. Insets are
representative cyclic voltammograms.
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response relationship of D2 agonist, quinpirole (A) and B-HT
B
Figure 3.3 Concentration-response
920 (B) on inhibiting electrically stimulated DA efflux in the CPu ((■),
), NAc core (∆)
( and
shell (●).
). No difference was observed for quinpirole (one
(one-way
way ANOVA (Tukey post-test);
post
F2,19 = 0.60; P = 0.56) or B-HT
HT 920 (F2,14 = 0.52; P = 0.61) between their half maximal
effective concentrations (EC50) in the CPu, NAc core, or NAc shell.
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Table 3.1 Potency (EC50, nM) and efficacy (%) values for dopamine D2 and D3 agonists
in the striatum, determined using voltammetry.
Caudate putamen

Nucleus
accumbens core

Nucleus
accumbens shell

Drug

EC50 ±
SEM
(nM)

Mean ±
SEM
Efficacy
(%)

EC50 ±
SEM
(nM)

Mean ±
SEM
Efficacy
(%)

EC50 ±
SEM
(nM)

Mean ±
SEM
Efficacy
(%)

7-OH-DPAT

325 ± 119

48 ± 9

59 ± 9

23 ± 1

44 ± 8

19 ± 2

(+)-PD 128907

250 ± 77

43 ± 5

163 ± 47

36 ± 6

65 ± 12

29 ± 3

Quinpirole

114 ± 35

28 ± 6

66 ± 33

34 ± 6

69 ± 16

33 ± 4

B-HT 920

102 ± 32

18 ± 3

82 ± 29

28 ± 6

70 ± 18

30 ± 2

The reported efficacy values are at a dose of 1 µM for all agonists.
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3.3.2 Effect of dopamine D3 agonists on electrically stimulated dopamine release
The effect of the D3 agonists 7-OH-DPAT and (+)-PD 128907 on a single pulse
stimulated DA release was evaluated as described above for D2 agonists.
Concentrations of 7-OH-DPAT greater than 30 nM significantly reduced electricallystimulated DA release in all striatal regions (P < 0.0001). Representative voltammetric
plots of DA concentration versus time in the NAc shell in the absence and presence of
7-OH-DPAT (0.03, 0.1, and 1 µM) are shown in Figure 3.2B. Similar to the DA D2
agonists, dose response curves were analyzed by curve fitting analysis, which revealed
the potency (EC50) and efficacy of the DA D3 agonist to decrease electrically stimulated
DA release in the striatum. The log EC50 values and corresponding EC50s for 7-OHDPAT were – 6.5 ± 0.2 (325 ± 119 nM, n = 5) for CPu, – 7.2 ± 0.07 (59 ± 9 nM, n = 5)
for NAc core, and – 7.4 ± 0.09 (44 ± 8 nM, n = 5) for NAc shell. The log EC50 values and
corresponding EC50’s for (+)-PD 128907 were – 6.6 ± 0.2 (250 ± 77 nM, n = 5), – 6.8 ±
0.1 (163 ± 47 nM, n = 5), and – 7.2 ± 0.08 (65 ± 12 nM, n = 5) for CPu, NAc core, and
NAc shell, respectively. The EC50 values for 7-OH-DPAT are presented in Table 3.1.
Unlike the DA D2 agonists, the EC50 values for the D3 agonist 7-OH-DPAT were
significantly different across the brain regions in the striatum as analyzed with one-way
ANOVA (F2,14 = 7.0; P < 0.01; Figure 3.4A). A Tukey post-test revealed a significant
leftward shift toward lower values in the EC50 between the dorsal CPu and the NAc core
(P < 0.05) and the dorsal CPu to the NAc shell (P < 0.05). However, the Tukey posttest revealed no difference between the 7-OH-DPAT EC50 values in the core versus the
shell. This shift in EC50 values indicates that the DA D3 receptors function is higher in
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response relationship of D3 agonists 7
7-OH-DPAT
DPAT (A) and (+)(+)
Figure 3.4 Concentration-response
PD 128907 (B) on inhibiting electrically stimulated DA efflux in the CPu (■),
(
NAc core
(∆) and shell (●).
). The dose response curves across these striatal brain regions were
significantly different
nt for the D3 agonists, 7
7-OH-DPAT (F2,14 = 7.0; P < 0.01) and (+)-PD
(+)
128907 (F2,14 = 11.24; P < 0.01) as analyzed by a one
one-way
way ANOVA (Tukey post-test).
post
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the NAc (includes both the core and shell), suggesting higher DA D3 receptor density in
the NAc versus the CPu. These results are also consistent with autoradiography
experiments, which showed that the DA D3 density is greater in the NAc as compared
to the CPu (20).
The effect of the DA D3-preferring agonist (+)-PD 128907 on electrically
stimulated DA release was similar to that of 7-OH-DPAT. Increasing concentrations of
(+)-PD 128907 decreased electrically stimulated DA in a dose-dependent manner
(Figure 3.4B). The EC50 values for (+)-PD 128907 are summarized in Table 3.1. The
(+)-PD 128907 EC50 values across these striatal brain regions were significantly
different as analyzed by a one-way ANOVA (F2,14 = 11.24; P < 0.01). A Tukey post-test
revealed the EC50 values in the NAc shell exhibited the greatest shift to lower values as
compared to the CPu (P < 0.01) and NAc core (P < 0.05). However, the Tukey post-test
showed no difference between the EC50 values for (+)-PD 128907 in the CPu and NAc
core. Based on the EC50 values, 7-OH-DPAT and (+)-PD 128907 had significant but
different effects on the brain regions studied. The ability of these DA D3 agonists to
lower the concentration of stimulated DA was greatest in the NAc shell and least
effective in the CPu. This suggests regional difference in potency of these agonists to
inhibit electrically stimulated DA release, which may reflect D2/D3 receptor selectivity.
This is the first report that we are aware of that has compared the response of
DA agonist in sub-anatomical striatal brain regions to distinguish their selectivity for D2or D3-autoreceptors. Agonists for the DA D2 and D3 receptors, when perfused across a
slice, can bind and activate their respective receptors located on both pre- and postsynaptic surfaces. In this study, voltammetry was used to characterize DA release
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during agonist perfusion, however only presynaptic autoreceptors that regulate DA
release were evaluated. Shifts in voltammetric dose response curves are most often
associated with receptor functionality, but changes in receptor sensitivity and density
cannot be ruled out (160). Using slice FSCV, DA D2 and D3 agonists give distinct dose
response curves and EC50 values that are dependent on the brain region examined.
The dose response curves and EC50 of DA D2 agonists exhibit less variation across the
CPu, NAc core, and shell as compared to the more D3 selective agonists, which
demonstrated a significant shift to lower EC50s in their dose response curves and a
reduction in EC50 values from the CPu to the NAc shell. Additionally, the EC50 values
obtained from these voltammetry studies (for D2 and D3 agonists) directly correlate with
D2 and D3 receptor density, as measured by autoradiography (20, 119-122, 154, 155,
158). This correlation suggests that voltammetry can be used to determine receptor
density in different regions of the brain. Taken together, these results indicate that DA
D2 agonists are relatively more potent in the CPu than DA D3 agonists. These results
suggest that combining slice voltammetry and receptor localization may be a novel
method to characterize agonists as more D2- or D3-preferring.
3.3.3 The efficacy of dopamine D2 and D3 agonists
The relative maximum response of DA D2 and D3 agonists in the dorsal and
ventral striatum were used to determine if there was a difference in efficacy between
these agonists across these regions. In order to directly compare the maximum
inhibition of each of the agonists for decreasing DA release, the efficacy of each agonist
at a concentration of 1 µM was compared. This concentration was chosen to evaluate
drug efficacy because all drugs respond to this agonist concentration. This comparison
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was used to determine the relative activity of each agonist to decrease DA release in
each of these brain regions, which we believe reflects the preference of these drugs to
activate D2 or D3 receptors. This comparison was conducted for each brain region and
the efficacies are expressed as percent of the drug effect relative to the pre-drug value
(Table 3.1). Thus, a low percentage reflects high efficacy for the given agonist.
The DA D3 agonists exhibited the highest efficacy (greatest inhibition of
electrically stimulated DA release) at 1 µM in the NAc shell, with 19 ± 2% and 29 ± 3%
maximal stimulated DA release as a percent of pre-drug values (defined as a 100%) for
7-OH-DPAT and (+)-PD 128907, respectively. The DA D3 agonists in the CPu showed
an efficacy of 48 ± 9% for 7-OH-DPAT and 43 ± 5% for (+)-PD 128907, which suggests
that the D3 agonists have the ability to decrease DA release, but when compared to the
ability of D2 agonists, do not produce a maximum effect at this concentration. In
contrast, but consistent with the homogenous distribution of the D2 receptor, the
efficacy of D2 agonist quinpirole was approximately the same across the different brain
regions, 28 ± 6% for CPu, 34 ± 6% for NAc core, and 33 ± 4% for NAc shell. As for
quinpirole, B-HT 920 exhibited a similar effect with values of 18 ± 3%, 28 ± 6%, and 30
± 2% for the CPu, NAc core, and shell, respectively.
3.3.4 Effect of dopamine D2 and D3 agonists on dopamine uptake in the striatum
The main mechanism by which D2 and D3 agonists regulate extracellular DA
levels is by inhibiting DA release, although D2 receptors are also known to influence DA
synthesis as well. However, there is considerable evidence indicating that both DA D2
and D3 receptors regulate DA transporter function (108, 152, 161-166). If DA D2 or D3
agonists modulate the activity of the DA transporter, then this would suggest another
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mechanism for these agonists to regulate extracellular DA levels. Many of the initial
findings that linked the ability of DA D2 and D3 agonists to modulate Vmax of the DA
transporter used rotating disk voltammetry or chronoamperometry (108, 163, 166). An
advantage of using electrochemical techniques is their rapid data collection rate, which
is on the order of seconds and therefore provides the temporal resolution to discriminate
differences in uptake rates. The objective of the following experiments was to evaluate
DA uptake rates in the presence of increasing concentrations of DA D2 and D3
agonists.
As described in Section 2.2.5, the Michaelis-Menten based kinetic model was
used to evaluate release ([DA]p) and uptake kinetics (Vmax and Km). When analyzing DA
current versus time plots, Km values were fixed at 0.16 µM, allowing for manipulation of
DA peak amplitude (release) and DA uptake (Vmax) in the presence or absence of a DA
D2 or D3 agonist in striatal regions (139, 140). The effect of 0.001, 0.01, 0.03, 0.1, 0.3,
1, 3, and 10 µM of quinpirole, B-HT 920, 7-OH-DPAT, or (+)-PD 128907 on DA uptake
was evaluated. The results show a significant decrease in Vmax in the presence of D2 or
D3 receptor agonist only in the CPu and at very high concentrations of the agonist
(quinpirole: F7,90 = 13; P < 0.0001; B-HT 920: F8,71 = 8.9; P < 0.0001; 7-OH DPAT: F8,117
= 4.8; P < 0.0001; (+)-PD 128907: F7,66 = 16; P < 0.0001; Figure 3.5).
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Figure 3.5 Effect of dopamine (DA) D2 and D3 agonist concentrations on electrically
evoked DA uptake rates in the caudate putamen (CPu). (A) quin
quinpirole,
pirole, (B) B-HT
B
920,
(C) 7-OH-DPAT, (D) (+)-PD
PD 128907. Each concentration
concentration-uptake
uptake rate curve was
analyzed with one-way
way ANOVA (** P < 0.01; *** P < 0.001).
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No difference (one-way ANOVA (Dunnett's test)) in DA uptake rates was
observed in the NAc core (F6,38 = 0.67; P = 0.67) or shell (F7,79 = 1.9; P = 0.085) (Figure
3.6 parts A and B) with increasing concentration of quinpirole. Similarly, increasing
concentrations of the D2 agonist B-HT 920 did not affect DA uptake rates in the NAc
core (F7,50 = 2.2; P = 0.057), and shell (F7,50 = 2.1; P = 0.062), as shown in Figure 3.6
parts C and D, respectively. DA uptake rates were also evaluated in the absence and
presence of the D3 agonist, 7-OH-DPAT or (+)-PD 128907. Similar to the DA D2
agonists quinpirole and B-HT 920, DA uptake rates were not significantly different in the
NAc when increasing concentrations of 7-OH-DPAT or (+)-PD 128907 were added to
the slices, NAc core [7-OH-DPAT: (F7,72 = 0.67; P = 0.69); (+)-PD 128907: (F7,46 = 1.7; P
= 0.15)] shown in Figure 3.7 parts A and C, respectively or NAc shell [7-OH-DPAT:
(F6,105 = 1.4; P = 0.23); (+)-PD 128907: (F7,110 = 1.6; P = 0.14)] shown in Figure 3.7 parts
B and D, respectively.
Our results from mouse brain slices show only a decrease in Vmax at the highest
concentrations of agonists applied in the CPu. However, previous electrochemical
studies reported an increase in DA clearance in the presence of a D2 agonist, and a
decrease in DA clearance by D2-like receptor antagonist (163, 166, 170). However,
these data are not conclusive because Dickinson et al. reported no difference in DA
clearance in the presence of raclopride, a known D2 antagonist (80). These previous
studies, which evaluated the effect of DA agonists or antagonists on DA clearance, did
not use FSCV, but other electrochemical methods.
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Figure 3.6 Effect of the dopamine (DA) D2 agonist concentration on DA uptake in
nucleus accumbens (NAc). Specifically, the effects of quinpirole on the NAc core (A)
and NAc shell (B), and B-HT
HT 920 on the NAc core (C) and NAc shell (D).
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Figure 3.7 Effect off the dopamine (DA) D3 agonist concentration on DA uptake in
nucleus accumbens (NAc). Specifically, the effects of 7
7-OH-DPAT
DPAT on the NAc core (A)
and NAc shell (B), and (+)-PD
PD 128907 on the NAc core (C) and NAc shell (D).
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The discrepancy in uptake rates between our results and these previous studies
could be a result of different experimental parameters used in FSCV as compared to
chronoamperometry or rotating disk voltammetry, such as brain slices versus an intact
system (in vivo), or inducing DA depolarization by employing one pulse stimulation
(endogenous DA release) versus applying exogenous DA. Interestingly, most FSCV
experiments that measure the effect of D2-agonists on DA peak amplitude do not report
uptake rates (67, 69-71, 73, 76, 82, 102). This approach is most likely due to an a priori
assumption that only electrically stimulated DA release (or DA amplitude) has been
altered in the presence of agonists (126). A study by Joseph et al. measured the DA
uptake rate using FSCV, and in the presence of quinpirole noted that the uptake rate in
CPu was not different (70). Joseph et al. suggested that alterations in DA uptake
kinetics are not observed because (1) DA uptake rates are maximally accelerated or (2)
temporal resolution of FSCV is not adequate to resolve these elevated DA uptake rates
(70).
DA transporter activity is regulated by either receptors or second-messenger
linked signal transduction pathways. Briefly, activation of protein kinase C (PKC),
extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phosphatidylinositol-3kinase (PI3K) have all been shown to influence DA transporter activity (171-173).
Although voltammetric studies suggest modulation of DA transport via DA receptors,
only recently have the second-messenger pathways between DA receptors and
transporters been examined (152, 162, 165). Specifically, Bolan et al. demonstrated that
D2 receptor activation enhanced cell surface expression of the DA transporter by
ERK1/2 (162). Additionally, Lee et al. demonstrated a direct protein-protein interaction
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between the D2 receptor and the DA transporter, and this direct physical coupling
promoted DA transporter expression to the cell surface (165). For example, an increase
in Vmax was observed with no difference in Km (165). In a subsequent study, acute D3
receptor activation was shown to modulate DA transporter activity by both ERK1/2 and
PI3K, but prolonged D3 receptor activation induced a reduction in the cell surface DA
transporter expression (152). In our study, cumulative dose response curves were used
to evaluate the DA uptake rate and as a result, the slice was bathed with an agonist for
at least 2 hours before concentrations greater than 0.3 µM are applied. Our agonist
results suggest low concentrations do not influence DA uptake rate, which may
represent acute activation. However, a combination of prolonged exposure and agonist
concentrations greater than 0.3 µM do demonstrate a significant decrease in DA uptake
rate in the CPu, in agreement with previous findings (152). Because this decrease in DA
uptake rate was observed with both D2 and D3 agonists, we speculate that a possible
mechanism for receptors regulating transporter expression and/or function may be
through the ERK1/2 pathway. However, future studies would have to assess this
proposed mechanism.
The fact that DA uptake rate is influenced only by high concentrations of agonist
in the CPu, while no difference in uptake is observed in the NAc core and shell suggests
that this may be a brain region specific phenomenon. The DA transporter density within
the striatum is known to vary depending on the sub-anatomical location, with the CPu
having the greatest density of DA transporters, while the NAc core and shell have
considerably less (90, 96, 148, 149). We hypothesize this lack of agonist effect on DA
uptake rate in the NAc may be a result of fewer DA transporters as compared to the
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CPu. The density of DA transporters is reduced in the NAc as compared to the CPu,
while D2-like receptor density remains the same or is increased in the NAc. Taken
together, these data suggest fewer DA transporters are coupled and/or are not
responsive to D2-like receptor agonists in the accumbens. Hence, no effect of these
agonists in the NAc core or shell is observed versus the CPu.
3.3.5 Effect of dopamine antagonists in the CPu
DA D2 and D3 receptor antagonists block their respective receptors and activate
DA synthesis and release in presynaptic terminals (174-176). To demonstrate
reversibility of the electrically evoked DA signal, an antagonist was applied to brain
slices immediately after agonist application. The objective was to determine if DA D2like and D3 antagonists can selectively reverse their respective agonist response. The
CPu was chosen as the brain region to characterize these antagonist effects, because it
is known to exhibit the greatest discrepancy between DA D2 and D3 receptor levels. In
these studies only one concentration of the DA D2 or D3 receptor agonist (300 nM) was
applied to the slice. This agonist concentration was chosen based on the dose response
curves that we generated demonstrating approximately 40 – 60% decrease in the DA
release. Immediately after agonist application, a non-selective DA D2 or selective D3
antagonist (10 µM) was applied to the slice. As shown by Schmitz et al., even after a ten
minute perfusion with 500 nM of quinpirole the DA peak amplitude as recorded by
FSCV was attenuated for at least an additional 22 minutes after the removal of
quinpirole, demonstrating the response of the agonist was not washed out when the
buffer was changed to aCSF (125). Immediately after quinpirole either sulpiride (a nonselective DA antagonist) or nafadotride (a selective DA D3 antagonist) was perfused
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over the slice. The D2 agonist effect in the CPu was reversed fully only by the sulpiride
(Figure 3.8A), while nafadotride increased electrically stimulated DA levels to
approximately 70% of the pre-drug value (Figure 3.7B). Hence, the D3 antagonist had
the ability to increase maximal stimulated DA release by only 10% in the CPu. Similarly,
after 7-OH-DPAT perfusion in the CPu, an approximately 40% decrease in the
electrically stimulated DA response was observed. However, upon perfusion of sulpiride
or nafadotride the electrically stimulated DA response returned to pre-drug levels
(100%; Figure 3.8 parts C and D). Thus, it appears that the effect of a DA D2 agonist is
only reversible after infusion of a non-selective D2 antagonist, suggesting that
nafadotride is acting primarily at either available DA D3 receptors within the CPu, where
there is low density of these receptors present, or alternatively, nafadotride is elevating
DA levels by interacting at available DA D2 receptors (20, 154, 155).
However, we believe that nafadotride is not acting at the D2 receptors because
with the application of such a high concentration (10 µM), we would expect to observe a
greater response due to the higher D2 receptor functionality and/or density present
within the CPu. Nafadotride is unable to fully reverse the effect of quinpirole because of
the lower abundance of D3 receptors available within this brain region, and the
levoisomer of nafadotride is known to have a greater affinity to the DA D3 receptors
than to the D2 receptors (177). Within the CPu, we have demonstrated that sulpiride
can fully reverse the effects of quinpirole, while nafadotride is unable to reverse these
effects. Because only the non-selective DA antagonist reversed the agonist response,
this further supports the hypothesis that the DA D2 receptors are more functional in the
CPu than the D3 receptors.
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Figure 3.8 Effect of 300 nM quinpirole reversed with 10 µM sulpiride or partially
reversed by nafadotride (A and B, respectively) or 7
7-OH-DPAT
DPAT reversed with 10 µM
nafadotride or sulpiride (C and D, respectively) on electrically evoked dopamine in
dorsal CPu (n = 3 for each trial).
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However, when the DA D3 agonist 7-OH-DPAT is applied to the CPu, both
antagonists, sulpiride and nafadotride, reverse the DA response. The ability for both
antagonists to reverse the DA D3 agonist is a result of sulpiride being a non-selective
DA antagonist, with a high affinity for D2 and D3 receptors. As a result of sulpiride’s
promiscuity, it is able to reverse the effect of the D3 agonist in the CPu. Previous work
using slice FSCV showed that higher concentrations of sulpiride and similar nonselective DA antagonists like clozapine and haloperidol had the ability to attenuate the
7-OH-DPAT-induced inhibition of electrically stimulated DA release in the NAc core
(76). Our results with quinpirole-sulpiride and 7-OH-DPAT-sulpiride demonstrate that
sulpiride is indeed a non-selective DA antagonist with high affinity for both the D2 and
D3 receptors. In order to demonstrate exclusive receptor reversibility of the D3 receptor
in the CPu, a very selective D2 antagonist would need to be applied. Unfortunately,
many of the classic antipsychotic DA antagonists are not very selective.
The D3 antagonist nafadotride is described as a highly potent, preferential D3
antagonist. When an excess of nafadotride is applied to the CPu, it easily reverses the
agonist effects. This reversal is most likely a result of its ability to compete with 7-OHDPAT for available DA D3 receptors. Additionally, based on the results with quinpirolenafadotride in the CPu (Figure 3.7B), it appears that nafadotride is not very effective at
activating the DA D2 receptor, suggesting that nafadotride is a more selective D3
receptor antagonist. Taken together, these agonist-antagonist treatments suggest that
within the CPu a non-selective DA antagonist in excess concentration can easily
reverse the inhibition of D2- and D3-receptor agonists, but a selective D3 antagonist
can reverse only the effects of a D3 agonist.
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3.4 Conclusions
The results presented here demonstrate that the striatal region of the brain can
be used as a tool to determine whether or not agonists are selective for D2- or D3autoreceptors. The advantage of studying these effects in the striatum is the distinct
localization of D2 and D3 receptors. Using slice FSCV we demonstrated that the D2
receptor functionality is uniform in the striatum. Specifically, commercially available D2
agonists (quinpirole and B-HT 920) showed similar EC50 values throughout the striatum.
However, the D3 receptor functionality is localized in the NAc shell. More specifically,
DA agonists with more D3-like properties (7-OH-DPAT and (+)-PD 128907
demonstrated a significant leftward shift in their dose response curves, which
correspond with a reduction in EC50 values from the dorsal CPu to the NAc shell. Our
results, which examine autoreceptor function, complement the autoradiography work
that has mapped the distribution of DA D2 and D3 receptors. Although FSCV cannot
distinguish receptor density from sensitivity, these results demonstrate a simple and fast
method for determining DA functionality with D2 and D3 receptors. We believe that by
exploiting the unique receptor density within the striatum, voltammetry may be used as
a tool to characterize D2-like agonists as either D2- or D3-preferring. Mapping these
receptors can offer powerful insight into the neuropathology of disorders involving these
receptors, as well the mode of action of pharmacological agents.
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CHAPTER 4
Aberrant Striatal Dopamine Dynamics in Brain-Derived Neurotrophic
Factor-Deficient Mice
(Portions from Bosse, Maina, et al., Accepted in Journal of Neurochemistry)
4.1 Introduction
As a trophic factor, brain-derived neurotrophic factor (BDNF) plays an important
role in neurogenesis, survival, growth, and synaptic plasticity of neurons to ensure
normal development and maintenance of the adult mammalian brain (21, 22, 178, 179).
BDNF is one of the most abundant neurotrophic factors in the mammalian brain with the
highest levels of mRNA and protein occurring in the hippocampus, substantia nigra
(SN), ventral tegmental area (VTA), and frontal cortex (24, 180). For example, within the
VTA approximately 90% of the dopaminergic neurons contain BDNF mRNA (181). Both
anterograde and retrograde transport of BDNF is known to occur in the midbrain
dopamine (DA) neurons. Anterograde transport involves axonal movement of BDNF
from cell bodies in the midbrain to nerve terminals in the striatum (24, 180). Besides
anterograde transport, corticostriatal glutamate afferents are known to supply BDNF to
the DA rich striatum (24, 180). Released BDNF interacts with its receptor tyrosine
kinase B (TrkB) locally causing rapid physiological effects on neuronal transmission by
activating downstream signaling pathways (see Section 1.2.3).
In cultured cells, BDNF increases the density of tyrosine hydroxylase (TH)positive fibers (a marker of DA neurons), DA release, and uptake rates (182-184). In
brain slices, exogenous BDNF is known to increase the turnover ratio between DA and
its catabolite 3,4-dihydroxyphenylacetic acid (DOPAC) as well as potentiating the
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activity-dependent release of DA (29-31). In organotypic brain slice cultures of rat
hippocampus, BDNF enhances quantal neurotransmitter release by increasing the
number of docked synaptic vesicles within presynaptic terminals (185).
The role of BDNF is critical for an organism’s survival because mice lacking
BDNF (null mutants; BDNF-/-) exhibit impaired motor function/coordination and do not
survive beyond three weeks of age (34, 186). The BDNF-/- mice have a reduced number
of vesicles docked at presynaptic active zones, as well as reduced long-term
potentiation (LTP) in the hippocampus as compared to wildtype mice (187). Mice that
have been engineered to have reduced endogenous BDNF levels appear to be
hyperactive, a phenotype that is often associated with a dysregulation of the
nigrostriatal DA system (34, 188). Accordingly, numerous studies have highlighted that
BDNF heterozygous (BDNF+/-) mice exhibit increased tissue DA concentrations
(reflective of intracellular levels) in the striatum, as well as decreased DA release in
superfused striatal tissue fragments (35, 189). Furthermore, BDNF conditional knockout
mice show reduced electrically evoked DA release in the caudate putamen (CPu) and
nucleus accumbens (NAc) shell, but not in the core as measured by amperometry (39).
Taken together, these studies suggest that BDNF can augment striatal DA function in a
region-specific manner, but the mechanism of how BDNF modulates DA function
remains elusive.
BDNF appears to modulate DA release-regulating receptors. BDNF-/- and
BDNF+/- mice have reduced DA D3 receptor levels in the CPu, NAc core and shell, and
the Islands of Calleja (36-38). A recent study in BDNF conditional knockout mice also
shows altered DA D2 receptor expression in the CPu (39). However, others have
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reported that BDNF deficiency in mice does not alter the expression of DA D2
receptors, TH, or the DA transporter (37, 133). Furthermore, it has been hypothesized
that, in the NAc, BDNF regulates expression of DA D3 receptors and not extracellular
DA levels (188). Taken together, these results suggest that reduced BDNF levels can
regulate the DA system. Our general hypothesis is that BDNF strongly regulates many
facets of DA transmission in the striatal complex.
BDNF hypofunction has been linked to numerous DA related neurological
diseases, such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease,
schizophrenia, attention deficit hyperactivity disorder (ADHD), addiction, and depression
(42, 46, 53, 54, 112, 113, 115-117, 190). Understanding the role of low, endogenous
BDNF levels in modulating presynaptic DA dynamics will provide critical information that
may lead to better treatment options for these neurological diseases. The main
objective of this study was to understand how BDNF modulates the DA system in the
striatal complex that can be divided into three discrete brain regions that include the
CPu, NAc core and shell (10). Complementary neurochemical methods such as slice
fast scan cyclic voltammetry (FSCV) and in vivo microdialysis (performed by Kelly
Bosse, Ph.D.) were used. Slice FSCV provides real-time (every 100 ms) measurement
of presynaptic dynamics such as DA release and uptake in brain slices. Inherent
advantage of FSCV is that it employs microelectrodes (diameter ~ 7 microns) that
provide good spatial resolution to probe the DA system in sub-anatomical regions of the
striatum (NAc core and shell). The use of FSCV to evaluate the dopaminergic system
provides an opportunity to probe DA autoreceptor functionality and the ability of
exogenous BDNF to influence presynaptic DA dynamics in wildtype and BDNF+/- mice.
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In vivo microdialysis in freely moving mice was used to measure extracellular basal
levels of DA by use of the zero net flux method, as well as extracellular levels of DA
catabolites DOPAC and homovanillic acid (HVA). Coupling microdialysis to HPLCelectrochemical detection provides the sensitivity to measure the low levels of
extracellular DA in the brain. Finally, brain tissue analysis was performed to evaluate
the effect of low BDNF levels on DA synthesis by measuring the accumulation of LDOPA, the DA synthesis precursor.
4.2 Materials and methods
Wildtype and BDNF+/- mice offspring were raised as a colony in house and
genotyped as described in Section 2.2. BDNF protein levels in BDNF+/- mice are ~ 50%
less compared to those in wildtype mice, as quantified using enzyme-linked
immunosorbent assay (ELISA) in our laboratory (142). Male BDNF+/- and wildtype mice
aged 8 – 16 weeks were used for in vivo microdialysis, slice FSCV, and L-DOPA tissue
content experiments.
4.2.1 In vivo microdialysis
Kelly Bosse, Ph.D. performed all the microdialysis experiments on adult mice with the
assistance from Marion France. The microdialysis experiments conducted by Dr. Bosse
involved stereotaxic surgery, probe implantation, sample collection, HPLC separation
with electrochemical detection, chromatographic analysis, statistical data analysis, and
graphing. Analyses of L-DOPA content in the tissue was performed by Kelly E. Bosse,
Ph.D. with assistance from Joseph Roberts.
In vivo microdialysis experiments were performed as described in Section 2.5.
Briefly, a microdialysis probe was inserted through a guide cannula implanted in the
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CPu of mice during stereotaxic surgery. Following overnight perfusion of the probe with
artificial cerebrospinal fluid (aCSF) at a flow rate of 0.4 µL/min, dialysate samples were
collected every 20 minutes at a flow rate of 1.1 µL/min from freely moving mice. The
dialysate was analyzed for DA, DOPAC, and HVA using HPLC separation and
electrochemical quantification (Section 2.6). The zero net flux technique (Section 2.5)
was utilized to estimate basal extracellular levels of DA in the CPu (103, 143). A second
set of experiments, examined extracellular DA levels after a local perfusion with a high
K+ aCSF that induces neuronal depolarization and vesicular-mediated release (Section
2.5). L-DOPA accumulation was measured by tissue content analysis in both genotypes
as described in Section 2.7.
4.2.2 Slice FSCV
Slice FSCV experiments were performed as previously described in Section 2.4
with minor modifications. Electrically stimulated (350 µA, 60 Hz, 4 ms wide) DA release
and uptake rates following single or multiple (5) pulse stimulation were evaluated in the
CPu, NAc core, and NAc shell. Additionally, the effect of exogenous BDNF perfusion on
DA release and uptake rates in the CPu was evaluated. BDNF was dissolved in
oxygenated aCSF to a final concentration of 100 ng/mL. Upon obtaining stable baseline
recordings, BDNF (PeproTech inc., Rocky Hill, NJ) was perfused (1 mL/min flow rate)
over a slice from BDNF+/- or wildtype mice for 30 minutes and DA recordings were made
every 5 minutes. BDNF activity was inhibited by perfusing the slice with 1 µM K252a
(Figure 4.1), a TrkB receptor antagonist (Tocris Bioscience, Ellisville, MO). Following
the 30 minute perfusion with K252a, the same slice was perfused with 100 ng/mL BDNF
for another 30 minutes with DA recordings every 5 minutes. Dose-response plots for DA
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Figure 4.1 Chemical structure of K252a, tyrosine kinase B inhibitor.
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release and uptake rates were also generated with both BDNF (50, 100, and 200
ng/mL) and K252a (0.1 0.3, 1 and 3 µM). Each concentration was perfused over a slice
for 30 minutes.
To assess DA D2 and D3 autoreceptor functionality, the DA D3 receptor agonist
7-OH-DPAT or DA D2 receptor agonist quinpirole was perfused with cumulative
concentrations (0.001 – 10 µM) at a flow rate of 1 mL/min following stable baseline
recordings. The log of the concentration of the agonists plotted against normalized
concentration of DA to obtain a dose-response curve for each genotype, from which the
corresponding EC50 values were obtained. Previous findings from Sections 3.3.1 and
3.3.2 suggest that D2 autoreceptor functionality is homogenous across the striatal
regions whereas D3 autoreceptor functionality is greatest in the NAc shell (94).
Therefore, D2 autoreceptor functionality was evaluated only in the CPu, whereas D3
receptor was evaluated in the NAc shell.
4.2.3 Data analysis
Kelly Bosse, Ph.D. performed all the data and statistical analyses of the microdialysis
results.
All values are reported as means ± standard errors of the means (SEMs) of at
least four different animals, with and the statistical significance defined as P < 0.05.
Zero net flux data were analyzed by linear regression to determine the x-intercept
(DAext) and slope (Ed) for individual wildtype and BDNF+/- mice. Differences in DAext
between genotypes were determined by a two-tailed Student’s t-test. Differences in high
K+-stimulated extracellular DA levels were assessed using a two-way ANOVA with
genotype as the independent variable and time as the repeated measure. Bonferroni
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multiple comparison analysis was used for post-test. Area under the DA concentration
curve was calculated from the four 20-minutes samples following high-K+ perfusion
(from 80 to 140 minutes) using the trapezoidal method (GraphPad Prism software).
Data are reported as area under curve (AUC) in arbitrary units ± SEMs, and statistical
significance was determined by Student’s t-test. Levels of L-DOPA were expressed in
ng and normalized to mg wet weight of brain tissue. Pair-wise comparisons using
Student’s t-test (two-tailed) were made to evaluate genotypic differences on DA release
per pulse ([DA]p) and uptake rate (Vmax) evaluated with FSCV, L-DOPA tissue
accumulation, and extracellular catabolite levels (DOPAC and HVA). When five-pulse
stimulation was used in FSCV, the AUC of the current versus time plots was used to
determine DA release by normalizing the data obtained from one electrode placement
as a ratio of AUC (5p)/ AUC (1p). Two-way ANOVA with Bonferroni post-test was used
to test the interaction between genotype and treatment (BDNF perfusion) or region
(multiple pulse effect) on DA release with FSCV. One-way ANOVA (Dunnett’s post-test)
was used to determine the dose dependent effect of BDNF or K252a on DA release and
uptake rates. Additionally, Student’s-t test (two-tailed) was used to evaluate the
genotype difference in autoreceptor functionality when quinpirole or 7-OH-DPAT was
perfused on brain slices. Effect of quinpirole or 7-OH-DPAT treatments on DA uptake
rate was evaluated using a one-way ANOVA with Tukey post-test, where means were
compared to the pre-drug values.
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4.3 Results
4.3.1 Basal and stimulated extracellular concentrations of dopamine in the CPu
Microdialysis results were obtained by Kelly E. Bosse, Ph.D.
To determine the impact of low endogenous levels of BDNF on DA dynamics,
basal and K+-stimulated extracellular DA concentrations were evaluated using in vivo
microdialysis in the CPu of BDNF+/- mice. The basal concentrations of extracellular DA
were estimated with the zero net flux method (Figure 4.2). This quantitative
microdialysis technique approximates relative “in vivo” probe recovery using extraction
fraction (Ed) values determined from the slopes of the zero net flux regression lines
(143). The extraction fraction is considered to be a measurement of transportermediated uptake and often changes in Ed values are thought to be reflective of
alterations in neurotransmitter uptake (86). Apparent extracellular DA levels, corrected
for recovery, were significantly higher in BDNF+/- mice (12 ± 0.4 nM, n = 6) as compared
to wildtype (5 ± 0.2 nM, n = 6, P < 0.001; Figure 4.2, inset). However, average Ed values
were not different between the wildtype (0.21 ± 0.04) and BDNF+/- (0.23 ± 0.02) mice.
Genotypic differences in non-specific, depolarization-mediated DA transmission
were also assessed using microdialysis. In line with the zero net flux data, BDNF+/- mice
exhibited elevated mean baseline concentrations of extracellular DA (2.3 ± 0.2 nM, n =
12, averaged from three samples) compared to wildtype mice (1.2 ± 0.2 nM, n = 12, P <
0.001) as measured by conventional microdialysis. A 20 minute perfusion of high-K+
(120 mM) aCSF through the microdialysis probe resulted in elevated extracellular
concentrations of DA (Figure 4.3). Two-way ANOVA analysis revealed a significant
main effect of time (F6,66 = 24.29), genotype (F1,66 = 11.83), and genotype x time
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Figure 4.2 Linear regression analysis of dopamine (DA) levels in the CPu of wildtype
(WT) and BDNF+/- mice determined by zero net flux. The xx-intercept
intercept (point of zero net
flux) represents an estimate
mate of basal extracellular DA levels (DAext). Inset shows the
mean ± SEM apparent DAext values (n = 6 mice per group). ***P < 0.001 compared to
WT mice (Student’s t-test). Figure courtesy of Kelly E. Bosse, Ph.D. and Tiffany A.
Mathews, Ph.D.
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Figure 4.3 Extracellular dopamine (DA) concentrations in the CPu of wildtype (WT) and
BDNF+/- mice following 20 minute perfusion of high-potassium (120 mM K+) aCSF. Data
are means ± SEM (n = 6 mice per group). *P < 0.05; ***P < 0.001, compared to WT
mice (two-way ANOVA). Inset shows the area under the curve (AUC) for the cumulative
increase in extracellular DA over four 20 min samples (80 – 140 min) following high-K+
perfusion. Data are mean AUC ± SEM. *P < 0.05 compared to WT mice (Student’s ttest). Figure courtesy of Kelly E. Bosse, Ph.D. and Tiffany A. Mathews, Ph.D.
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interaction (F6,66 = 3.44). These findings indicate that while high-K+ administration
increased dialysate DA levels in both wildtype and BDNF+/- mice, the extent of increase
was different with respect to genotype. Subsequent Bonferroni post-test results show
that the peak increase in DA following high-K+ stimulation in BDNF+/- mice (10-fold; 28 ±
6 nM) was potentiated relative to the increase observed in wildtype mice (6-fold; 14 ± 2
nM, P < 0.001). AUC analysis verified that BDNF+/- mice have a significantly greater
cumulative increase in dialysate DA following high-K+ perfusion as compared to wildtype
mice (P < 0.05; Figure 4.3, inset).
4.3.2 L-DOPA and catabolite concentrations in the CPu
Tissue content studies to determine L-DOPA levels were performed by Kelly E. Bosse,
Ph.D. with assistance from Joseph Roberts.
DA synthesis was determined by measuring the tissue accumulation of L-DOPA
in the CPu following inhibition of L-aromatic acid decarboxylase with NSD-1015. No
statistical difference was detected between the average striatal tissue levels of L-DOPA
in wildtype mice (380 ± 25 ng/mg wet weight (ww), n = 13) and BDNF+/- mice (430 ± 40
ng/mg ww, n = 11, P = 0.28; Figure 4.4A). DA catabolism was evaluated by measuring
the extraneuronal concentration of the DA catabolites, DOPAC and HVA, from baseline
dialysis samples.
The mean extracellular concentrations, determined from triplicate analysis, for
both DOPAC (wildtype: 410 ± 70 nM, n = 16; BDNF+/-: 330 ± 90 nM, n = 10, P = 0.66)
and HVA (wildtype: 465 ± 65 nM, n = 16; BDNF+/-: 560 ± 120 nM, n = 10, P = 0.47) were
also comparable across the two genotypes (Figure 4.4B). Together, these data indicate

94

Figure 4.4 Dopamine (DA) synthesis and catabolism in the caudate putamen (CPu) of
wildtype (WT) and BDNF+/- mice. (A) L-DOPA
DOPA tissue accumulation following treatment
with NSD-1015
1015 and GBL. Data are means ± SEMs and expressed as L-DOPA ng/mg
wet weight (ww) of tissue (n = 11 – 13 mice per group). (B) Extracellular concentration
of the DA catabolites DOPAC and HVA, as measured by microdialysis. Data are means
± SEMs of uncorrected baseline values (n = 10 – 16 mice per group). Figure courtesy of
Kelly E. Bosse, Ph.D. and Tiffany A. Mathews, Ph.D.
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that constitutive depletion of BDNF does not result in altered rates of DA synthesis or
catabolism.
4.3.3 Electrically evoked dopamine release and uptake rates in the striatum
FSCV was used to examine single pulse, electrically stimulated DA release and
uptake rates in the CPu and NAc. As described previously (Section 2.2.5), the
Michaelis-Menten based kinetic model was used to evaluate DA release ([DA]p), uptake
rate (maximum velocity; Vmax), and affinity of DA for the DA transporter (apparent Km) by
fitting DA current versus time traces. For analysis, Km values were fixed to 0.16 µM,
allowing for non-linear fitting of DA peak amplitude (release) and DA uptake (Vmax).
Representative false color plots (Figure 4.5 parts A and B), and their corresponding DA
concentration versus time plots (Figure 4.5 parts C and D) are shown for wildtype and
BDNF+/- mice brain slices in the CPu. Electrically stimulated DA release was reduced by
~ 37% in BDNF+/- mice (1.2 ± 0.1 µM, n = 26) as compared to wildtype mice (1.9 ± 0.1
µM, n = 23; Figure 4.5E). The rate at which DA was cleared from the extracellular space
by the DA transporter (uptake rate) was also attenuated by ~ 36% in BDNF+/- mice (2.7
± 0.1 µM/s, n = 26) relative to the rates obtained in wildtype mice (4.2 ± 0.1 µM/s, n =
23; Figure 4.5F). A two-tailed t-test revealed that the decreases in both parameters, DA
release and uptake rate, were significant in BDNF+/- mice as compared to wildtype mice
(P < 0.0001).
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Figure 4.5 Electrically evoked dopamine (DA) release measured using slice FSCV
following single-pulse
pulse stimulation in dorsal caudate putamen (CPu) of wildtype (WT) and
BDNF+/- mice. Representative color plots from (A) WT and (B) BDNF+/- mice display time
(x-axis),
axis), applied potential versus Ag/AgCl reference electrode (y
(y-axis),
axis), and current in
pseudo-color.
color. The concentration versus time traces from (C) WT and (D) BDNF+/- mice
are shown below their corresponding color plots, and the insets display
d
the
corresponding cyclic voltammograms. (E) Maximum electrically evoked DA release and
(F) DA uptake rates measured from several locations within the CPu. Data are means ±
SEMs (n = 23 – 26 mice per group). ***
***P < 0.0001 as compared to WT mice (Student’s
(Stud
t-test).
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To determine if presynaptic DA dynamics are similar or different across the discrete
sub-regions of the striatum, recordings were made from the NAc core and shell.
Similarly, electrically evoked DA release was significantly lower in the NAc of BDNF+/mice as compared to wildtype mice. In the NAc core, an ~ 36% reduction in DA release
was observed (wildtype: 1.1 ± 0.2 µM, n = 8 and BDNF+/-: 0.7 ± 0.08 µM, n = 9; Figure
4.6A). An ~ 33% reduction in evoked DA release was observed in the NAc shell
(wildtype: 0.6 ± 0.05 µM, n = 12 and BDNF+/-: 0.4 ± 0.04 µM, n = 12; Figure 4.6A). A
two-tailed t-test revealed a significant decrease in DA release between the two
genotypes (NAc core: P = 0.024 and NAc shell: P = 0.034). However, no significant
genotype difference in uptake rates was observed in the NAc core (wildtype: 2.3 ± 0.2
µM/s, n = 8 and BDNF+/-: 2.0 ± 0.2 µM/s, n = 9) and NAc shell (wildtype: 1.2 ± 0.08
µM/s, n = 12 and BDNF+/-: 1.1 ± 0.08 µM/s, n = 12; Figure 4.6B). A two-tailed t-test
revealed no genotype difference in the uptake rates (NAc core: P = 0.22 and NAc shell:
P = 0.22).
To better understand how low, endogenous BDNF levels influence electrically
evoked DA release, the number of stimulation pulses (p) was varied from 1 to 5. Upon
electrode placement and obtaining a stable baseline, both 1 pulse and 5 pulse FSCV
measurements were made in the same location, to reduce the impact of regional
variation. Area under curve (AUC) in arbitrary units was used to analyze the maximal
evoked DA release levels.
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Figure 4.6 Single pulse electrically evoked dopamine (DA) release (A) and maximum
velocity (Vmax, uptake rate) (B) measured using slice FSCV in nucleus accumbens (NAc)
+/of wildtype (WT) and BDNF+/
mice. Data are means ± SEMs (n = 8 – 12 mice per
group). *P < 0.05 as compared to WT mice (Student’s tt-test).
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Increasing the number of pulses led to an increase in stimulated DA release in
both wildtype and BDNF+/- mice (Figure 4.7 parts A and B, respectively). The data was
then normalized to a ratio (DA5p/DA1p, AUC; Figure 4.7C). The ratios for wildtype mice
were: CPu, 1.5 ± 0.1, n = 12; NAc core, 2.1 ± 0.3, n = 8; and NAc shell, 3.0 ± 0.4, n = 9.
Additionally, the ratios for BDNF+/- mice were: CPu, 1.7 ± 0.1, n = 13; NAc core, 2.2 ±
0.3, n = 6; and NAc shell, 2.2 ± 0.3, n = 9. Two-way ANOVA analysis revealed a
significant main effect of striatal region (F1,40 = 20.25, P < 0.0001) and genotype x
striatal region interaction (F1,40 = 4.60, P = 0.038). However, no significance genotype
effect was observed (F1,40 = 2.26, P = 0.14). Bonferroni post-test revealed only a
significant difference (P < 0.001) between NAc shell and CPu of wildtype mice, but not
BDNF+/- mice. Taken together, these results indicate a reduction in stimulated DA5p
release in the NAc shell of BDNF-deficient mice.
4.3.4 Effect of exogenous BDNF on electrically evoked dopamine release
Numerous reports suggest that exogenously applied BDNF is able to enhance
DA release (29-31). To understand how exogenous of BDNF influences presynaptic DA
dynamics, electrically evoked DA release (Figure 4.8A), and uptake rates (Figure 4.8B)
were monitored every 5 minutes following direct application of BDNF (100 ng/mL) to a
slice for 30 minutes. Two-way ANOVA of electrically stimulated DA release showed a
significant main effect of treatment (F1,36 = 33.01, P < 0.0001), genotype (F1,36 = 218.5,
P < 0.0001), and a genotype x treatment interaction (F1,36 = 15.56, P < 0.001).
Bonferroni post-test revealed that exogenous application of BDNF significantly
increases DA release by ~ 17% in BDNF+/- mice (P < 0.001, n = 5), with no effect in
wildtype mice (n = 5). BDNF-mediated increase in electrically evoked DA release was
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Figure 4.7 Effect of single and multiple pulse (1p and 5p) stimulation on dopamine (DA)
release on brain slices, measured as area under curve (AUC) u
using
sing FSCV. AUC
obtained in caudate putamen (CPu) and nucleus accumbens (NAc core and NAc shell)
of wildtype (WT) (A) and BDNF+/- (B) mice. (C) Ratio of DA release (DA5p/DA1p) in WT
and BDNF+/- mice. Data are means ± SEMs (n = 6 – 13 mice per group), two-way
two
ANOVA (Bonferroni post-test),
test), ***P < 0.001, no significance (ns, P > 0.05). NAc core
AUC ratio exempted for clarity.
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Figure 4.8 Effect of exogenous application of BDNF (100 ng/mL) on dopamine
d
(DA)
release and uptake rates in the caudate putamen (CPu) of wildtype (WT) and BDNF+/mice. (A) Normalized single pulse, electrically evoked DA release (represented as % of
WT baseline) and (B) DA uptake rates in WT and BDNF+/- mice before and after
af
30
minute perfusion of either 100 ng/mL BDNF, 1 µM K252a, or both in the CPu. Data are
means ± SEM (n = 4 – 5 mice per treatment group). ***
***P < 0.001 compared to untreated
+/BDNF mice (two-way
way ANOVA). **P < 0.05 as compared to WT mice baseline (one(one
way ANOVA).
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blocked by perfusion of TrkB inhibitor K252a in BDNF+/- mice. No change in DA uptake
rate was observed after BDNF perfusion in either wildtype or BDNF+/- mice. However,
perfusion of K252a on slices from wildtype mice lowered the uptake rate significantly as
analyzed using one-way ANOVA (Dunnett’s post-test, P < 0.05, n = 5 mice per group).
Increasing concentrations of exogenous BDNF (50, 100, and 200 ng/mL) led to a
dose-dependent increase in electrically stimulated DA release in BDNF+/- mice brain
slices (Figure 4.9A). One-way ANOVA (F3,36 = 9.42; P < 0.0001, n = 5) followed by
Dunnett’s post-test revealed that each concentration of BDNF increased DA release
significantly. However, no difference in Vmax (DA uptake rates) was observed upon
increasing BDNF concentration in BDNF+/- mice (F3,36 = 0.013; P = 1.00; n = 5; Figure
4.9B).
Our results from a single 30-minute treatment with 1 µM K252a showed a
significant reduction in DA uptake rates in wildtype mice but not BDNF+/- mice (Figure
4.8). To determine whether inhibition of the TrkB receptor is able to modulate DA
dynamics in a dose-dependent manner, increasing concentrations of K252a (0.1, 0.3, 1
and 3 µM) were perfused on brain slices of wildtype mice and single pulse electrically
evoked DA release and uptake rates were monitored. Perfusion of increasing
concentrations of K252a reduced the stimulated DA release significantly (relative to
baseline; Figure 4.10A) as analyzed using one-way ANOVA (F4,25 = 4.06; P = 0.011, n =
3). Interestingly, Dunnett’s post-test revealed a significant (P < 0.05) reduction in
stimulated DA release only at the highest concentration (3 µM), but not the other
concentrations of K252a applied. Increasing the concentration of K252a led to a
reduction in Vmax in a dose-dependent manner (Figure 4.10B). One-way ANOVA

103

Figure 4.9 Effect of increasing concentrations of BDNF (50, 100, and 200 ng/mL) on
dopamine (DA) release and uptake rat
rates
es in the caudate putamen (CPu) of BDNF+/mice. (A) Normalized single pulse electrically evoked DA release (represented as % of
baseline) and (B) Corresponding maximum velocity (Vmax) after perfusion of increasing
concentrations of BDNF. Data are means ± SEM (n = 5 mice). **P < 0.01, ***P
*** < 0.001
for baseline compared to BDNF treatments (one
(one-way
way ANOVA, Dunnett’s post-test).
post
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Figure 4.10 Effect of increasing concentrations of K252a (0.1 – 3 µM) on dopamine
(DA) release and uptake rates in the caudate putamen (CPu) of wildtype mice. (A)
Normalized single pulse electrically evoked DA release (represented as % of baseline)
and (B) corresponding maximum velocity (Vmax) after perfusion of increasing
concentrations of K252a. Data are means ± SEMs (n = 3 mice
mice). *P < 0.05, **P
** < 0.01,
***P < 0.001 for baseline as compared to K252a treatments (one-way
(one
ANOVA,
Dunnett’s post-test).
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analysis (F4,25 = 14.93; P < 0.0001, n = 3) followed by Dunnett’s post-test revealed that
each concentration of K252a significantly decreased Vmax.
4.3.5 Dopamine D3 and D2 autoreceptor functionality in BDNF+/- mice
Increasing concentrations of the DA D3 agonist 7-OH-DPAT were perfused over
a mouse brain slice to evoke D3 autoreceptor-mediated inhibition of DA release. Single
pulse electrically stimulated DA release was monitored in BDNF+/- and wildtype mice in
the NAc shell due to its high D3 receptor expression and sensitivity to D3 activation
(Section 3.3.2) (36). The log concentration of the D3 agonist was plotted against the
normalized concentration of DA to obtain dose response curves for each genotype and
corresponding EC50 values.
The EC50 value for wildtype mice was 39 ± 6 nM (n = 9) and 118 ± 16 nM (n = 5)
for the BDNF+/- mice. Analysis of the EC50 values using Student’s t-test revealed a
significant difference (P < 0.0001; Figure 4.11A). This suggests a reduction in DA D3
presynaptic receptor function in the NAc shell of BDNF+/- as compared to wildtype mice.
Additionally, we evaluated the effect of increasing 7-OH-DPAT concentration on DA
uptake rates. In the NAc shell, 7-OH-DPAT did not alter the uptake rates in either
wildtype (Figure 4.11B) or BDNF+/- mice (Figure 4.11C) as analyzed using one-way
ANOVA with Dunnett’s post-test (wildtype: F6,48 = 0.93, P = 0.48, n = 9 and BDNF+/-:
F6,33 = 1.26, P = 0.30, n = 5).
Similarly, the DA D2 receptor agonist quinpirole was used to probe the effect of
low levels of BDNF on the functionality of D2 autoreceptor in the CPu. Increasing
concentrations of quinpirole were perfused over a slice and FSCV was used to monitor
electrically stimulated DA release and uptake rates. The log concentration of quinpirole
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7-OH-DPAT
DPAT on DA release and
Figure 4.11 Effect of the dopamine (DA) D3 agonist 7
uptake rates as measured using FSCV in the nucleus accumbens (NAc) shell. (A) Dose
response curves for inhibition of electrically stimula
stimulated
ted DA efflux in the wildtype (WT)
and BDNF+/- mice. Effect of 7
7-OH-DPAT
DPAT concentrations on maximum velocity (Vmax) in
the NAc shell of WT mice (B) and BDNF+/- mice (C). Analysis of the EC50 values using
Student’s-tt test revealed significant reduction in DA D3 receptor functionality (***P <
0.0001). No change in uptake rates was observed for either genotype (one-way
(one
ANOVA, Dunnett’s post-test,
test, n = 5 for BDNF+/- mice and n = 9 for WT mice).
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Figure 4.12 Effect of dopamine (DA) D2 agonist quinpirole on DA release and uptake
rates measured using FSCV in the caudate putamen (CPu). (A) Dose response curves
for inhibition of electrically stimulated DA efflux in wildtype (WT) and BDNF+/- mice. The
effect of quinpirole on maximum velocity (Vmax) in WT mice (B) and
nd BDNF+/- mice (C).
Analysis of the EC50 values using Student’s
Student’s-t test revealed no significant
ignificant change in DA
D2 receptor functionality.. Concentrations greater than 0.1 µM reduced the uptake rate in
WT mice with no change in uptake rate observed in BDNF+/- mice (one-way
(one
ANOVA,
+/Dunnett’s post-test), **P < 0.01, ***P < 0.001 (n = 5 for BDNF mice and n = 7 for
wildtype mice).
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was plotted against the normalized concentration of DA to obtain dose response curves
for each genotype (Figure 4.12A) and the corresponding EC50 values. The EC50 value
for wildtype and BDNF+/- mice were 114 ± 35 nM (n = 7) and 156 ± 32 nM (n = 5),
respectively. The EC50 values were not different as analyzed using Student’s-t test. The
results show a significant decrease in Vmax (uptake rate) in the presence of high
concentrations of quinpirole in the CPu of wildtype mice (F6,52 = 6.67, P < 0.0001, n = 7;
Figure 4.12B), but not in BDNF+/- mice (F6,65 = 2.05, P = 0.074, n = 5; Figure 4.12C).
4.4 Discussion
4.4.1 Hyperdopaminergic state due to reduced dopamine release and clearance
There is considerable evidence suggesting the neurotrophic factor, BDNF
modulates the striatal DA system (35, 37, 133, 182, 191, 192). In the present study, two
complementary techniques, in vivo microdialysis and slice voltammetry were employed
to probe the role of low endogenous BDNF levels on striatal DA dynamics. Electrically
evoked DA release and uptake rates in the CPu were attenuated in BDNF+/- mice as
compared to their wildtype littermates. Exogenous BDNF perfusion partially restored the
reduced DA release observed in BDNF+/- mice. On the other hand, BDNF-deficient mice
exhibited no differences in DA synthesis or catabolism in the CPu. Interestingly, in the
NAc core and shell only electrically stimulated DA release was attenuated in BDNF+/mice, while no difference was observed in DA uptake rates. Together, these findings
suggest that BDNF regulates presynaptic DA homeostasis by altering DA release,
which appear to influence extracellular DA levels leading to a compensatory response
by DA transporter.
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This is the first study to use the microdialysis technique of zero net flux to
estimate "true” basal extracellular levels of DA in BDNF-deficient mice. Extraneuronal
DA levels in BDNF-deficient mice were elevated (~ 12 nM) in the CPu compared to
basal DA levels from wildtype mice (~ 5 nM). The slice FSCV results indicate reduced
uptake rates likely account for the increased basal levels of DA in BDNF+/- mice.
Furthermore, previous studies in the BDNF+/- mice have shown that DA transporter
expression is not altered, suggesting that low endogenous BDNF levels may alter the
function of the DA transporter (37, 133). One possible mechanism as to how BDNF may
mediate DA transporter activity is through the second-messengers linked to BDNF-TrkB
signal transduction pathways. Specifically, activation of protein kinase C (PKC),
extracellular signal-regulated kinases 1 and 2 (ERK1/2), and phosphatidylinositol-3kinase (PI3K) pathways have been linked to regulation of DA transporter activity (171173).
Extracellular levels of neurotransmitters measured by microdialysis represent a
balance between release and uptake processes, the effect of BDNF-deficiency on DA
exocytotic release and DA transporter-mediated uptake was differentiated with slice
FSCV. Both stimulated release and the velocity of DA uptake was reduced in BBDNF+/mice. Interestingly, this decrease in stimulated DA release and DA uptake rates in
BDNF+/- mice was similar to presynaptic DA dynamics observed in DA transporter
heterozygous mice (DAT+/- mice; with a 50% reduction in DA transporter expression)
(193). In DAT+/- mice, the decrease in stimulated DA release was hypothesized to be a
compensatory response to the excess extracellular DA levels due to the reduced
uptake. To determine if the low endogenous BDNF levels can directly contribute to the
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blunted DA release or uptake observed, exogenous BDNF was applied to the slice for
30 minutes. DA release upon stimulation was elevated by ~ 17% in the BDNF+/- mice,
while exogenous BDNF application lead to no alteration in DA uptake rates. Slice FSCV
measures DA release mainly from the readily releasable pool of vesicles (63, 194).
Since BDNF is thought to enhance quantal neurotransmitter release by increasing the
number of docked synaptic vesicles as well as increasing DA firing frequency within
presynaptic terminals, further experiments are necessary to determine if the decrease in
electrically stimulated DA release in BDNF-deficient mice is due to a decrease in one or
both of these parameters (185). Indeed, BDNF+/- mice have impaired hippocampal
presynaptic transmitter release that is associated with fewer docked vesicles in the
active zone and lower synaptosomal levels of synaptobrevin and synaptophysin, which
assist in vesicle docking and fusion (185, 187, 195). These effects are reversed with
addition of exogenous BDNF (187).
4.4.2 Reduced multiple-pulse electrically stimulated dopamine release in nucleus
accumbens
Neuronal DA transmission is dynamic, resulting from a combination of tonic DA
release (~ 4 Hz; ‘rhythmic firing’) and short, but intense burst firing of DA neurons
(phasic firing) (196). Extracellular DA levels measured over a period of 10 – 20 minutes
by in vivo microdialysis are thought to primarily reflect tonic DA release, where burst
firing is averaged over this period (103). DA transients resulting from bursts of DA cell
firing in the VTA are detected in the NAc using in vivo FSCV (56, 65, 91, 101, 197-199).
FSCV is ideal for measuring DA transients due to its fast temporal resolution (~ 100
ms), since DA transients are typically a few milliseconds in duration, FSCV allows for
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discrete detection of multiple bursts (89, 197). Results demonstrate that BDNF+/- mice
have reduced singe-pulse electrically stimulated DA release in the striatum (CPu and
NAc) as compared to their wildtype controls.
To better understand the role of low BDNF levels on DA release, the number of
stimulation pulses for DA release was varied (1p versus 5p) in the striatal complex
(CPu, NAc core and shell) in both wildtype and BDNF+/- mice. When examining pulse
trains, the AUC of the current versus time plot was examined and not the discrete
parameters of DA release and uptake. In both genotypes, the CPu showed the greatest
amount of electrically stimulated DA release, while the NAc shell had the least, which is
consistent with previous reports (101). When the AUC ratio (DA5p/DA1p) was evaluated,
wildtype mice had the lowest DA ratio in the CPu, while the shell had a significantly
greater ratio. Interestingly, the DA5p/DA1p ratio in the BDNF+/- mice was not different
between the CPu and NAc. Taken together, these results suggest that mice with low
endogenous BDNF levels may have impaired DA burst firing in the NAc shell. However,
to truly understand if burst firing is compromised in these mice future studies will need
to use in vivo FSCV to probe DA burst firing.
4.4.3 Reduced dopamine D3 autoreceptor function
Stimulation of DA D2-like receptors on presynaptic nerve terminals results in
feedback inhibition, which homeostatically regulates extracellular levels of DA via
inhibition of DA synthesis and release (19, 20). Our microdialysis data show that basal
extracellular DA levels are elevated in BDNF+/- mice as compared to wildtype mice,
hypothesized to result from the reduced DA uptake rates. However, the long-term
consequences of elevated extracellular DA levels may lead to either a change in
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autoreceptor expression or function in the CPu (14). Furthermore, numerous studies in
BDNF-deficient mice have demonstrated that BDNF modulates release-regulating DA
D3 receptor expression (36, 37, 200). For example, both mice lacking BDNF (BDNF
knockout) and BDNF+/- mice have reduced DA D3 levels in the CPu and NAc (36, 37).
Since our dialysis results indicate increased extracellular DA levels in the CPu,
our first step was to determine if these elevated extracellular levels lead to alterations in
presynaptic DA D2 receptor function. Interestingly, DA D2 autoreceptor function was not
altered by the increase in extracellular DA levels in the CPu, which has a high density of
D2 receptors (Section 3.3.1) (17, 158). This finding suggests release- and synthesisregulating DA D2 autoreceptors are not affected by the hyperdopaminergic state
observed in the CPu. Furthermore, our results are consistent with a previous study that
reported DA D2 receptor expression is not affected by BDNF deficiency in the NAc shell
(36). However, future work needs to evaluate the functionality of DA D2 autoreceptor in
other regions such NAc shell to determine whether modulation of DA D2 receptors is
region-specific in BDNF+/- mice.
Although no changes were seen in DA D2 receptors in the CPu, the next step
was to determine if BDNF+/- mice showed a decrease in DA D3 autoreceptor
functionality in the NAc, as has been previously documented (36, 37). Slice FSCV
results in the NAc shell indicated that BDNF+/- mice had diminished DA D3 autoreceptor
function compared to their wildtype littermates. This finding further highlights that low
BDNF levels directly regulate DA D3 receptor function. Although we have not evaluated
extracellular DA levels in the NAc using in vivo microdialysis, based on our slice
voltammetry release and uptake results we would expect to see no difference in
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extracellular DA levels. If this hypothesis does turn out to be valid it would further
support the hypothesis that BDNF expression directly regulates presynaptic D3
autoreceptors with no influence from extracellular DA levels. To our knowledge, this is
the first time that presynaptic DA D3 autoreceptor function has been shown to be
reduced, since previous studies utilized radioligands, which map both pre- and postsynaptic DA D3 receptor density. Overall, a more careful evaluation of D2-like
autoreceptors must be made in the striatum by examining not only extracellular DA
levels but also proteins such as BDNF to better understand how it controls the
functionality and/or expression of these receptors.
4.4.4 Exogenous BDNF increases electrically stimulated dopamine release
Interestingly, both in vivo microdialysis and slice voltammetry show opposite
differences in stimulated DA release in BDNF-deficient mice. To better under if BDNF
regulates DA release exogenous application of BDNF was applied to brain slices. When
a 100 ng/mL of BDNF was exogenously applied to a brain slice, only BDNF+/- mice
showed a ~ 17% increase in electrically stimulated DA release, while no difference in
DA uptake. However, exogenous BDNF did not affect electrically-stimulated DA release
in wildtype mice. These findings suggests that the BDNF receptor; TrkB, in BDNFdeficient mice is either (1) supersensitive and/or (2) exogenous application of BDNF
enhances DA release. This is not the first evidence suggesting that TrkB activation via
BDNF leads to an increase in synaptic transmission. For example, Lohof et al. were the
first to show that BDNF can acutely potentiate both stimulated synaptic responses and
the frequency of miniature synaptic events (201). Several subsequent reports have
shown that exogenously applied BDNF is indeed capable of enhancing synaptic events
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such as DA release both in vivo and in vitro (29-31). BDNF signaling is mediated by the
TrkB receptor (10, 22). To examine whether the TrkB receptor can mediate DA
dynamics of release and uptake, a potent non-selective Trk receptor antagonist, K252a,
was perfused over the slice for 30 minutes and DA dynamics were monitored every 5
minutes (202). Perfusion of K252a alone had no effect on electrically stimulated DA
release in either genotype. When the slices were treated with both BDNF and the TrkB
receptor antagonist, the BDNF-mediated increase in electrically evoked DA was blocked
in the BDNF+/- mice suggesting that the TrkB receptor mediates DA release.
However, K252a rapidly reduced the rate of DA uptake in the wildtype mice, but
not in the BDNF+/- mice. Considering no alterations were observed in DA transport when
exogenous BDNF was applied to the slices, these differences in DA uptake were
surprising in the presence of K252a. Upon increasing the concentration of K252a from
0.1 to 3 µM exhibited that K252a reduces the Vmax in a dose-dependent manner with no
effect on electrically stimulated DA release at lower concentrations. This is in agreement
with previous work where inhibition of tyrosine kinases by genistein or tyrphostin 23
resulted in a rapid (5 – 15 minute), dose-dependent decrease in [3H]DA uptake rate in
synaptosomal preparation (203).
The mechanisms underlying the ability of 1) exogenous BDNF to potentiate DA
release and 2) TrkB receptor inhibition with K252a to modulate DA uptake rate are not
known. However, previous studies have shown that BDNF perfusion to hippocampal
cells and nerve-muscle cultures rapidly increases cytoplasmic Ca2+ (204, 205).
Additionally, extracellular Ca2+ influx through voltage-gated Ca2+ ion channels and Nmethyl-D-aspartate receptors is required for BDNF-induced synaptic potentiation (204-

115
208). BDNF signaling through TrkB receptor increases intracellular Ca2+ concentration,
suggesting that TrkB activation may result in modulating downstream signaling events,
and consequently increasing DA available for release (209).
TrkB receptors undergo rapid BDNF-induced internalization and K252a prevents
TrkB internalization induced by BDNF (207, 208, 210). Current evidence suggests that
inhibition of tyrosine kinases, PI3K, MAPK, and ERK1/2 decreases DA transporter
activity by decreasing Vmax (152, 172, 173, 203, 211, 212). Therefore, inhibition of the
TrkB receptor using K252a appears to inhibit the BDNF-signaling events and ultimately
reducing DA transporter function. More studies are required to determine the specific
BDNF-signaling pathways that may be involved. Noteworthy, high concentrations of
K252a may have non-specific binding to other kinases including those that modulate DA
transporter activity directly such as Ca2+/calmodulin-dependent protein kinases II
(CaMKII) (213).
4.4 Conclusions
The main goal of this work was to understand how low, endogenous BDNF levels
regulate presynaptic DA dynamics in the striatal complex. The present results show that
electrically stimulated DA release and DA uptake rates are attenuated in the CPu of
mice expressing low BDNF levels compared to their wildtype littermates. Conversely,
DA release but not DA uptake was decreased in the NAc of BDNF+/- mice. DA synthesis
and metabolism were not altered, indicating that the increased basal extracellular DA
levels observed in the CPu of BDNF+/- mice using microdialysis is likely related to a
decrease in DA uptake function. Although our results highlight a change in DA
transporter function, we hypothesize that the alterations in DA release detected in
BDNF+/- mice is the primary mechanism by which endogenous BDNF regulates
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presynaptic DA dynamics. Thus, the alterations observed in the DA transporter function
are a compensatory response to reduced stimulated release. Exogenous BDNF rescues
DA release in a dose-dependent manner. Exact mechanism of how BDNF increases the
amount of DA released is unknown but our results combined with those obtained by
Pozzo-Miller et al. would suggest alterations in either the number of vesicles in the
readily releasable pool or alterations in the proteins required for the docking of the
vesicles in BDNF-deficient mice. Furthermore, the results not only indicate alterations in
DA release and uptake, but that low BDNF levels reduce DA D3 autoreceptor function.
Overall the results obtained reveal significant impairment in DA functions in mice
with reduced endogenous levels of BDNF. We hypothesize that the combination of low
endogenous BDNF levels with the observed hyperdopaminergic system may have
detrimental consequences for addiction liability and neurological disorders. Specifically,
the hyperdopaminergic state due to low BDNF levels suggests that BDNF hypofunction
may play crucial role in disorders related to enhanced dopaminergic transmission, such
as ADHD. Finally, this work has implications for the development of therapeutic agents
that will target BDNF signaling and possibly expression may lead to significant
alterations in the DA system.
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CHAPTER 5
The Impact of Low Endogenous BDNF Levels and Aging on Striatal
Dopamine Dynamics
5.1 Introduction
The age-related decline in structure and function of neuronal systems affects
both motor and memory functions (102, 133, 214, 215). These age-related neuronal
adaptations parallel human aging as well (216, 217). Dopamine (DA) neuron
dysregulation has been found to play a major role in motor and cognitive impairment in
rodents, non-human primates, and humans (218-222). Studies in humans have shown
that a decline in the number of dopaminergic neurons in the substantia nigra (SN)
occurs during the normal process of aging, and is accelerated in Parkinson’s disease
patients (222-225). Parkinson's disease is a neurological disorder that is associated with
greater than 80% loss of DA neurons in the striatum. The most severe symptoms
associated with Parkinson’s disease involve dysregulation in the control of motor
function, such as bradykinesia, resting tremor, and rigidity (10, 40, 226, 227).
The cause of normal age-related motor deficits is hypothesized to involve
alterations in the function of DA neurons, not neuronal loss, as demonstrated in animal
models of aging (214, 221, 228). There is considerable evidence that the reductions of
DA function are related to a decrease in DA release, DA uptake rate, and vesicular
monoamine transporter 2 (VMAT2) activity (214, 221, 229). However, others have
reported that age-related DA dysfunction involves neuronal changes, such as
reductions in both tyrosine hydroxylase (TH) and DA transporter densities in the SN of
aged rodents (230). Moreover, the reduction in DA neuron function and/or structure is
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associated with a decrease in locomotor activity in both aged rodents and humans (214,
221, 224, 225). However, the exact cause of the normal aging process on the DA
system remains unknown.
Survival of neurons depends on continuous support from neurotrophic factors
such as brain derived-neurotrophic factor (BDNF) and glial cell line-derived neurotrophic
factor (GDNF). Specifically, it has been reported that dopaminergic neuron
degeneration and/or dysfunction may be linked to age-related decreases in the levels of
GDNF, BDNF, and neurotrophin 3 (NT-3) (231-233). Neurotrophins such as BDNF,
GDNF, and NT-3 are involved in the regulation of growth, differentiation, survival, and
maintenance of nigrostriatal DA neurons that control motor coordination (21, 234).
Reduced expression of these trophic factors is proposed to enhance the vulnerability of
DA neurons to degeneration and/or dysfunction from external stressors and neurotoxins
with age (231, 233). In the normal process of aging, BDNF levels are known to decline
by 14 – 52% in the nigrostriatal system of 24 – 26 month old rats (179, 235).
Additionally, there is considerable evidence indicating that low levels of BDNF and
aging are linked to neurodegenerative disorders such as Huntington’s disease,
Parkinson’s disease, and Alzheimer’s disease (41, 42, 46, 115-117, 236, 237).
Specifically, BDNF deficiency may be a critical mediator in Parkinson's disease, as
surviving nigrostriatal DA neurons have reduced levels of BDNF. Additionally, there is a
considerable sub-population of Parkinson’s disease patients that have the val66met
single nucleotide BDNF gene polymorphism (41, 42, 116, 238, 239). These results
suggest a link between BDNF levels and age-related degeneration and/or dysfunction of
DA neurons.
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With respect to animal models, BDNF+/- mice aged 11 to 21 months have
reduced locomotor activity in beam walking, which is an assessment of fine motor
coordination, as compared to their wildtype littermates (34, 132). BDNF+/- mice also
exhibit enhanced age-related decline in accelerated rotarod performance (133). These
reductions in motor coordination in BDNF-deficient mice are hypothesized to be
associated with attenuation in nigrostriatal DA system function, because dopaminergic
axonal innervations in the dorsal striatum, SN, VTA, and NAc (core and shell) do not
differ between wildtype and BDNF+/- mice at 26 months of age (240). With respect to
key modulators of the striatal dopaminergic system, such as TH, DA transporter, and
VMAT2 expression, BDNF-deficient mice at 21 months of age are not different from
wildtype mice (133). Although DA transporter and VMAT2 expression are not different
between the two genotypes at 21 months of age, the function of the DA transporter
(from 12 months) and VMAT2 (from 3 months) is attenuated with age in the BDNF+/mice as compared to wildtype mice (133). With respect to stimulated DA release, high
K+- artificial cerebrospinal fluid (aCSF) in aged BDNF+/- mice exhibited a reduced DA
response compared to wildtype mice (133). Taken together, these findings emphasize
the crucial role of BDNF in augmenting DA dynamics during the aging process.
To better understand if lifelong decrements in BDNF levels and the aging
process influence the dopaminergic system, BDNF+/- mice were evaluated at ~ 18
months of age and compared to their wildtype littermate controls. To understand how
striatal DA dynamics adapt with respect to time, the results from ~ 18 month old mice
were compared with the younger (~ 3 month old) mice (CHAPTER 4). Characterization
of the ~ 3 month old BDNF+/- mice showed a hyperdopaminergic phenotype,
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characterized by both reduced DA uptake rates and elevated basal DA levels that are
believed to be attributed to the DA system compensating for reduced DA release
(CHAPTER 4). Therefore, we hypothesized that a lifetime with ~ 50% reduction in
BDNF protein levels would cause significant impairments on the DA system in BDNF+/mice compared to the wildtype mice. DA dynamics at ~ 18 months of age were
evaluated using slice FSCV to measure electrically stimulated DA release and DA
uptake rates. Additionally, in vivo microdialysis in freely moving mice was used to
measure extracellular basal levels of DA by use of the zero net flux method, as well as
extracellular levels of DA catabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA).
5.2 Materials and methods
Johnna A. Birbeck performed all the microdialysis experiments on aged mice (~ 18
months of age), which involved stereotaxic surgery, probe implantation, and sample
collection. Sample analysis included HPLC separation with electrochemical detection
and chromatographic data analysis.
Wildtype and BDNF+/- mice offspring were raised as a colony in house and
genotyped as described in Section 2.2. Male and female (BDNF+/- and wildtype) mice
aged to at least 18 months were used for all neurochemical measurements. In vivo
microdialysis experiments were performed as described in Section 2.5. Upon
stereotaxic surgery, a microdialysis probe was implanted for neurotransmitter sampling.
The dialysate from the CPu containing the analytes of interest (DA, DOPAC, and HVA)
was analyzed by HPLC coupled to an electrochemical detector. Zero net flux technique
was used to estimate basal extracellular levels of DA in the CPu of a freely behaving
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mouse as described in Section 2.5. Slice FSCV experiments were performed as
previously described in Section 2.4 with minor modifications.
5.2.1 Data analysis
Johnna A. Birbeck performed all the microdialysis samples analysis that included
chromatographic analysis, statistical data analysis and graphing. Microdialysis results
from the aged mice were directly compared to those of young adult mice, the results
were obtained by Kelly E. Bosse, Ph.D., and the details of her contributions can be
found in CHAPTER 4.
All values are reported as means ± standard errors of the means (SEMs). Zero
net flux data were analyzed by linear regression to determine the x-intercept (DAext) and
slope (Ed) for individual wildtype and BDNF+/- mice. Differences in DAext between
genotypes were determined by a two-tailed Student’s t-test. To evaluate the impact of
aging on DA dynamics, data for young adult mice (~ 3 months, CHAPTER 4) and the
aged mice (~ 18 months) were compared. Two-way ANOVA with a Bonferroni post-test
was used to determine the impact of the independent variables of genotype and aging
on stimulated DA release ([DA]p) and uptake rates (Vmax) evaluated with FSCV and
extracellular catabolite levels (DOPAC and HVA) as measured by in vivo microdialysis.
Results from one and five pulse stimulation were analyzed by determining the area
under the curve (AUC) from the resulting current versus time plots to determine DA
release (DA1p and DA5p, respectively). Data obtained from the one and five pulse
stimulations were normalized as a ratio (DA5p/DA1p), because the electrode placement
in the slice was not changed during the one and five pulse measurements. With respect
to the one and five pulse stimulation parameters, a two-way ANOVA with a Bonferroni

122
post-test was used to determine the impact of the independent variables of genotype
and brain region of interest. In all cases, statistical significance was defined as P < 0.05.
5.3 Results
5.3.1 DOPAC levels in aged BDNF-deficient mice
Johnna Birbeck performed all the microdialysis samples analyses that included
chromatographic analysis, statistical data analysis and graphing. Microdialysis results
from the aged mice were directly compared to those of young adult mice, the results
were obtained by Kelly E. Bosse, Ph.D., and the details of her contributions can be
found in CHAPTER 4.
To determine the long-term effect of low endogenous levels of BDNF on DA
dynamics, in vivo microdialysis was used to determine striatal basal DA levels and
extracellular concentrations of DA catabolites (DOPAC and HVA) in the CPu of aged
BDNF+/- and wildtype mice. The basal concentrations of extracellular DA were
determined using the zero net flux method (Figure 5.1). Apparent extracellular DA levels
(DAext), corrected for recovery, did not differ (P = 0.34; two-tailed t-test) in aged BDNF+/mice (7 ± 1 nM; n = 14) as compared to wildtype mice (6 ± 0.8 nM; n = 9). An advantage
of the zero net flux method is that it approximates relative “in vivo” probe recovery from
the slopes of the linear regression analyses, which is more commonly referred to as
extraction fraction (Ed). Previous studies have suggested that changes in the slope
relate to alterations in transporter. The average extraction fraction did not differ between
aged wildtype (0.48 ± 0.06) and BDNF+/- mice (0.35 ± 0.06). To better understand the
long-term consequences of low, endogenous BDNF levels on basal DA levels, a second
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Figure 5.1 Basal extracellular levels of dopamine (DA) in the caudate putamen (CPu) of
wildtype (WT) and BDNF+/- mice as measured using zero net flux. (A) Linear regression
analysis of basal DA levels in aged mice (~ 18 months old), determined by zero net flux.
The x-intercept
intercept represents an estimate of basal DA levels (DAext) and the slope of the
line corresponds to the extraction fraction ((Ed). (B) Summary of basal DA levels (DAext)
from the CPu of young (~ 3 months old) mice and aged mice. Data are means ± SEMs
of the apparent DAext (n = 6 – 14 mice). **P = 0.01, comparison of DAext levels between
young and aged BDNF+/- mice using Student’s tt-test. Figure courtesy of Johnna A.
Birbeck, Kelly E. Bosse, Ph.D., and Tiffany A. Mathews, Ph.D.
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comparison was made between young (~ 3 months old, Figure 5.1B) and aged (~ 18
months old) mice. The basal DA levels in young adult (~ 5 nM) and aged (~ 6 nM)
wildtype mice were not different (P = 0.86) as determined by zero net flux. In contrast,
BDNF+/- mice showed a significant decrease in basal DA levels (young mice ~ 12 nM vs
aged mice ~ 6 nM; P < 0.01).
DA catabolism was evaluated by measuring extracellular levels of DA
catabolites, DOPAC and HVA, from baseline dialysis samples (average of three
samples). Elevated extracellular DOPAC concentrations were observed in the CPu of
BDNF+/- versus wildtype controls, where DOPAC levels for aged BDNF+/- mice were 910
± 160 nM (n = 7), as compared to 460 ± 80 nM in aged wildtype mice (n = 14, Figure
5.2A). DOPAC concentrations in the young adult mice (Section 4.3.2) were ~ 410 nM
(wildtype) and ~ 330 nM (BDNF+/-). Two-way ANOVA revealed a significant main effect
of aging (F1,43 = 10.77, P = 0.002 ), genotype (F1,43 = 5.10, P = 0.03), and genotype x
aging interaction (F1,43 = 6.38 P = 0.02). A Bonferroni post-test revealed that aging has a
significant effect on extracellular DOPAC levels in BDNF+/- mice (P < 0.01), but not in
wildtype mice (P > 0.05). Extracellular HVA concentrations were not different between
aged wildtype and BDNF+/- mice (wildtype: 490 ± 70 nM, n = 14; BDNF+/-: 690 ± 100 nM,
n = 7; Figure 5.2B). Two-way ANOVA (Bonferroni post-test) analysis comparing the
HVA levels in the young adult mice (wildtype: ~ 465 nM; BDNF+/-: ~ 560 nM) and the
aged mice was carried out. There was no age-related or genotype difference in HVA
levels (Figure 5.2B). These data indicate that aging in BDNF-deficient mice results in an
elevation of DA catabolism process.
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caudate-putamen (CPu) of young and aged
Figure 5.2 Dopamine catabolism in the caudate
wildtype (WT) and BDNF+/- mice. (A) Extracellular DOPAC levels, as measured by
microdialysis. (B) Extracellular HVA levels, determined by microdialysis. Data are
reported as the mean ± SEM of uncorrected baseline values for young (~ 3 months)
months and
aged (~ 18 months) mice (n = 7 – 16 mice). Two-way
way ANOVA (Bonferroni post-test)
post
comparisons in DOPAC levels (*
(*P < 0.05, **P < 0.01). Figure courtesy of Johnna A.
Birbeck, Kelly E. Bosse, Ph.D., and Tiffany A. Mathews, Ph.D.
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5.3.2 Aging differences in electrically stimulated dopamine release and uptake
rates
FSCV was used to examine single pulse, electrically stimulated DA release and
uptake rates in the CPu and NAc of aged mice (~ 18 months). As described previously
(Section 2.2.5), the Michaelis-Menten based kinetic model was used to evaluate single
pulse stimulated DA release concentration ([DA]p) and uptake rate (maximum velocity,
Vmax) by fitting DA concentration versus time FSCV traces. No difference was observed
in electrically stimulated DA release in the CPu between aged BDNF+/- (2.0 ± 0.2 µM, n
= 14) and wildtype (1.7 ± 0.1 µM, n = 15) mice (Figure 5.3A). However, a comparison
between stimulated DA release concentrations in the young adult (Section 4.3.3) and
aged mice using two-way ANOVA revealed significant main effects of aging (F1,101 =
12.54, P = 0.0006), genotype (F1,101 = 4.19, P = 0.04), and genotype x aging interaction
(F1,101 = 21.22, P < 0.0001). Aging led to an increase in stimulated DA release in the
CPu of BDNF+/- mice (young: 1.2 µM; aged: 2.0 µM; P < 0.001)), but no effect of aging
was observed in the wildtype mice (P > 0.05; Bonferroni post-test; Figure 5.3A). DA
uptake rates were not different in the CPu of aged BDNF+/- mice (3.9 ± 0.2 µM/s, n = 14)
relative to the rates obtained from aged wildtype mice (3.9 ± 0.1 µM/s, n = 15; Figure
5.3B). A comparison between DA uptake rates in the young adult (Section 4.3.3) and
aged mice using two-way ANOVA revealed significant main effects of aging (F1,121 =
4.78, P = 0.03), genotype (F1,121 = 17.23, P < 0.0001), and genotype x aging interaction
(F1,121 = 14.93, P = 0.0002). Bonferroni post-test revealed only a significant increase (P
< 0.001) in Vmax of BDNF+/- mice (young: 2.7 µM/s; aged: 3.9 µM/s; P = 0.0005; Figure
5.3B).
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Figure 5.3 Presynaptic dopamine (DA) dynamics in young and aged mice in the
caudate putamen (CPu). Single pulse electrically evoked DA release (A) and maximum
velocity (Vmax, uptake rate) (B) measured using FSCV in the caudate putamen (CPu) of
wildtype (WT) and BDNF+/- mice. Data are reported as means ± SEMs for young (~ 3
months) and aged (~ 18 months) mice (n = 14 – 26 mice per group). ***P
*** < 0.001 for
aging effect in BDNF+/- mice (two
(two-way ANOVA, Bonferroni post-test).
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In the NAc core, electrically evoked DA release did not differ between aged
wildtype (0.7 ± 0.2 µM, n = 12) and BDNF+/- (1.0 ± 0.1 µM, n = 8) mice (Figure 5.4A). A
comparison between stimulated DA concentrations in the young adult (Section 4.3.3)
and aged mice using two-way ANOVA did not reveal significant effects of aging and
genotype, but a significant genotype x aging interaction (F1,33 = 14.47, P = 0.0006) was
observed. Interestingly, wildtype mice showed a significant decrease (Bonferroni posttest, P < 0.05) in stimulated DA release as a result of aging (young: 1.1 µM; aged: 0.7
µM; P < 0.05; Figure 5.4A). In contrast, BDNF+/- mice showed a significant increase
(Bonferroni post-test, P < 0.05) in stimulated DA release in the NAc core as a result of
aging (young: 0.7 µM; aged: 1.0 µM; P = 0.03, Figure 5.4A). DA uptake rates did not
differ in the NAc core of aged wildtype mice (2.0 ± 0.2 µM/s, n = 12) compared to aged
BDNF+/- mice (2.6 ± 0.2 µM/s, n = 8; Figure 5.4B). Two-way ANOVA (Bonferroni posttest) comparisons between DA uptake rates in the NAc core of young adult (wildtype:
2.3 µM/s and BDNF+/-: 2.0 µM/s) and aged mice did not indicate any genotype
difference or aging effect (Figure 5.4B).
Similar to the CPu and NAc core, no difference in evoked DA release was
observed between aged wildtype (0.3 ± 0.04 µM, n = 11) and BDNF+/- (0.4 ± 0.03 µM, n
= 12) mice in the NAc shell (Figure 5.5A). However, a significant decrease (two-way
ANOVA: Bonferroni post-test, P < 0.01) in stimulated DA release was observed in NAc
shell of wildtype mice (young: 0.6 µM; aged: 0.3 µM; Figure 5.5A). In contrast to the
other striatal regions, BDNF+/- mice showed no aging effect (Bonferroni post-test, P >
0.05) in stimulated DA release in the NAc shell (Figure 5.4A).
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Figure 5.4 Presynaptic dopamine (DA) dynamics from the nucleus accumbens (NAc)
core measured using FSCV. (A) Single pulse electrically evoked DA release and (B)
maximum velocity (Vmax, DA uptake rate) between young and aged wildtype (WT) and
BDNF+/- mice. Data are reported as means ± SEMs for young (~ 3 months) and old (~
18 months) mice (n = 8 – 12 mice per group). **P < 0.05 for aging effect comparisons in
stimulated DA release (two-way
way ANOVA, Bonferro
Bonferroni post-test).
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Additionally, no genotype difference (two-way ANOVA) in DA uptake rates were
observed in the NAc shell of aged mice (wildtype: 0.8 ± 0.1 µM/s, n = 11; BDNF+/-: 1.0 ±
0.1 µM/s, n = 12; Figure 5.5B). A significant decrease (Bonferroni post-test, P < 0.01) in
DA uptake rates was observed in the NAc shell of aged wildtype mice (young: 1.2 µM/s;
vs. aged: 0.8 µM/s; P = 0.005, Figure 5.5B). No aging effect was observed in DA uptake
rates of BDNF+/- mice (Figure 5.5B).
To better understand the combined effects of low BDNF levels and aging on
electrically evoked DA release, the numbers of stimulation pulses (p) were varied from 1
to 5. Once a stable electrically evoked DA release was obtained in a given location,
stimulation parameters were varied from 1p to 5p. Area under the curve (AUC) was
used to monitor the maximal evoked DA release. Increasing the number of pulses led to
an increase in the stimulated DA release in both wildtype and BDNF+/- mice (Figure
5.6A and 5.6B, respectively). To reduce the variation from one placement to the other,
AUC data was normalized a ration (DA5p/DA1p; Figure 5.6C). Striatal ratios for aged
wildtype mice were CPu: 1.2 ± 0.1, n = 15, NAc core: 1.8 ± 0.2, n = 14, and NAc shell:
2.1 ± 0.1, n = 12. Striatal ratios for aged BDNF+/- mice were CPu: 1.2 ± 0.04, n = 11,
NAc core: 1.5 ± 0.07, n = 6, and NAc shell: 2.5 ± 0.1, n = 7. Two-way ANOVA analysis
revealed a significant effect of the striatal region of interest (F2,59 = 44.04, P < 0.0001).
However, no difference was observed between the aged genotypes (F1,59 = 0.2072, P =
0.65). Also there was no genotype x striatal region interaction (F2,59 = 4.129, P = 0.021).
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Figure 5.5 Presynaptic dopamine (DA) dynamics from the nucleus accumbens (NAc)
shell measured using FSCV.. (A) Single pulse electrically evoked DA release and (B)
maximum velocity (Vmax, uptake rate) in the NAc shell of young and aged wildtype (WT)
and BDNF+/- mice. Data are reported as means ± SEMs for young (~ 3 months) and old
(~ 18 months) mice (n = 11 – 12 mice per group). **P < 0.01 for aging effect comparison
(two-way
way ANOVA, Bonferroni post
post-test).
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Figure 5.6 Effect of single (1p) or multiple pulse (5p) stimulation on electrically evoked
dopamine (DA) across the striatum in aged wildtype (WT) and BDNF+/- mice, measured
using FSCV. (A) Release in the caudate putamen (CPu) and nucleus accumbens (NAc)
core and shell in aged wildtype mice are reported as area under the curve (AUC). (B)
Release in the CPu, and NAc core and shell in aged BDNF+/- mice. (C) Ratio
Ra of DA
release (DA5p/DA1p) in aged WT and BDNF+/- mice. Data are reported as means ±
SEMs (n = 6 – 15 mice per group), analyzed using two
two-way
way ANOVA (Bonferroni postpost
test), ***P < 0.001 (differences within groups).
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Bonferroni post-test revealed a significant difference (P < 0.001) between NAc shell and
CPu in both aged wildtype and aged BDNF+/- mice (Figure 5.6C). A significant
difference was observed between the CPu and NAc core of the aged wildtype mice (P <
0.001), whereas no difference was observed in the aged BDNF+/- mice (Figure 5.6C).
To further understand the impact of aging on DA release upon multiple pulse
stimulations, the DA release ratios (DA5p/DA1p) of young adult (~ 3 months) and aged (~
18 months) mice were compared using a two-tailed t-test (Figure 5.7). Aging
significantly decreased electrically evoked DA release in the CPu (P < 0.001; Figure
5.7A) and NAc shell (P < 0.05) of wildtype mice, but no difference was observed in NAc
core (P > 0.05). In the BDNF+/- mice, aging led to a signficant decrease in DA release in
CPu (P = 0.03) and NAc core (P = 0.04; Figure 5.7B). Interestingly, in the NAc shell of
aged BDNF+/- mice, DA5p was significantly increased (P = 0.02) as a result of aging, in
line with aging-related increase in single pulse DA release observed in the CPu and
NAc core. These results indicate that in the absence or presence of BDNF, aging
reduces DA release (DA5p) in both genotypes, except in the NAc core of wildtype mice
where no change was observed.
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Figure 5.7 Effect of aging on 1 and 5 pulse stimulations of dopamine (DA) release
measured by FSCV. (A) The effect of age on stimulated DA release in young and aged
wildtype (WT) mice across the striatum. (B) The effect of age and reduced BDNF
expression on stimulated DA release in young and aged BDNF+/- mice in the CPu, NAc
core, and shell. Data are shown as means ± SEMs of DA release (DA5p/DA1p) in WT
and BDNF+/- mice (n = 6 – 13 mice per group). **P < 0.05, **P < 0.01 for the effect of
age on the brain region
ion of interest (Student’s tt-test).
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5.4 Discussion
The main objective of the present study was to determine the long-term effect of
low endogenous BDNF levels on DA dynamics. This was accomplished by using slice
FSCV and in vivo microdialysis to probe DA dynamics in aged BDNF+/- and wildtype
mice. Contrary to our hypothesis that low BDNF levels would greatly attenuate DA
dynamics in aged mice, no genotypic differences in stimulated DA release, DA uptake,
or basal extracellular DA levels were observed. Interestingly, extracellular levels of
DOPAC were elevated in aged BDNF+/- mice as compared to aged wildtype mice, while
no genotypic difference was observed in HVA levels. Overall, aged BDNF+/- mice
appear to have an elevated catabolism process as compared to the wildtype mice.
To further understand the impact of aging and low endogenous BDNF levels on
DA dynamics, the results from the aged mice (~ 18 months) were compared to those
obtained from young adult mice (~ 3 months). Three-month-old BDNF+/- mice have a
hyperdopaminergic phenotype that is attributed to both reduced electrically evoked DA
release and reduced function of the DA transporter (CHAPTER 4). These DA
alterations, as measured by FSCV, were not observed in aged BDNF+/- mice. A
significant decrease in basal extracellular DA levels, as measured by the zero net flux
method, was observed in aged BDNF+/- mice as compared to their younger
counterparts, but no difference in basal extracellular DA levels between young and aged
wildtype mice was observed. The basal levels of DA determined from aged and young
wildtype, as well as aged BDNF+/- mice were all similar (~ 6 nM) and are consistent with
striatal DAext values previously reported for adult C57BL/6 mice (241). However, aged
mice with reduced BDNF expression exhibited a significant increase in DOPAC levels
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as compared to aged wildtype mice. However, no age-related difference in HVA levels
were observed between young and old mice.
BDNF+/- mice have a hyperdopaminergic phenotype at the age of ~ 3 – 4 months
due to reduced DA transport (CHAPTER 4). Surprisingly, at this age, levels of DOPAC
are not altered as expected due to the elevated basal extracellular DA levels in these
mice. Aged (11 – 24 months) wildtype (C57Bl/6) and DAT+/- mice have an elevated
DOPAC/DA ratio, although at a greater magnitude in the DAT+/- mice (242). Similarly,
we observed elevated DOPAC levels in the aged BDNF+/- mice. Increased DOPAC
levels are mainly attributed to an elevated catabolism rate (242-244). However, we did
not observe significant change in HVA levels with age in either BDNF+/- or wildtype mice.
Tissue content DA levels were not altered in the aged DAT+/- mice but decreased DA
levels were observed from the age of 11 months in wildtype mice (242). In our study,
extraneuronal DA levels were attenuated in the old BDNF+/- mice as compared to the
young mice, but no change was observed with age in wildtype mice. Taken together,
the age-related high rate of catabolism appears to reduce the elevated extracellular DA
levels in the BDNF-deficient mice, similar to levels for wildtype mice.
Dysregulation of motor function in Parkinson's disease patients is attributed to
loss of more than 80% of DA neurons in the striatum (10, 40, 226, 245). However, agerelated motor deficits are thought to mainly involve alterations in functional parameters
of the DA system, not neuronal loss, as demonstrated in animal models of aging (214,
221, 228). Specifically, it is believed that changes, such as decreased DA uptake by the
DA transporter, reduced DA release, and decreased VMAT2 activity, may lead to the
age-related motor deficits (214, 221, 229). In wildtype mice, aging decreased electrically
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evoked DA release (1p stimulation) in the NAc (core and shell), but no difference in
stimulated DA release in the CPu was observed. Interestingly, DA uptake rates were
significantly decreased only in the NAc shell, but not in the NAc core or CPu of aged
wildtype mice as compared to the young adult mice. Overall, wildtype mice show an
age-related decrease in presynaptic DA release and uptake functions that is regionspecific. Currently, it is not known which parameter within the DA system is the primary
effect of aging. The FSCV data suggests that both DA release and DA uptake are
reduced with age. However, this decrease in both parameters is not parallel across all
brain regions, as the CPu appears resistant to changes in DA release and uptake, while
the NAc core shows no difference in DA uptake between young and aged wildtype
mice. These results suggest that the NAc shell is most susceptible to age-related
alterations in wildtype mice, which is interesting because aging research has generally
not been focused on the NAc. Most aging research has focused on the CPu, due to its
role in regulating movement, as seen in the neurodegenerative disease of Parkinson’s.
The primary functions associated with the NAc are natural or biological rewards, like
eating, drinking, procreation, and investigation (246). Additionally, it is interesting that
the anatomically distinct region of the NAc shell is more susceptible to presynaptic DA
changes as compared to the core. Although these voltammetry results are unable to
pinpoint an exact mechanism, they do suggest a need for further evaluation of DA
parameters within the VTA-NAc region during the normal aging process.
In contrast to wildtype mice, aged BDNF+/- mice exhibit a potentiation in
electrically stimulated DA release (1p stimulation) in the CPu and NAc core, but no
difference in DA release was seen in the NAc shell. DA uptake rates were significantly
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elevated only in the CPu, while no difference in DA uptake was seen in the NAc core or
shell of aged BDNF+/- mice. These results are very surprising, because our initial
hypothesis was that the DA dynamics of aged BDNF+/- mice would be more susceptible
to the combined effects of age and low BDNF levels as compared to wildtype mice.
Overall, a lifetime of low endogenous BDNF levels in mice appear to lead to
enhancement in electrically stimulated DA release and DA uptake rates in the CPu. The
presynaptic DA dynamics in aged BDNF+/- mice appear to ‘normalize’, as measured by
voltammetry and dialysis, such that they appear neurochemically similar to the wildtype
mice. Others who have examined the effect of aging in BDNF+/- mice have shown that
they have reduced locomotor activity in beam walking and accelerated rotarod
performance as compared to the aged wildtype (11 – 21 months old) mice (34, 133,
134).
Exactly how BDNF mediates DA dynamics remains unknown, although it has
been hypothesized that intracellular BDNF prevents synaptic fatigue (185, 187, 247).
This suggests that BDNF may enhance long-term potentiation (LTP) induction at highfrequency stimuli. Our previous findings demonstrated that three-month-old adult mice
with low BDNF levels have reduced DA available for release in the NAc shell when the
number of stimulation pulses is increased as compared to three-month-old wildtype
mice (Section 4.4.2). To understand how aging and BDNF deficiency affect DA release,
we evaluated electrically stimulated DA release in the striatal complex using 1 and 5
pulse stimulation parameters (101). No genotype difference was observed in DA
release as the number of stimulation pulses increased in aged wildtype and BDNF+/mice. To understand the impact of the presence or reduction of BDNF and aging on DA
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release, three-month-old adult and aged (~ 18 months) mice were compared. Aged
wildtype mice exhibited a significant decrease in DA5p release in the CPu and NAc shell,
with no difference in NAc core as compared to their younger counterparts. Aged
BDNF+/- mice showed a signficant decrease in DA5p release in the CPu and NAc core
compared to the younger BDNF+/- mice. Taken together, these multiple pulse stimulation
results indicate a reduction in DA release upon aging in both genotypes. In contrast, an
increase in DA5p release was observed in the NAc shell of BDNF+/- mice. This difference
highlights an enhanced DA release in the NAc shell of aged BDNF+/- mice that was not
observed upon single pulse stimulation. The NAc shell is known to be more responsive
to multiple pulse stimulation, which is in line with burst firing during rewarding events
(56, 101, 197).
These findings demonstrate that low BDNF levels in early life may have
detrimental consequences on DA system functions in the striatum, such as reduced DA
release, DA uptake, and elevated basal DA levels. However, the DA system appears to
adapt with age. In mice deficient in BDNF, the presynaptic DA dynamics appear to
neurochemically adapt such that they appear more like wildtype mice. However, the
contribution of age and BDNF levels to this phenomenon is unknown and future studies
must be performed to better understand if this is a gradual shift or a sudden change. In
either case, it will be very interesting to understand what molecular targets may
contribute to this shift in the aging BDNF+/- mice. A simplistic hypothesis is that an
enhanced catabolism process in the CPu is able to significantly decrease the elevated
basal extracellular DA levels in young adult mice. If these changes, either in monoamine
oxidase (MAO) expression or function, are indeed enough to regulate extracellular DA

140
levels, then the system could try compensating by enhancing DA release and DA
uptake rates during the aging process. To confirm this hypothesis, studies evaluating
MAO must be conducted to better detail its role.
5.5 Conclusions
In wildtype mice, age-related reductions in DA release were observed in the
striatal complex, with the NAc shell being more susceptible to reduction in DA clearance
as well. No significant alterations were observed in basal DA concentrations or
catabolism processes due to aging. Overall, only a decline in presynaptic DA function
was observed in the aged wildtype mice.
Despite the fact that reduced BDNF levels are linked to a dysfunctional DA
system in human and animal models, our current study failed to find BDNF-related
reduction in presynaptic DA dynamics in aged BDNF-deficient mice (41, 133, 190, 231,
233, 236). In fact, stimulated DA release, DA uptake rates, and catabolism by MAO
appear enhanced. The hyperdopaminergic phenotype observed in three-month-old
BDNF-deficient mice was reversed with age, leading to normal levels of basal DA
levels. Increase in DA release in BDNF-deficient mice highlights enhancement in
dopaminergic neuron presynaptic function with age. These findings from aged mice
highlight adaptations in the dopaminergic system as a result of the normal aging
process in mice with reduced BDNF levels. Future studies are required to examine
different discrete time points to determine at what age the neurochemical adaptations
‘switch’ to make the BDNF-deficient mice appear more like aged wildtype mice. The role
of BDNF appears to be more important in the development of the DA system, but not for
the maintenance of the neurons (248). During neuronal development, low BDNF levels
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may alter DA transmission. However, at old age, low endogenous BDNF levels alone do
not appear to be critical in DA dysregulation.
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CHAPTER 6
Effect of Low Endogenous BDNF levels on Dopamine Transporter
Function
6.1 Introduction
Extracellular dopamine (DA) signaling is terminated primarily through rapid
reuptake by the DA transporter, regulating the lifetime of extraneuronal DA following its
release. The Na+ and Cl- dependent DA transporter consists of 12 transmembrane
regions, each with functional roles (10, 249). The first five regions from the N-terminal of
the DA transporter are thought to be involved in ion-dependent substrate transport
(250). Methamphetamine and other DA transporter inhibitors target the transmembrane
regions six through eight, while the remaining regions through the C-terminus are
involved in substrate affinity and stereoselectivity (249-252).
Drugs of abuse such as methamphetamine and cocaine are known to increase
extracellular DA by interacting with the DA transporter, albeit different mechanisms (10,
253). Methamphetamine competitively inhibits DA reuptake at the DA transporter, as
well as reversing DA transport, these effects combined lead to increased extraneuronal
DA levels (5-7, 253). Once inside the neuron, methamphetamine modulates vesicular
monoamine transporter (VMAT) activity (6, 254-257). As a potent competitive DA
antagonist at the VMAT, methamphetamine limits sequestration of cytoplasmic DA into
vesicles (255). This results in DA efflux that is independent of the presynaptic neuron
firing activity.
Besides being a highly addictive substance, prolonged high doses of
methamphetamine are known to be neurotoxic (258-261). Specifically, animal models
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indicate numerous neurochemical impairments within the striatal DA system, such as
long-lasting intracellular depletions of DA, its catabolites 3,4-dihydroxyphenylacetic acid
(DOPAC) and homovanillic acid (HVA), as well as tyrosine hydroxylase (TH) activity
(259-261). The ability of methamphetamine to induce dopaminergic deficits appears to
be region specific, with the caudate putamen (CPu) being more susceptible and the
nucleus accumbens (NAc) being relatively resistant to the long-term DA system
dysregulation (262, 263). Moreover, neurotoxicity of methamphetamine appears to be
dependent on age, brain-derived neurotrophic factor (BDNF) levels, gender, stress, and
temperature (35, 258-260, 264).
With respect to methamphetamine neurotoxicity, Dluzen and co-workers showed
that there is less severe damage to the nigrostriatal dopaminergic system in BDNF
heterozygous mutant (BDNF+/-) mice as compared to their wildtype littermates (35, 134).
However, the role of low BDNF levels on the reduced neurotoxicity is still a subject of
considerable debate. Our findings from CHAPTER 4 show that BDNF+/- mice have
attenuated DA uptake rates as compared to their wildtype littermates (Figure 4.4),
suggesting that expression or function of the DA transporter is reduced. Interestingly,
autoradiographic methods show no difference in DA transporter expression between
wildtype and BDNF+/- mice (37, 133).
The main objective of this study was to evaluate DA transporter function in a
mouse model with low endogenous BDNF levels. Slice FSCV was used to probe the
effects of methamphetamine by monitoring inhibition of DA uptake, as previously
reported (14, 62, 68, 90, 265, 266). Methamphetamine induces rapid and reversible
competitive inhibition of DA uptake through the DA transporter (6, 14, 62). Therefore,
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methamphetamine was used as tool to probe DA transporter kinetic parameters such as
maximum velocity (Vmax), apparent Michaelis-Menten constant (apparent Km), and
stimulated DA concentration per pulse [DA]p using slice FSCV from wildtype and
BDNF+/- mice. We hypothesized that decreased DA transporter function in the BDNF+/mice will manifest as a decrease in methamphetamine’s affinity towards the DA
transporter. Additionally, in vivo microdialysis was used to evaluate the role of BDNF
levels on methamphetamine-induced DA release in freely moving mice.
6.2 Materials and methods
Kelly Bosse, Ph.D. performed all the microdialysis experiments on young mice (3 – 4
months of age). Johnna A. Birbeck performed all the microdialysis experiments on aged
mice (~ 18 months of age). In all cases, microdialysis experiments conducted by either
Dr. Bosse or Johnna Birbeck involved stereotaxic surgery, probe implantation, sample
collection,

methamphetamine

injection,

HPLC

separation

with

electrochemical

detection, and chromatographic data analysis.
BDNF wildtype and BDNF+/- mice were raised as a colony in house and
genotyped as described in Section 2.2. Male (BDNF+/- and wildtype) mice aged ~ 3 – 4
months (young) or both male and female mice aged ~ 18 months were used for slice
FSCV experiments and in vivo microdialysis. Slice FSCV experiments were performed
as previously described in Section 2.4 with minor modifications. Single pulse stimulation
was used to electrically evoke DA release in the caudate putamen (CPu) every five
minutes. Upon obtaining a stable baseline, increasing concentrations (0.01 – 10 µM) of
methamphetamine (Sigma-Aldrich, St. Louis, MO) were perfused over brain slices from
either

young

or

aged

(wildtype

or

BDNF+/-)

mice.

Each

concentration

of
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methamphetamine was perfused for 30 minutes, with DA being electrically evoked
every five minutes.
In vivo microdialysis experiments in young adult and aged mice were performed
by Kelly E. Bosse, Ph.D. and Johnna A. Birbeck, respectively, as described in Section
2.5. Briefly, upon stereotaxic surgery, a microdialysis probe was implanted in the CPu
for sampling. After recovery and equilibration, at least three dialysate baseline samples
were collected for 20 minutes. An intraperitoneal (i.p.) injection of methamphetamine
(1.0 mg/kg) was administered immediately after collection of the third baseline sample.
At least six dialysate samples containing methamphetamine-induced DA release were
collected every 20 minutes. The extraneuronal DA concentration from each dialysate
sample was determined through separation and quantification using HPLC coupled to
an electrochemical detector as described in Section 2.6.
6.2.1 Data analysis
Kelly E. Bosse, Ph.D. and Johnna A. Birbeck performed statistical analysis and
graphing of the microdialysis data.
All values are reported as means ± standard errors of the means (SEMs) of at
least five animals. Slice FSCV data were analyzed by fitting the current versus time
traces to a Michaelis-Menten kinetic based model to determine changes in [DA]p, Vmax,
and apparent Km (“apparent” affinity of DA for its transporter) (62, 68, 90, 138).
Competitive inhibition of DA uptake is reflected as an increase in apparent Km (62, 68).
The relationship between inhibition constant (Ki) and apparent Km is described by
Equation 4, where [i] is the concentration of inhibitor (e.g. methamphetamine) and Km is
the Michaelis-Menten constant. As previously reported, Ki values were calculated from
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the slope of a linear regression plot of methamphetamine concentration versus the
apparent Km values (Equation 5), where the Km was 0.16 µM, as previously reported
(62, 68, 139, 140). Apparent Km values resulting from effect of higher concentrations of
methamphetamine (> 0.3 µM) were excluded to properly fit the linear regression. At
these high concentrations, methamphetamine reduced stimulated DA release besides
inhibiting DA uptake. The DA uptake process obeys the Michaelis-Menten kinetics with
the assumption that each stimulation pulse releases a constant amount of DA (14, 62).

Dose

response

Apparent Km = Km x (1 + [i]/Ki)

(4)

Slope = ∆y/∆x = Km/Ki

(5)

curves

were

plotted

as

log

concentration

(M)

of

methamphetamine versus percent of baseline (maximal stimulated DA release) and the
data were fitted using a non-linear regression curve to determine the half maximal
effective concentration (IC50; concentration of inhibitor at which DA release is half the
maximum). Differences in methamphetamine’s effect on DA apparent Km values and
stimulated DA release were assessed using a two-way ANOVA with genotype as the
independent variable and concentration of methamphetamine as the repeated measure.
The effect of methamphetamine on Vmax was analyzed using a one-way ANOVA with a
Dunnett's post-test to compare pre-drug Vmax values to treatments. Finally, the effect of
BDNF levels on methamphetamine-induced extracellular DA levels as measured by
microdialysis was assessed using a two-way ANOVA, with genotype as the
independent variable and time as the repeated measure. In all cases, statistical
significance is defined as P < 0.05.
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6.3 Results
Methamphetamine dose-dependently inhibited DA uptake in both genotypes (P <
0.0001). Representative pre-drug and 0.3 µM methamphetamine induced concentration
versus time traces and their corresponding cyclic voltammograms from wildtype mice
are shown in Figure 6.1A. In the presence of methamphetamine, the “apparent” affinity
of DA for its transporter is decreased, as evaluated by linear and non-linear fitting
(Figure 6.1B – E). Dose dependent decrease in affinity of DA for its transporter is
represented as an increase in apparent Km values. Young (~ 3 months) and aged (~ 18
months) mice show dose dependent increase in the apparent Km values in both wildtype
and BDNF+/- mice (Figures 6.1B & C). Analysis of the non-linear dose response curves
for the young BDNF+/- and wildtype mice using two-way ANOVA revealed significant
effects of methamphetamine treatment (F7,142 = 65.77, P < 0.0001), genotype (F1,142 =
12.93, P = 0.0004), and genotype x treatment interaction (F7,142 = 3.15, P = 0.0040). The
apparent Km values were attenuated in the young BDNF+/- mice as compared to their
wildtype littermates (Figure 6.1B). Higher apparent Km values indicate greater uptake
inhibition in the young wildtype than in the BDNF+/- mice. Data analysis for the aged
mice using two-way ANOVA revealed a significant main effect of methamphetamine
treatment (F6,317 = 96.50, P < 0.0001), but with no genotype difference (F1,317 = 0.018, P
= 0.89) or genotype x treatment interaction (F1,317 = 0.14, P = 0.99). Overall, the effect of
BDNF levels on methamphetamine treatment was only observed in the young mice.
To quantitatively characterize DA uptake inhibition, Ki values were calculated
from the linear regression of apparent Km values using Equation 5 (Figure 6.1D). A low
Ki value represents high drug potency while a high Ki value represents low drug potency
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Figure 6.1 Effect of methamphetamine (inset, chemical structure) on apparent Km
values obtained using slice FSCV in young (~ 3 months) and aged (~ 18 months) mice
of wildtype (WT) and BDNF+/-- mice. (A) Representative concentration versus time plots
(left) and cyclic voltammograms (right), before (pre
(pre-drug)
drug) and after perfusion of 0.3 µM
methamphetamine in WT mice. (B & C) Non
Non-linear fitting of dose-dependent
dependent increase in
apparent Km values with increasing methamphetamine concentrations in young and
aged mice, respectively. (D & E) Linear regression plots of the apparent Km values in
young
ng and aged mice, respectively, with omission of methamphetamine concentrations
greater than 0.3 µM, because they significantly reduce DA release upon electrical
stimulation. Data are reported means ± SEMs (n = 6 – 14 mice per group), analyzed
using two-way ANOVA, ***P < 0.0001.
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(62). The Ki for methamphetamine was lower in young wildtype (0.011 ± 0.001 µM, n =
7) as compared to the BDNF+/- (0.024 ± 0.001 µM, n = 6) mice, suggesting that
methamphetamine is more potent in the wildtype mice than the BDNF+/- mice. In
contrast, the calculated Ki values for methamphetamine from the aged mice (Figure
6.1E) were similar for both genotypes (wildtype; 0.026 ± 0.002 µM, n = 14 and BDNF+/mice; 0.021 ± 0.002 µM, n = 12). Overall these results suggest that methamphetamine
potency is decreased in young mice with low endogenous BDNF levels as compared to
wildtype littermates, with no potency difference in the aged mice.
To determine the role of low endogenous BDNF levels on DA release, electrically
evoked DA release was evaluated with increasing methamphetamine concentrations.
Methamphetamine limits the presynaptic neuron’s ability to use VMAT by disrupting the
proton gradient required for sequestration of cytoplasmic DA into vesicles (255)
Methamphetamine causes DA efflux that is independent of electrical stimulation or
neuron firing activity (255). The maximal electrically stimulated DA release, normalized
as percent of baseline, significantly decreased in a dose-dependent manner with
increasing concentrations of methamphetamine in both genotypes (Figure 6.2). In this
study, IC50 values obtained from the dose-response curves are defined as the
concentration of methamphetamine required to attenuate electrically stimulated DA
release by 50%, relative to the pre-drug baseline. The IC50 values from young mice
were 0.055 ± 0.003 µM (wildtype, n = 7) and 0.060 ± 0.003 µM (BDNF+/-, n = 6). The
IC50 values from aged mice were 0.066 ± 0.002 µM (wildtype, n = 14) and 0.066 ± 0.002
µM (BDNF+/-, n = 12), which were similar to the IC50 values of the young mice. Two-way
ANOVA revealed that methamphetamine treatment significantly reduced stimulated DA
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Figure 6.2 Effect of methamphetamine on electrically stimulated dopamine (DA) release
as measured using slice FSCV. Dose
Dose-dependent
dependent decrease in maximal stimulated DA
release relative to percentage of baseline in: (A) young adult mice (~ 3 months) and (B)
aged (~ 18 months)
onths) mice in both wildtype (WT) and BDNF+/- mice. Data are means ±
SEMs (n = 6 – 14 mice per group), analyzed using two
two-way ANOVA.
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release in both young (F7,143 = 66.74, P < 0.0001, Figure 6.2A) and aged (F6,326 = 346.8,
P < 0.0001; Figure 6.2B) mice. However, no main effect of genotype was observed in
young (F1,143 = 0.35, P = 0.56) or aged (F1,326 = 0.52, P = 0.47) mice. Overall, the results
suggest that BDNF expression does not play a role in the methamphetamine-induced
vesicular depletion of DA.
Perfusion of methamphetamine did not alter the maximum velocity (Vmax) in either
genotype (Figure 6.3), as analyzed by one-way ANOVA (Dunnett's post-test). No
difference was observed between the pre-drug Vmax and Vmax after methamphetamine
treatments in ~ 3 month old wildtype (F7,98 = 1.37, P = 0.23) or BDNF+/- mice (F8.73 =
0.90, P = 0.52), Figures 6.3A and 6.3C, respectively. Similarly, increasing concentration
of methamphetamine did not affect the Vmax in the ~ 18 month old wildtype (F6,179 = 0.44,
P = 0.85; Figure 6.3B) or BDNF+/- (F6,143 = 0.89, P = 0.51; Figure 6.3D) mice.
Genotypic differences in methamphetamine-induced DA release were assessed
using in vivo microdialysis. Microdialysis results were obtained by Johnna A. Birbeck
and Kelly E. Bosse, Ph.D. Methamphetamine i.p. injection (1.0 mg/kg) resulted in a 300
– 500% increase in extracellular concentrations of DA, relative to percent baseline, in
both young and aged wildtype and BDNF+/- mice (Figure 6.4). Two-way ANOVA
analysis revealed a significant main effect of methamphetamine treatment (F8,115 =
14.87, P < 0.0001), but no genotype effect (F1,115 = 0.12, P = 0.73), or treatment x
genotype interaction (F8,115 = 0.53, P = 0.83) in young mice. Similarly, aged mice
revealed a significant main effect of methamphetamine treatment (F8,231 = 9.36, P <
0.0001), but no
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Figure 6.3 Effect of methamphetamine concentration on dopamine uptake, quantified
by maximum velocity (Vmax), as measured using slice FSCV in the caudate putamen
(CPu). Vmax values were not different after perfusion of methamphetamine in young
adult (~ 3 months) wildtype and BDNF+/- mice (A & C, respectively), and aged (~ 18
+/months) wildtype and BDNF+/
mice (B & D, respectively). Data are reported as means ±
SEMs (n = 6 – 14 mice per group).
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Figure 6.4 The acute effect intraperitoneal injection of methamphetamine (METH; 1.0
mg/kg) on extracellular dopamine (DA) concentrations in the caudate putamen (CPu) of
young and aged (wildtype (WT) and BDNF+/-) mice. Extracellular DA levels are
expressed as a percentage relative to baseline in (A) young (~ 3 months) and (B) aged
(~ 18 months) mice. METH-induced
induced extracellular DA levels are not different between the
genotypes
pes in young and aged mice. Each fraction number (#) was collected for a period
of 20 minutes. Data are reported as means ± SEMs (n = 7 - 20 mice per group). Figure
courtesy of Johnna A. Birbeck, Kelly E. Bosse, Ph.D., and Tiffany A. Mathews, Ph.D.
Ph.D

154
genotype effect (F1,231 = 2.44, P = 0.11), or treatment x genotype interaction (F8,231 =
0.35, P = 0.94). Overall, these findings indicate that low BDNF levels did not alter
methamphetamine-induced DA release in vivo.
6.4 Discussion
The primary objective of the present study was to determine the effect of low
endogenous BDNF levels on DA transporter function throughout the animal’s lifetime.
This study was prompted by our previous findings that showed reduced DA uptake rates
in young adult BDNF+/- mice as compared to their wildtype littermates (CHAPTER 4). To
determine the extent of how low endogenous BDNF levels may alter or disrupt DA
transport function, a competitive inhibitor of DA transporter methamphetamine was
used. Slice FSCV was used to probe DA transporter function due to its fast temporal
resolution (milliseconds) providing a relative comparison of DA uptake kinetic
parameters. It has been previously reported that BDNF deficiency does not alter the
expression of DA transporter; therefore, we predicted that BDNF+/- mice have altered DA
uptake function leading to the observed decrease in uptake rates (37, 133). A dosedependent increase in apparent Km values with increasing methamphetamine
concentration was observed in both genotypes and age groups. Interestingly, young
BDNF-deficient mice appear to have a lower apparent Km as compared to their wildtype
littermates, suggesting a reduction in DA transport function. However, such BDNFdependent reduction in DA transport function was not observed in the aged BDNF+/mice suggesting the mice adapt with time.
DA uptake rates through the DA transporter are described by Michaelis-Menten
kinetics with the following assumptions: (1) each electrical stimulation releases a
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constant amount of DA, (2) the primary mechanism from clearing DA from the synapse
is by the DA transporter, and (3) the uptake process is saturable (14, 267, 268). In slice
FSCV, the Km value is inversely related to DA’s affinity for its transporter. In the
presence of a competitive inhibitor like methamphetamine, the apparent Km increases
linearly indicating a low affinity of DA for its transporter (14, 62). Overall, the
concentration of DA needed to reach Vmax in the presence of methamphetamine is
greater than the concentration of DA needed in its absence.
An inverse relationship exists between Ki and potency of an uptake inhibitor; with
a high Ki value representing lower inhibitor potency while a low Ki value represents
higher potency of the inhibitor. In this study, Ki values were calculated from the apparent
Km values (see Equation 5). Young wildtype mice had a lower Ki value as compared to
young BDNF+/- or the aged mice. Overall, the Ki values obtained for methamphetamine
(0.011 – 0.026 µM) from both genotypes were lower than previously reported Ki from
C57Bl/6J mice (0.47 µM) using FSCV (62). Our Ki values were lower than previously
reported because concentrations of methamphetamine greater than 0.3 µM reduce the
electrically-stimulated DA release, in agreement with John and Jones observations with
high concentrations of DA releasers (62). A net decrease in the amount of DA available
for release alters the uptake process, an effect observed with amphetamines and not
other uptake inhibitors such as cocaine (68, 193). However, this effect on stimulated DA
release in the presence of methamphetamine does not appear to be dependent on
BDNF levels.
Maximum velocity (Vmax), which is proposed to be proportional to the number of
DA transporters, was not altered by methamphetamine perfusion. This observation is in
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agreement with other studies that have shown that both amphetamine and
methamphetamine do not alter the Vmax during DA inhibition (62, 269). Acute treatment
of brain slices using methamphetamine is unlikely to cause degeneration of DA neurons
or alter DA transporter density. With respect to age, there is evidence that aged BDNFdeficient mice, greater than 18 months old show no difference in DA transporter
expression (133). Taken together, these findings further imply that low BDNF levels play
a major role in altering DA transport function at a young age (~ 3 months of age) but low
endogenous BDNF levels appear to have no overt effect on DA transporter expression.
Normally, transport of extracellular DA into the neuron is unidirectional, with the
inward transport rate being greater than the rate of outward transport (14, 270). The
presence of high extracellular concentrations DA for prolonged periods of time is
thought to lower the rate of inward DA transport (reuptake) by the DA transporter (14).
In addition, methamphetamine is hypothesized to favor the DA transporter to face
inward most of the time, promoting DA efflux (267). If one of the functional consequence
of the observed decreased Vmax in the young BDNF+/- mice is the presence of more
inward facing DA transporters, then this would suggests that the effect of inhibition of
DA transport by methamphetamine is reduced. Indeed, our results show reduced DA
inhibition (higher Ki value) in young BDNF+/- mice as compared to wildtype mice.
There is considerable evidence showing that protein kinases, such as protein
kinase C (PKC) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulate DA
transporter functions, including its orientation through phosphorylation (213, 271-274).
Specifically, PKC activation causes phosphorylation of DA transporter at the Nterminus, an event required for amphetamine-mediated DA efflux (272, 274).
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Interestingly, BDNF signaling through TrkB receptor activation is known to regulate
numerous intracellular signaling pathways like PKC (10, 22). However, our current
findings are unable to determine the exact role of reduced BDNF levels on protein
kinases in the modulation of DA transporter.
It has been hypothesized that neurotoxic regiments of amphetamine molecules
release sequestered DA from vesicles into the more oxidizing intracellular environment,
facilitating the formation of reactive oxygen species such as superoxide radicals,
hydroxyl radicals, and quinines (131, 275). Furthermore, it is hypothesized that DA
neurons are more susceptible to degeneration due to the increased formation of
reactive oxygen species that can destroy numerous biological functions within DA
neurons. Intraneuronal sequestration of DA is important in preventing formation of
reactive

oxygen

species

because

VMAT2

knock-out

mice

have

increased

methamphetamine-induced neurotoxicity (276). However, DA transporter knock-out
mice are protected against methamphetamine-induced DA depletion and reactive
oxygen species production in the striatum (277). This is attributed to reduced access of
methamphetamine into the neuron (277). Interestingly, previous work has shown that a
neurotoxic dose of methamphetamine causes more damage to the nigrostriatal
dopaminergic system of wildtype mice as compared to BDNF+/- mice (35, 134). Others
have shown that pre-treatment with BDNF protects neurons (29, 278, 279). Our findings
suggest that young BDNF+/- mice would appear to be more resistant to a neurotoxic
regiment of methamphetamine because they have decreased DA transporter function
as compared to wildtype mice. Finally, our initial characterization and these
methamphetamine results suggest that, due to the reduced DA transporter function in
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the young BDNF+/- mice, methamphetamine access into the neuron is decreased. Thus,
young BDNF+/- mice would be more resistant to methamphetamine neurotoxicity as
compared to the young wildtype or aged mice.
6.5 Conclusions
The results herein suggest that low endogenous BDNF levels may modulate DA
transporter function as evaluated using methamphetamine. Young BDNF+/- mice have
reduced effectiveness of methamphetamine in competitively inhibiting DA uptake as
compared to wildtype mice. The reduced apparent Km values in young BDNF+/- mice as
compared to wildtype littermates, further suggests that the observed functional
decrease in DA uptake may be a result of the reduced affinity of DA for its transporter.
Overall, the methamphetamine results confirm our hypothesis that, only young BDNF+/mice have reduced DA uptake function, with no change in DA transporter density
because the Vmax was not altered. DA transport function in the aged mice was not
different, as hypothesized because DA uptake rates in wildtype and BDNF+/- mice were
similar.
Most often the addictive properties of drugs of abuse such as methamphetamine
involve the mesolimbic dopaminergic system (10). However, the actions of abused
drugs are not limited to only one system or brain region, but involve the interaction of
numerous neurotransmitters, small molecules, and proteins. More specifically, recent
studies have suggested that BDNF may play a pivotal role in addiction (53, 54, 112,
113, 280). Our finding highlights that; BDNF may modulate the DA transporter, a
common target for drugs of abuse such as cocaine and methamphetamine.
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CHAPTER 7
Conclusions and Future Directions
Brain-derived neurotrophic factor (BDNF) hypofunction is implicated in several
neurological disorders and diseases that affect the dopamine (DA) system, such as
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, schizophrenia,
attention deficit hyperactivity disorder (ADHD), addiction, and depression (42, 46, 53,
54, 112, 113, 115-117, 190). However, it is not known whether the BDNF hypofunction
is the cause of these diseases/disorders or a result. Overall, our findings indicate that
BDNF hypofunction can modulate presynaptic DA dynamics in the striatum, suggesting
that low levels BDNF may play a role in the susceptibility to DA-related neurological
diseases and disorders. The specific conclusions from the work undertaken here, as
well as the studies needed to better understand the role of the BDNF on DA system are
summarized in this chapter.
7.1 Characterization of dopamine D2 and D3 autoreceptors
Slice fast scan cyclic voltammetry (FSCV) and DA agonists were used to
characterize the functionality of the DA D2 and D3 autoreceptors in the mouse striatum.
The DA D2 agonists studied demonstrated that the DA D2 autoreceptors have a similar
functionality in the caudate putamen (CPu), nucleus accumbens (NAc) core and NAc
shell. However, the DA D3 autoreceptors functionality is localized in discrete regions,
with the largest response to DA D3 agonists being in the NAc shell, followed by NAc
core, and then the CPu. The analytical method developed provides a unique way of
probing

presynaptic

DA

D2

and

D3

receptors.

The

findings

complement

autoradiography studies, which are unable to differentiate expression of presynaptic and
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post-synaptic DA D2 and D3 receptors (20, 119-122, 154, 155, 158). Taken together
these findings suggest that presynaptic DA D2 receptors are homogenously distributed
in the striatum, while DA D3 autoreceptors are localized in the NAc shell. Furthermore,
the Mathews’ laboratory developed this slice FSCV assay to determine how low levels
of endogenous BDNF influence presynaptic DA D2 and D3 autoreceptor functionality
within the striatum (CHAPTER 4).
Taking advantage of the expression of each of the DA D2-like autoreceptors
within the discrete striatal regions will be useful to differentiate the specificity of D2-like
drug candidates, by determining DA D2 or D3 drug preference. Using slice voltammetry
to characterize DA agonists and antagonists as either more D2- or D3-preferring will
provide critical information regarding potential therapeutic selectivity, potency, efficacy,
and dose dependency. Using slice FSCV assay to map presynaptic DA D2 and D3
autoreceptor functionality will also offer insight into the neurological diseases when used
in genetically modified animal models.
7.2 Effect of low BDNF levels on dopamine dynamics
The overarching objectives of the “BDNF project” were to understand if and how
low endogenous BDNF levels alter presynaptic DA dynamics using the complementary
neurochemical techniques of in vivo microdialysis and slice FSCV. Our findings suggest
that BDNF is indeed a powerful modulator of presynaptic DA dynamics. Low levels of
BDNF appear to cause hyperdopaminergia in the CPu, characterized by elevated
extracellular basal DA concentration and decreased DA uptake rates (Figure 7.1).
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brain
Figure 7.1 Schematic diagram showing the impact of low endogenous brain-derived
neurotrophic factor (BDNF) levels on dopamine (DA) dynamics as measured using in
vivo microdialysis and slice FSCV in the caudate putamen (CPu). BDNF+/- mice have
reduced BDNF levels, elevated extr
extracellular
acellular DA levels (hyperdopaminergia), reduced
DA uptake function, and reduced DA release as compared to wildtype mice.
Abbreviations: TH, tyrosine hydroxylase; L-DOPA, L-3,4-dihydroxyphenylalanine;
dihydroxyphenylalanine; AADC,
L-aromatic
aromatic amino acid decarboxylase; VMAT, vesicu
vesicular
lar monoamine transporter; DAT,
DA transporter; TrkB, tyrosine kinase B.
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To further probe the observed decrease in DA transporter uptake rates in
BDNF+/- mice, the DA transporter substrate methamphetamine was used as a tool to
evaluate the DA transporter kinetics. Low, endogenous BDNF levels in young mice lead
to reduction in the affinity of DA for its transporter (CHAPTER 6). Therefore, the
observed reduction in striatal DA uptake rate is primarily due to reduction in DA
transport function. We hypothesize that the observed decrease in DA uptake in BDNF+/mice could be a result of the DA system trying to overcompensate for the increase in
basal extracellular DA levels. Future studies are warranted to determine if this
combination of low BDNF levels and a hyperdopaminergic system increase the
susceptibility to neurological disorders.
Slice voltammetry revealed that young BDNF+/- mice have decreased stimulated
DA release in the CPu. This finding was surprising because in vivo microdialysis
showed an increase in extracellular basal DA levels with no difference in DA synthesis
rates. Furthermore, evidence from the Pozzo-Miller laboratory suggests that in the
hippocampus, BDNF enhances quantal neurotransmitter release by increasing the
number of docked synaptic vesicles within presynaptic terminals (185). Taken together,
these findings suggest that similar to the hippocampus, the CPu may have fewer
docked vesicles, which may lead to the observed decrease in stimulated DA release.
Furthermore, this decrease in DA release can be quickly reversed with an acute
perfusion of 100 ng/mL of BDNF over the slice (see Figure 4.7A), suggesting that a
primary role of BDNF is to regulate DA release. Taken together, our overarching
hypothesis is that at a very young age, extracellular DA levels are low due to the
decrease in docked vesicles and/or their content. As a result of these low extracellular
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DA levels, the DA system tries to compensate by decreasing the function of the DA
transporter. However, due to the increase in extracellular DA levels observed in mice
aged ~ 3 months, it appears that the system overcompensates. Therefore to better
understand these paradoxical findings, future experiments should focus on determining
whether and how BDNF signaling modulates DA vesicular recruitment and/or
mobilization of the vesicle pools.
Although the findings obtained using slice FSCV provide an important foundation
toward understanding how low BDNF levels modulate presynaptic DA dynamics, in vivo
FSCV will deliver important details regarding burst-firing patterns in the BDNF-deficient
mice. Unlike in vivo microdialysis, which predominantly measures tonic extracellular DA
levels (‘baseline’) and averages phasic (or burst) firing over a period of 20 minutes, in
vivo FSCV measures DA every 100 ms allowing for a unique insight into naturally
occurring DA transients (phasic firing) (56, 75, 89, 196). Furthermore, in vivo
voltammetry is not limited to measuring naturally occurring DA, but can measure
electrically stimulated DA release, which provides a sufficient amount of DA, permitting
evaluation of DA uptake parameters in vivo (64, 65, 281, 282).
Our results and other studies indicate that exogenous BDNF can acutely
potentiate DA release in the CPu (CHAPTER 4) (29-31, 201). Exactly how BDNF
mediates presynaptic DA mechanisms however, remains elusive. Extracellular BDNF
binds to the tyrosine kinase (TrkB) receptor, and upon activation, numerous
downstream intracellular signaling cascades are initiated including phospholipase C, γ
(PLCγ), phosphotidylinositol-3 kinase (PI3K), and mitogen-activated protein kinase
(MAPK) pathways (CHAPTER 1) (10, 283). However, in order for exogenous BDNF to
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acutely modulate DA release, a rapid signaling event may be required. Signaling via the
PLCγ pathway appears to be the most likely intracellular pathway which BDNF could
rapidly increase DA release in the CPu. Activation of the PLCγ leads to synthesis of
inositol 1,4,5 triphosphate (IP3), through its receptor, IP3 then stimulates sarcoplasmic
reticulum to release Ca2+ (Figure 7.2) (23, 209, 284).
Several studies have linked cytoplasmic Ca2+ concentration in modulation of
neurotransmitter trafficking and docking of vesicles (209, 285, 286). For example, Neal
et al. demonstrated that increased intracellular Ca2+ and influx of extracellular Ca2+ are
important in enhancing BDNF-mediated DA release from amacrine cells of rabbit eye
retina (209). However, no studies have evaluated the role of BDNF-signaling mediated
Ca2+ release and regulation of presynaptic DA release in the striatum. To determine the
mechanism through which BDNF mediates DA release, future experiments are required
to determine if and how PLCγ pathway activation is involved in striatal DA release.
There are a few limitations of using BDNF to probe DA dynamics. First,
purchasing BDNF is expensive, making most researchers to use very low
concentrations to better understand its therapeutic benefits. Secondly, as a large protein
(27 kDa), BDNF cannot easily pass through the blood-brain barrier, and the only
effective delivery method is direct infusions into the brain. For example, phase I/II
clinical trials using recombinant human BDNF have been unsuccessful in amyotrophic
lateral sclerosis patients mainly due to poor delivery method and a short half-life (287).
However, recent studies have identified 7,8-dihydroxyflavone, a selective high-affinity
TrkB agonist that initiates TrkB dimerization, autophosphorylation, and activation of
downstream signaling cascades (288-291).
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Figure 7.2 Schematic representation of the possible mechanism through which
exogenous brain-derived
derived neurotrophic factor (BDNF) signaling through tyrosine kinase
B (TrkB) receptor acutely increases dopamine (DA) release in the presynaptic terminal.
Abbreviations used: TH, tyrosine hydroxylase; L-DOPA, 3,4-dihydroxyphenylalanine;
dihydroxyphenylalanine;
AADC, L-aromatic
aromatic amino acid decarboxylase; VMAT, vesicular monoamine transporter;
DAT, DA transporter; PLCγ,
γ, phospholipase C
Cγ;; PI3K, phosphatidylinositol-3-kinase;
phosphatidylinositol
IP3, inositol-1,4,5-triphosphate;
ate; IP3R, IP3 receptor.
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Now that there an opportunity to use 7,8-dihydroxyflavone, one of the most
critical questions regarding this small molecule is whether it can modulate
neurotransmitter dynamics, or simply put, how does it influence the DA system? Future
studies will use 7,8-dihydroxyflavone to probe DA dynamics with neurochemical
techniques including FSCV and microdialysis to provide a better understanding of TrkBsignaling role in neurotransmission and therapeutic relevance of the TrkB receptor
agonist.
Although the majority of this dissertation research has focused on the dorsal
striatum (caudate-putamen; CPu), another brain region of interest is the nucleus
accumbens (NAc). This region is involved in addiction and there is considerable
evidence that low BDNF levels may predispose individuals to addiction (53, 54, 112,
113, 280). Thus, the primary question is whether low endogenous BDNF levels in the
NAc have the same effect as they do in the CPu. In the NAc, electrically stimulated DA
release is reduced, with no difference in DA uptake rates, further suggesting that BDNF
is a key mediator of DA release. Additionally, low, endogenous BDNF levels appear to
lead to reduction in the release-regulating DA D3 autoreceptor function in the NAc shell.
Taken together, these alterations in the NAc suggest the impact of low endogenous
BDNF levels throughout the striatum. Although initial characterization has focused on
using only slice voltammetry to examine DA alterations in the NAc, future studies will
determine basal extracellular DA levels in NAc using microdialysis. By examining both
dorsal and ventral striatum, we hope to have a better understanding of how low BDNF
levels influence DA dynamics in a brain region dependent manner.
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7.3 Low BDNF levels, aging and dopamine dynamics
Finally, our last study was to evaluate age-related impact of the low endogenous
BDNF levels on presynaptic striatal DA dynamics. For example, there is a natural agerelated decline in striatal presynaptic dopaminergic functions of stimulated DA release
and clearance observed in NAc of wildtype mice. In contrast, DA release, uptake, and
catabolism appear to be enhanced in aged BDNF-deficient mice. These results
suggest that aging plays a significant role in ‘normalizing’ the hyperdopaminergic
phenotype observed in ~ 3 month old BDNF+/- mice, highlighting possible neuronal DA
adaptations during the aging process. Taken together, the role of endogenous BDNF
levels appear to be more critical during the development of DA system and not for long
term maintenance of presynaptic DA function. Future studies will examine discrete time
points to determine at what age the neurochemical adaptations ‘switch’ to make the
BDNF-deficient mice appear more like wildtype mice. Once the approximate time point
is known, future studies will then focus on the neurobiology or neurochemistry to
understand what is leading to this ‘normalization’ in the BDNF-deficient mice.
Overall, the intrinsic function of reduced BDNF levels appears to be concomitant
reduction of DA release in young BDNF-deficient mice. However, in the aged BDNFdeficient mice, DA is release is similar to wildtype mice. These results suggest that,
excess extracellular basal DA are reduced through increased DA uptake and DA
catabolism over the animal’s lifetime. Future experiments will focus on determining
whether the increase in catabolism is due to increased expression of the DA
transporter and/or monoamine oxidase (MAO) or its function.
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The overarching goals of this these studies are to better understand how low
endogenous BDNF levels modulate DA neuronal transmission within the striatum. Our
findings suggest that, in young animals that there are significant alterations in
numerous presynaptic functions within the striatum, which may ultimately lead to
increase susceptibility to neurological diseases. Although these findings provide the
necessary foundation in understanding this complex relationship between BDNF and
DA, obviously future studies will examine how BDNF signaling mediates dopaminergic
system with age or in the presence of either an illicit drug or therapeutic drug to better
understand the complex relationship between BDNF signaling and DA system.
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Many neurological diseases and disorders are a result of alterations with
neurotransmitters, neuromodulators, and/or proteins. Specifically, one protein that has
been linked to numerous neurological diseases and disorders such as Parkinson’s
disease, Huntington’s disease, addiction, attention deficit hyperactivity disorder (ADHD),
and depression is brain-derived neurotrophic factor (BDNF). As a trophic factor, BDNF
role is to assist in the growth, survival, and differentiation of neurons. However, there is
increasing evidence that BDNF may mediate neurotransmitter dynamics. Our goals
were to understand how endogenous BDNF levels and aging modulate the dopamine
(DA) dynamics in the mouse striatum. Two complementary neurochemical techniques,
slice (in vitro) fast scan cyclic voltammetry (FSCV) and in vivo microdialysis were used
to characterize striatal DA dynamics in wildtype and BDNF heterozygous mutant
(BDNF+/-) mice.
Overall, our findings highlight that (1) we were able to develop a reliable FSCV
assay to characterize DA release-regulating D2 and D3 autoreceptors functionality in
the striatum of

wildtype (C57BL/6) mice, (2) BDNF+/- mice appear to be
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hyperdopaminergic at young age, which may be a consequence of reduced DA release
and DA transporter functions, (3) perfusion of exogenous BDNF on brain slices from
young BDNF+/- mice increases the electrically evoked DA release in a dose-dependent
manner, and (4) neurochemically, aged BDNF+/- mice are more similar to their wildtype
littermates. Taken together, these results suggest that, during neuronal development,
low BDNF levels can modulate DA dynamics, increasing susceptibility to neurological
diseases and disorders. However, a life-time of low BDNF levels alone does not appear
to be critical in DA dynamics dysregulation with age.
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